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ZNF804A has recently been identified as a disease candidate gene for several severe 
neuropsychiatric disorders including bipolar disorder, schizophrenia and autism. Schizophrenia is 
known to share several clinical, genetic, pathophysiological, neuroanatomical and cognitive features 
with bipolar disorder, and thus ZNF804A may represent a useful target for investigating the common 
mechanisms underpinning these diseases. The latest advances in stem cell research have provided a 
wide variety of cellular models for studying these mechanisms in cultures of human neurons. One of 
these lines, a conditionally immortalised, cortically derived human neural progenitor cell (NPC) line 
(CTX0E16), offers a valuable tool for studying ZNF804A in human cortical neurons. 
The primary aims of the current investigation were to characterise neurons derived from the 
CTX0E16 NPC line and to subsequently employ this line in conjunction with other neuronal models in 
the study of ZNF804A expression, subcellular localisation and biological function, specifically focusing 
on its potential impact on neuronal morphology. To this end, neuronal cultures differentiated from the 
CTX0E16 cell line were characterised using a broad set of techniques. These cells were shown to 
predominately adopt a glutamatergic fate, and demonstrated the morphology, functional responses, 
synaptic expression and electrophysiological characteristics consistent with immature cortical pyramidal 
neurons. When examined in human neurons, ZNF804A was shown to be distributed throughout the 
neuron and demonstrated a novel distribution at putative synapses. ZNF804A was also located within 
the nucleus of both NPCs and neurons. Interestingly, this pattern changed as NPCs terminally 
differentiated into excitatory neurons. Moreover, in mature neurons, the presence of ZNF804A within 
the nucleus was modulated by activity-dependent stimulation. siRNA-mediated knockdown of ZNF804A 
revealed a role for this protein in early neurite outgrowth, an effect potentially mediated by neuroligin 
4x. Knockdown of the rodent homologue, Zfp804A, further revealed a role in the maintenance and 
plasticity of dendritic spines in mature neurons. Collectively, these data show that the CTX0E16 cell 
line provides a useful model of human cortical neuron development and disease, and that ZNF804A 
plays a role in the development, maintenance and plasticity of key aspects of pyramidal neuron 
morphology. As alterations in these factors are thought to be central to the pathophysiology of 
schizophrenia and bipolar disorder, it is thus possible that ZNF804A represents a common risk factor 
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CHAPTER 1: INTRODUCTION 
1.1 FOREWARD 
Psychiatric disorders are common and highly debilitating conditions which affect a wide range 
of cognitive, emotional and behavioural characteristics. These disorders are highly heritable and 
commonly share clinical features and exhibit co-morbidity with one another. The overlapping clinical 
features are often accompanied by common environmental and genetic risk factors; alterations in 
cellular morphology and function; and even similar changes in gross neuroanatomy and functional 
connectivity, suggesting that some of these diseases share aspects of their etiology (Carroll and Owen, 
2009; Kraguljac et al., 2012; Lake and Hurwitz, 2007; Murray et al., 2004; van Os and Kapur, 2009; 
Peri et al., 2012). Schizophrenia and bipolar disorder have previously been shown to share many of 
these pathological features and risk factors (Goldstein et al., 2002; Lake and Hurwitz, 2007); 
understanding how the common etiologies for these disorders contribute to their overlapping clinical 
presentation is a crucial topic for future research. Previous attempts to tackle this question have relied 
on multiple approaches, including searching for common genetic risk factors, developing animal models 
of disease, identifying similar disturbances in neuroanatomy and functional connectivity, assessing 
comparable cognitive and behavioural phenotypes and investigating cellular pathology and the 
corresponding mechanisms underlying it (Green, 2006; Nestler and Hyman, 2010; van Os and Kapur, 
2009; Rimol et al., 2012; Strakowski et al., 2005). Genetic variants in several genes have now been 
identified as risk loci for both schizophrenia and bipolar disorder, including ZNF804A, TCF4 and 
CACNA1C (O’Donovan et al., 2009). Recent advances in human stem cell technology have provided a 
wide array of experimental tools with which common mechanisms contributing to similar 
neuropsychiatric disorders like bipolar disorder and schizophrenia can be studied (Bray et al., 2012). 
These cell lines offer an advantage over animal models of such diseases as they permit investigations 
of human-specific mechanisms of development and disease at the cellular and molecular level. 
However, stem cell lines require thorough experimental validation prior to being employed in the study 
of psychiatric diseases, and each stem cell paradigm possesses both strengths and weaknesses in 
tackling this problem. This chapter will outline these disorders, the common features linking them 
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including ZNF804A, the currently available stem cell models, and the aims of the current investigation 
as they relate to these topics. 
1.2 SCHIZOPHRENIA 
Schizophrenia is a severe neuropsychiatric disease which occurs at a lifetime prevalence of 
around 1% in the general population (McGrath et al., 2008). This disorder is typically diagnosed based 
on whether a patient’s clinical presentation adheres to criteria outlined in the Diagnostic and Statistical 
Manual of Mental Disorders V (DSM-V) or the 10th International Classification of Diseases (ICD-10) 
(Jakobsen et al., 2005; Tandon et al., 2013). These features can be broadly separated into three 
categories: ‘positive’ symptoms including hallucinations, delusions and thought disorder (also termed 
as ‘psychosis’); ‘negative’ symptoms including avolition, blunted affect, anhedonia, alogia and 
asociality; and cognitive impairments, including deficits in attention, memory and executive function 
(van Os and Kapur, 2009). The onset of schizophrenia typically occurs between the ages of 18 and 25 
in men, while in women peak onset occurs around a decade later on average (Canuso and Pandina, 
2007). However, there is also growing evidence to support the existence of a prodromal phase 2-4 
years prior to the onset of the first positive symptoms, consisting of cognitive deficits, social isolation 
and affective dysregulation (Cornblatt et al., 2003; Olvet et al., 2010).  
The clinical features of schizophrenia are notoriously heterogeneous in their development, 
presentation and prognosis and thus attempts to establish defining characteristics within this broad 
diagnosis have often proved challenging (van Os and Kapur, 2009). Given the considerable inter-patient 
variability in the clinical presentation of schizophrenia, it is perhaps unsurprising that patients with 
bipolar disorder exhibiting psychotic symptoms are sometimes misdiagnosed as being schizophrenic 
(McElroy et al., 1996). Attempts to establish a framework through which these disorders may be reliably 
distinguished remain the subject of considerable debate within the psychiatric and scientific 
communities (Craddock and Owen, 2005; Lake and Hurwitz, 2007).  
1.3 BIPOLAR DISORDER 
Bipolar disorder is another severe neuropsychiatric disorder with estimates of lifetime 
prevalence ranging from 1-3% depending on the diagnostic criteria used (Merikangas and Lamers, 
2012; Pini et al., 2005). Unlike schizophrenia, bipolar disorder is primarily defined by the presence of 
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large alterations in mood, and in the DSM-V classification system can be subdivided into bipolar type I 
and bipolar type II (Angst, 2013). Bipolar type I patients possess a number of clinical features in common 
with the positive symptoms of schizophrenia: patients experience periods of mania characterised by 
greatly elevated or irritable mood which at their apogee may progress to psychotic symptoms – 
hallucinations, delusions and thought disorder (See Figure 1.1). These manic episodes are also 
accompanied by periods of depression, marked by a decrease in mood, anhedonia, alterations in eating 
and sleeping habits and decreases in energy, motor activity and self esteem and recurring thoughts of 
death; in extreme cases these depressive periods may also feature psychotic symptoms (Phillips and 
Kupfer, 2013). In contrast to this, bipolar type II is characterised clinically by attenuated manic episodes 
(also known as hypomania), periods of elevated or irritated mood without the development of psychosis; 





Figure 1.1 (overleaf): Behavioural and cognitive features of prototypical patients diagnosed with 
schizophrenia, schizoaffective disorder or bipolar disorder. Adapted from van Os and Kapur (2009). 
As in schizophrenia, bipolar disorder occurs with roughly equal lifetime prevalence across 
genders (around 1% and 0.5% for bipolar type I and II respectively) (Diflorio and Jones, 2010). However, 
the peak age of onset is slightly earlier than in schizophrenia, with both male and female patients 
typically developing the disorder during the mid teens to mid 20s (Angst et al., 2002). In addition to this, 
there is also evidence to support the existence of a bipolar prodromal phase with clinical features 
indistinguishable to the schizophrenia prodrome (Olvet et al., 2010).  
Despite the clinical similarities, traditionally schizophrenia and bipolar disorder have been 
treated as discrete diagnostic categories. However, this dualistic view has come under increasing 
scrutiny in recent years (see Figure 1.2). The DMS-V additionally contains a third diagnostic category, 
schizoaffective disorder, which encompasses cases that exhibit features of both schizophrenia and 
bipolar disorder. Furthermore, there is a growing body of clinical, epidemiological, genetic, 
neurobiological and neuroanatomical evidence supporting diagnostic models which propose a clinical 
continuum between the previous categories of schizophrenia and bipolar disorder. Specifically, previous 
research has found similar alterations in brain structure (Ellison-Wright and Bullmore, 2010), 
metabolism (Kraguljac et al., 2012; Pennington et al., 2008) and neurotransmission (particularly 
GABAergic, glutamatergic and dopaminergic signalling (Cherlyn et al., 2010; Cousins et al., 2009; Stone 
et al., 2007; Torrey et al., 2005)); neuropsychological impairments (Schretlen et al., 2007); responses 
to pharmacological treatment (Post, 1999); and genetic or epidemiological risk factors (Carroll and 
Owen, 2009) in both disorders. The literature on these similarities is extensive and thus a full outlining 
of the similarities and differences within each individual category is beyond the scope of this chapter. 
However, the overlapping genetic features of schizophrenia and bipolar disorder will be briefly outlined 




Figure 1.2: Schematic of diagnostic models of psychosis. A: The original dichotomy proposed by Emil 
Kraepelin in the 19th century – two dicrete diagnoses. B: The introduction of schizoaffective disorder as 
a diagnostic category in 1933 – three discrete diagnoses with zones of rarity inbetween. C: Psychosis 
as a continuum (Crow, 1986). D: ‘One disorder’ model proposed by Craddock and Owen, 2005; Lake 
and Hurwitz, 2007. Figure adapted from Lake and Hurwitz, 2007. 
1.4 THE GENETICS OF PSYCHOSIS 
In light of the numerous common pathological features of schizophrenia and bipolar disorder, it 
is perhaps unsurprising that these two diseases have also been linked in a wide variety of 
epidemiological and genetic studies. The risk of schizophrenia has previously been found to be 
significantly increased in the offspring of bipolar patients, while the offspring of schizophrenics are 
likewise significantly more likely to develop mood disorders; offspring of patients with either disorder 
are also at significantly higher risk of developing the same disorder as their parent (Lichtenstein et al., 
2009). Schizophrenia and bipolar disorder are both thought to possess strong genetic components to 
their etiology, with around 80-85% of the risk of developing these disorders being determined by 
heritable factors, as estimated by twin studies and meta-analyses (Cardno and Gottesman, 2000; 
Cardno et al., 1999). Indeed, around 50-70% of this genetic component has been estimated to be 
shared between the two disorders (Lichtenstein et al., 2009). The genetic architecture of these diseases 
is highly heterogeneous, with numerous common genetic variants with small effect sizes as well as rare 
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variants with moderate effects both thought to contribute to their overall risk of developing either 
disorder.  
Early attempts to establish ‘risk genes’ using candidate gene association studies and genome 
wide linkage studies focused on finding genetic variants which produced highly penetrant effects, 
though many of these studies have produced conflicting results and a lack of replication. Despite this, 
a handful of candidate genes have been linked to both schizophrenia and bipolar disorder including 
DISC1, which codes for a protein involved in neural progenitor cell proliferation, synapse formation, 
cAMP signalling, neurite outgrowth, neuronal migration and neuronal integration (Hattori et al., 2010; 
Hayashi-Takagi et al., 2010; Kamiya et al., 2005; Lee et al., 2011; Mao et al., 2009; Millar et al., 2005; 
St Clair et al., 1990). Further evidence has implicated mutations in the gene coding for Neuregulin-1 
(Nrg-1), a protein that plays an important role in neurite outgrowth and also regulates glial cell 
development, axon myelination and ensheathment and excitatory and inhibitory synaptic plasticity 
(Georgieva et al., 2008; Stefansson et al., 2002); and mixed findings regarding a polymorphism in the 
COMT gene coding for catechol-O-methyl-transferase, an enzyme responsible for midbrain dopamine 
catabolism and thus playing a crucial role in dopaminergic neurotransmission (Williams et al., 2007). 
Despite these findings, candidate gene association studies lack the power required to detect common 
genetic variants of low effect, and rare variants of moderate effect. 
The advent of the first genome-wide association study (GWAS) in 2005 provided a powerful 
new tool with which novel single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) 
associated with either disorder could be discovered (Klein et al., 2005). This technique offered a 
particular advantage over previous methods as it permits detection of rare variants with moderate 
effects on risk and common variants with low effects on risk of disease development with a degree of 
confidence not previously possible and without an a priori hypothesis. SNPs have previously been 
estimated to contribute a substantial portion of the variance in liability for both schizophrenia and bipolar 
disorder, and the genetic correlation of common SNPs between these two disorders is high. Psychiatric 
disease-associated SNPs may convey a biological impact in one of several ways. SNPs occurring within 
the exons of a gene may be synonymous or non-synonymous. Synonymous SNPs are polymorphisms 
that do not alter the resulting amino acid sequence of the encoded protein, while non-synonymous 
variants change this sequence with potential consequences in the form of structural and/or functional 
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alterations of the protein (Cichon et al., 2009). Alterations in the amino acid sequence at binding sites 
may affect the protein’s binding affinity for other molecules, while structural changes arising from SNPs 
such as altered folding or cleavage may impact the accessibility of these binding sites (Zhang et al., 
2014). It is worth noting however that even synonymous SNPs may influence disease by modulating 
protein folding as well as mRNA structure, stability and splicing, with downstream consequences for the 
structure, function and level of expression of the resulting proteins (Gandal et al., 2016; Zhang et al., 
2014). 
In addition to SNPs within coding sequences, the vast majority of SNPs exhibiting genome-
wide significance do not directly alter protein structure and occur in noncoding regions, either within 
introns or between genes. These SNPs may instead impact the transcription or splicing of a given gene 
via a disruption of regulatory sequences within the genome or by interfering with the binding of 
transcription factors, splicing factors or microRNAs within promoter and enhancer regions  (Zhang et 
al., 2014). However, noncoding SNPs reaching genome-wide significance may also be indirectly linked 
to a disease via a non-random association with one or more other genomic variants, known as linkage 
disequilibrium. The causative variants associated with these SNPs can be subsequently uncovered 
using de novo polymorphism discovery and high density linkage disequilibrium mapping (Williams et 
al., 2011; Zhang et al., 2014).  
Since their inception, GWA studies have uncovered a growing number of susceptibility loci 
associated with both bipolar disorder and schizophrenia, some of which are highlighted in Figure 1.3. 
These risk loci offer exciting new directions for future research into common mechanisms between 
these disorders. In particular, the genetic risk factors shared between these disorders appear to suggest 
a common pathophysiology particularly related to alterations in mechanisms underlying the formation 
of neural circuits. However, the earliest and best replicated genetic variant discovered via GWAS to be 
associated with a broad psychosis diagnosis was the T/G rs1344706 SNP, located within intron 2 of the 
ZNF804A gene (O’Donovan et al., 2009). Understanding how the function of ZNF804A relates to the 
other pathways highlighted by previous genetic studies will thus be critical in further elucidating the link 




Figure 1.3: Venn diagram of selected GWAS-discovered genes with previously reported links to 
schizophrenia and/or bipolar disorder. This diagram is not an exhaustive list. (Anitha et al., 2014; Bi et 
al., 2012; Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Ferreira et al., 2008; 
Green et al., 2013; Ivorra et al., 2014; Jamain et al., 2003; Li et al., 2015; Mühleisen et al., 2012; Need 
et al., 2009; O’Donovan et al., 2009; Psychiatric GWAS Consortium Bipolar Disorder Working Group, 
2011; Ripke et al., 2013; Stefansson et al., 2009; Uchino and Waga, 2013; Weiss et al., 2003; Wright 
et al., 2013; Xu et al., 2014; Yuan et al., 2012). 
1.5 ZNF804A 
1.5.1 GENETIC STUDIES 
The T allele of the rs1344706 SNP was first discovered to be associated with schizophrenia in 
a GWAS conducted by O’Donovan et al. in 2008, and this association was strengthened when bipolar 
disorder was included in the affected cohort, indicating that the variant conferred an increased risk of 
psychosis in general. Since this initial finding multiple subsequent studies have replicated associations 
with both schizophrenia and bipolar disorder in multiple cohorts (Riley et al., 2010a; Steinberg et al., 
2011; Zaharie et al., 2012), while a 2011 meta-analysis combining data from multiple cohorts to produce 
a dataset of approximately 60,000 subjects further confirmed this association and found the rs1344706 
SNP to provide the strongest association out of multiple markers within the gene (Williams et al., 2011). 
This initial meta-analysis cohort predominately consisted of European subjects, and initial attempts to 
replicate these findings among individual Asian cohorts were inconsistent (Chen et al., 2012; Li et al., 
2013; Yang et al., 2013; Zhang et al., 2011). However, another recent meta-analysis of GWA studies, 
this time in a combined Asian cohort of approximately 30,000 subjects, found a smaller but still 
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significant effect of this variant on psychosis risk (Huang et al., 2016). Both of these meta-analyses 
have estimated that possession of the T allele of the rs1344706 SNP increases the risk of developing 
schizophrenia and bipolar disorder by around 10% (odds ratios (ORs) of 1.08 and 1.10 respectively). 
Since the initial discovery of a susceptibility locus at rs1344706, several other ZNF804A 
variants have been found to be associated with psychotic disease. The meta-analysis in the combined 
Asian cohort discovered a further SNP at rs1366842 within exon 4 of the ZNF804A gene which 
contributed a similar increase in risk (OR = 1.095) (Huang et al., 2016). A further SNP at rs7597593 
within ZNF804A intron 1 was found to be associated with schizophrenia in a 2010 study by Riley et al. 
studying a European cohort, and a subsequent follow up study combining multiple cohorts found this 
association was specifically sex modulated, occurring in females (OR = 1.29) but not in males. This 
SNP has been found to be in moderate linkage disequilibrium with rs1344706, indicating that it was at 
least partially independent from this locus. A further SNP at rs359895 has been reported as influencing 
ZNF804A promoter activity and found to be associated with schizophrenia in several Han Chinese 
cohorts (OR = 0.70), though evidence regarding this effect is mixed (Li et al., 2011; Zhang et al., 2015). 
In addition to the evidence regarding SNPs at the ZNF804A locus, a number of rare ZNF804A copy 
number variants have been discovered in psychosis patients, including an entire deletion of the 
ZNF804A gene and a duplication of exon 1, which were not observed in healthy controls and thus were 
significantly associated with the broad disease category of psychosis (Steinberg et al., 2011). However, 
other CNV studies have not been able to successfully detect CNVs associated with bipolar disorder or 
schizophrenia at the ZNF804A locus (Stone et al., 2008; Walsh et al., 2008). 
Interestingly, variants at the ZNF804A locus have also been found to be associated with other 
psychiatric disorders. Rs1344706 and rs7597593 were both found to be associated with heroin 
addiction (OR = 1.16 and OR = 1.142 respectively) (Sun et al., 2015); while several CNVs at the 
ZNF804A locus have been found in a group of eight verbally deficient boys with autism (Anitha et al., 
2014). Furthermore, a SNP at rs7603001 within ZNF804A intron 2 was found to be significantly 
associated with autism; this association strengthened in families of autistic individuals with verbal 
deficiencies (Anitha et al., 2014). This association with autism is particularly of note due to the growing 
body of evidence implicating genetic risk factors, disease mechanisms and pathology common to both 
autism and schizophrenia (Burbach and Van Der Zwaag, 2009).  
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As described above, SNPs may be located within coding regions of a gene, directly impacting protein 
structure, or may instead be found within noncoding regions and impact the expression or splicing of a 
gene. The rs1344706 SNP, located within intron 2 of the ZNF804A gene, has previously been found to 
influence ZNF804A expression in adult and fetal brain and binding affinity for nuclear proteins (Hess 
and Glatt, 2013). The risk allele of this SNP was previously found to directly reduce expression of the 
full length ZNF804A transcript in second trimester fetal brain tissue (Hill and Bray, 2012), and is also 
associated indirectly with an increase in allelic expression in the adult frontal, temporal and parietal 
cortices (Riley et al., 2010a; Williams et al., 2011); this indirect increase in expression is thought to be 
through additional regulatory variants at the ZNF804A locus rather than directly due to the effects of the 
rs1344706 genotype itself. A subsequent study determined that this effect in the fetal brain was actually 
due to reductions in the novel ZNF804AE3E4 transcript rather than the full length variant.  
1.5.2 ZNF804A ISOFORMS AND MOTIFS 
The full length ZNF804A gene consists of four exons of varying length and numerous alternative 
splice variants for this gene have been predicted and observed. A recent bioinformatic assessment of 
the ZNF804A gene found a total of eleven predicted ZNF804A isoforms using AceView and the 
Alternative Splicing Gallery, some of which exhibiting truncated or excised exons. Subsequent 
assessments of expression levels for each of the four ZNF804A exons highlighted two potential 
ZNF804A variants, termed variant b and variant c - a 602 amino acid isoform with a truncated 5’ end 
and a 54 amino acid isoform with a truncated 3’ end respectively; the latter consisting predominately of 
exon 2 (Hess and Glatt, 2013). 
A recent study conducted in a lymphoblastoid cell line and post-mortem human brain tissue 
found an alternative exon, termed exon 2.2. This exon was determined to comprise part of a novel 
mRNA variant consisting of exon 2.2 and exon 2 and predicted to code for a truncated 88 amino acid 
protein. Interestingly, this novel transcript was found to be differentially expressed in schizophrenia 
subjects relative to healthy controls (Okada et al., 2012). In addition to this, a study conducted by Tao 
et al. (2014) discovered a novel ZNF804A transcript consisting of exon 3, exon 4 and a new 5’ 
untranslated region within intron 2 close to the rs1344706 SNP, using RNAseq, 5′ RACE, end-to-end 
PCR, and quantitative reverse transcription PCR. Bioinformatic analysis of the expression pattern of 
each of the four ZNF804A exons in human post-mortem brain tissue has provided additional support 
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for the existence of this variant, as the 3’ exons appeared to be preferentially expressed relative to exon 
1 and 2 throughout development and adulthood (Hess et al., 2015). 
The full length ZNF804A protein is 1209 amino acids in length and possesses a predicted 
weight of around 137 kDa (Tao et al., 2014). ZNF804A possesses a predicted Cys2His2 (C2H2) zinc 
finger domain on exon 2 and is thus a member of the zinc finger protein superfamily, a group of proteins 
characterised by a common structural motif consisting of a relatively short sequence folded around one 
or more zinc ions. Zinc finger proteins possess numerous functions and can be further subcategorised 
according to the particular form of zinc finger motif they possess; classical C2H2 ZNF domains in 
particular typically possess a repeated 28-30 amino acid with two cysteines and two histidines acting 
as the conserved chelating region for a single zinc ion (Krishna, 2003). C2H2 ZNF proteins are known 
to possess multiple functions including mediating protein-protein interactions and binding to specific 
RNA sequences (Brayer and Segal, 2008; Brown, 2005). However, C2H2 zinc finger domain proteins 
are perhaps best known for acting as transcription factors, binding to the major groove of DNA 
sequences through the N-terminus of the alpha helix portion of this motif (Krishna, 2003). In the human 
brain, zinc finger proteins have been previously found to regulate a wide variety of functions, including 
synaptic signalling, neurite outgrowth and neuronal proliferation (Aruga et al., 1994; Fenster et al., 2000; 
Hattori et al., 2007); C2H2 zinc finger proteins have previously been implicated in the pathways 
underlying neurodevelopmental disease (Bardoni et al., 1999). Thus, the possession of this particular 
domain may represent a mediator through which the protein functions and thus may indicate how 
mutations in the ZNF804A gene confer an increased risk of developing psychiatric disease in humans. 
Interestingly, not all of the predicted or observed ZNF804A isoforms possess the zinc finger 
binding domain, and thus lack any obvious ability to bind DNA sequences or act as a transcription 
factor. Specifically, while the full length, variant c and disease-associated exon 2.2 transcripts are 
predicted to express the C2H2 ZNF domain, the predicted variant b and the putative disease-associated 
ZNF804AE3E4 variant lack exon 2 and thus do not possess this motif (Hess and Glatt, 2013; Okada et 
al., 2012; Tao et al., 2014). Structural analysis of the full length ZNF804A amino acid sequence 
conducted by Hess et al. (2015) suggested that this protein possessed a predominately disorganised 
configuration, with around 86% of the full length model displaying random coiling. However, this analysis 
also revealed that the N-terminal of the full length ZNF804A protein forms a compact structure 
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consisting of two β-sheets and two α-helices coming into close contact with one another in a manner 
consistent with a typical C2H2 zinc finger domain, with minor structural deviations consistent with either 
an artefact of the folding algorithm or an atypical ZNF motif structure. Furthermore, models computed 
for the variant b and c isoforms suggested that the correct folding of the C2H2 ZNF domain was 
conserved in the variant c isoform while the variant b isoform (lacking the putative ZNF domain) was 
around 95% intrinsically disordered.  
The full length ZNF804A isoform also possesses two predicted nuclear localisation signals 
(NLS), on exon 2 and exon 4 of the protein (Hess and Glatt, 2013). NLS are amino acid sequences 
which mark a given protein for import into the nucleus via a system of nuclear transport (Pemberton 
and Paschal, 2005). The presence of these signals on the full length ZNF804A protein is particularly of 
note given the presence of the putative DNA-binding domain on this protein. Thus, these motifs could 
potentially act in conjunction with the ZNF domain to promote transport of this protein into the cell 
nucleus where it may act as a transcription factor via the zinc finger motif. 
1.5.3 REGIONAL AND TEMPORAL EXPRESSION OF ZNF804A 
ZNF804A has been previously found to be expressed within the human brain throughout fetal 
development and adulthood, peaking at around the third trimester of gestation in the hippocampus, 
dorsolateral prefrontal cortex and anterior cingulate cortex (Hess and Glatt, 2013; Hill and Bray, 2012). 
Similarly, in the developing rat brain the rat homologue of ZNF804A, ZFP804A, reaches peak 
expression at birth then gradually decreases as the pup matures, with particularly strong expression 
being seen within the hippocampus (Chang et al., 2015). Furthermore, in cultured rat primary cortical 
neurons expression of Zfp804A has been found to peak at the 4th day in vitro (DIV4); this expression is 
also enhanced following treatment with glutamate in an NMDA receptor-dependent manner (Chang et 
al., 2015; Hinna et al., 2015). 
In addition to alterations in ZNF804A expression during development, ZNF804A isoforms have 
also been found to exhibit differential expression in patients with severe neuropsychiatric illnesses 
relative to controls. Expression of the novel ZNF804AE3E4 transcript was significantly reduced in the 
dorsolateral prefrontal cortex of schizophrenics, but not bipolar patients relative to controls, while the 
full length transcript was found to be reduced in the bipolar group alone (Tao et al., 2014). Reduced 
expression of the full length ZNF804A transcript has also been observed in the post-mortem anterior 
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cingulate cortex of autistic individuals relative to controls (Anitha et al., 2014). Taken with the findings 
of a link between variants at the ZNF804A locus and an increased risk of psychotic illnesses, these 
results suggest the ZNF804A may have an influential role in early brain development which, if disrupted, 
may contribute to later development of psychiatric diseases like schizophrenia and bipolar disorder. 
1.5.4 ZNF804A AND BRAIN STRUCTURE 
Since the discovery of a link between variants at ZNF804A loci and several neuropsychiatric 
disorders, multiple studies have attempted to determine whether these variants or otherwise expression 
of the ZNF804A gene are similarly linked to alterations in gross neuroanatomical structures with 
relevance to these diseases. An initial MRI study conducted by Lencz et al. (2010) in healthy volunteers 
found that individuals homozygous for the risk allele of the rs1344706 SNP exhibited an increase in 
total white matter volumes relative to carriers of the other allele, a finding which has since been 
replicated (Wassink et al., 2012). These individuals further demonstrated grey matter reductions in 
several cortical regions comprising the ‘default mode’ network, structures known to exhibit synchronised 
activity in the absence of a cognitively demanding task (Raichle et al., 2001). Conversely, a further 
study demonstrated that in schizophrenia patients, possession of both risk alleles was associated with 
relatively spared grey matter volumes in a number of regions in the hippocampus and neocortex 
(Donohoe et al., 2011). Despite this, subsequent studies have found mixed success in replicating many 
of these effects on white matter and grey matter volume in specific regions of the cortex (Nenadic et 
al., 2015; Wassink et al., 2012).  
A number of studies have also attempted to determine the effect of rs1344706 genotype on 
cortical thinning, a well characterised pathology in schizophrenic brains (Rimol et al., 2012). The first of 
these utilised a combinatorial MRI/DTI approach to investigate cortical structure in healthy subjects. 
Individuals homozygous for the risk allele of the rs1344706 SNP were found to exhibit reduced cortical 
grey matter thickness within several regions including the anterior cingulate cortex (Voineskos et al., 
2011). This finding is particularly of note given the grey matter reductions in the anterior cingulate cortex 
common to both schizophrenia and bipolar disorder (Ellison-Wright and Bullmore, 2010). Following this, 
a further MRI study found that homozygous risk allele carriers with schizophrenia exhibited greater 
cortical thickness in the prefrontal or temporal cortex and less pronounced aberrant temporal cortical 
folding than schizophrenics possessing the non-risk allele, while the reverse was seen in healthy control 
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homozygotes versus healthy carriers of the non-risk allele (Schultz et al., 2013); similar contrasting 
effects on cortical thinning depending on diagnostic status could be seen in a subsequent study on a 
Han Chinese cohort (Wei et al., 2015). However, subsequent research could find no such associations 
with rs1344706 genotype and cortical thickness regardless of region (Bergmann et al., 2013). 
Studies have also assessed the impact of rs1344706 genotype on white matter integrity in 
patient and control groups, though again results here have been mixed. An MRI-based study of white 
matter density has found possession of both copies of the risk allele for this SNP to have divergent 
effects on white matter integrity in the prefrontal lobe of schizophrenic patients and healthy individuals 
relative to those of non-risk allele carriers (Wei et al., 2012). Carriers of the ZNF804A risk allele have 
also previously been found to possess reduced white matter integrity in a white network of white matter 
tracts and regions of the parietal and cingulate cortex in several studies of schizophrenic patients and 
healthy controls, including areas of the ‘default mode’ network (Ikuta et al., 2014; Kuswanto et al., 2012; 
Mallas et al., 2016; Zhang et al., 2016). Despite this, not all groups have been able to replicate 
associations between white matter integrity and rs1344706 genotype (Wei et al., 2013).  
Collectively, the literature appears broadly to demonstrate effects of rs1344706 genotype on 
grey matter volume, cortical thickness and white matter integrity, particularly in regions within the 
‘default mode’ network. Moreover, effects of the homozygous risk-allele genotype appear to diverge 
within the psychosis and healthy control subgroups. Although evidence is conflicting on some findings, 
there is also a suggestion that the risk allele is generally associated with potentially pathological 
changes in a wide range of regions in healthy controls, while in the schizophrenic group possession of 
this allele is linked to a less pronounced pathology relative to the nonrisk allele. 
1.5.5 ZNF804A, FUNCTIONAL CONNECTIVITY AND NEUROCOGNITIVE 
PHENOTYPES 
In conjunction with neuroanatomical effects of variants at the ZNF804A locus, there is also a 
growing body of literature suggesting further alterations in functional connectivity between cortical and 
subcortical regions, as well as the patterns of activity in individual structures. Possession of the 
rs1344706 risk allele has previously been found to be associated with altered intra- and inter-
hemispheric connectivity within the dorsolateral prefrontal cortex (dlPFC) and increased connectivity 
between this region, the hippocampus (HC) and the amygdala during a working memory task (Esslinger 
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et al., 2009, 2011; Paulus et al., 2013; Rasetti et al., 2011; Zhang et al., 2016); increased activation in 
the right dlPFC during a working memory task (Linden et al., 2013); enhanced PFC-ACC coupling (a 
phenotype associated with executive function deficits and schizophrenia) (Thurin et al., 2013); and 
reductions in hippocampal theta waves (thought to co-ordinate PFC-HC activity) (Cousijn et al., 2015). 
Finally, EEG recordings of healthy subjects during another working memory task found that 
homozygous risk allele carriers demonstrated an attenuated form of an electroencephalographic 
endophenotype associated with psychosis (Saville et al., 2015). Taken together, the previous literature 
indicates that functionally the rs1344706 genotype influences connectivity between and activity within 
the prefrontal cortex, anterior cingulate cortex and hippocampus –areas known to exhibit pathological 
alterations in schizophrenia and/or bipolar disorder. 
The structural and functional consequences of possession of the rs1344706 risk allele are also 
accompanied with a number of distinct neurocognitive phenotypes. Homozygous risk allele carriers 
exhibit impairments in executive control and visuomotor performance in healthy controls, suggesting 
this SNP may contribute to the cognitive impairment seen in schizophrenia (Balog et al., 2011; Lencz 
et al., 2010). However, other studies have not found any associations between genotype at this locus 
and performance in working memory, spatial memory or sustained attention tasks in psychologically 
healthy individuals (Esslinger et al., 2011; Paulus et al., 2013; Stefanis et al., 2012), indicating that this 
deficit is limited to visuomotor skills in this group. Disease-associated variants at rs1344706 and 
rs7597593 were also associated with positive schizotypy-related factors including self-rated paranoia 
and ideas of reference, behavioural traits related to the positive symptoms of schizophrenia (Stefanis 
et al., 2012). Interestingly, the effect of the risk allele also extended to cognitive attributes in psychiatric 
disease. Rs1344706 risk allele homozygotes exhibited poorer decision making than non-risk allele 
carriers in a study of heroin addicts (Sun et al., 2015), and in patients with schizophrenia possession of 
the risk allele was associated with more severe psychotic symptoms and impairments in visual memory 
(Hashimoto et al., 2010; Wassink et al., 2012). However, risk allele also an attenuation of the deficits in 
working and episodic memory typically seen in schizophrenia (Walters et al., 2010). Finally, 
schizophrenic carriers of the risk allele at rs1344706 demonstrated positive symptoms that were more 
resistant to treatment with atypical antipsychotics than those of patients with a non-risk allele (Mössner 
et al., 2012). Collectively, these studies suggest that the rs1344706 risk allele is preferentially 
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associated with a schizophrenia subpopulation characterised by a more intense, treatment-resistant 
positive symptomology, but attenuated cognitive deficits. 
1.5.6 CELLULAR AND MOLECULAR STUDIES OF ZNF804A 
In contrast to the functional and structural imaging studies of ZNF804A, relatively few 
investigations have attempted to assess the functions of this gene at the cellular and molecular level. 
The pre-existing literature has focused predominately on a putative role of the ZNF804A protein as a 
transcription factor in a large variety of in vitro paradigms. The first of these studies, conducted by Hill 
et al. (2012), found that siRNA-mediated silencing of ZNF804A expression in a conditionally 
immortalised, cortically-derived human neural progenitor cell (hNPC) line found resulting alterations in 
the expression of several genes involved in cell adhesion as well as C2ORF10 and STMN3, a gene 
known to influence neurite outgrowth, axonal arborisation and dendritic branching. A further 
investigation has found overexpression of GFP-tagged ZNF804A in rat NPCs to influence expression 
of the schizophrenia-linked genes PRSS16, COMT, DRD2 and PDE4B (Girgenti et al., 2012). A further 
study conducted in HEK cells transfected with a myc-tagged ZNF804A construct found overexpression 
of this protein to upregulated expression of several genes involved in TGF-β signalling (Umeda-Yano 
et al., 2013). TGF-β signalling is a cellular pathway known to be involved in several processes including 
neural development, cellular differentiation, adult neurogenesis and neuroprotection (Ageta et al., 2008; 
König et al., 2005; Liu and Niswander, 2005); pathological alterations in this pathway have also been 
implicated in the etiology of schizophrenia (Frydecka et al., 2013). 
SNAP25 has also been identified as a potential target of ZNF804A in a study showing a 
reduction in expression of this protein in neural SH-SY5Y cells following siRNA-mediated knockdown 
of ZNF804A, as well as a positive correlation between the expression levels of these proteins in SH-
SY5Y cultures (Anitha et al., 2014). This protein is a key component of the SNARE complex (Chen and 
Scheller, 2001), and plays a role in the regulation of exocytosis, growth of axons and dendrites, 
regulation of dendritic spine density and synaptic plasticity (Antonucci et al., 2013; Fossati et al., 2015; 
Grosse et al., 1999; Osen-Sand et al., 1993; Tomasoni et al., 2013). In the human brain, SNAP25 levels 
have been further found to correlate with ZNF804A expression in the anterior cingulate cortex, a key 
region seen to exhibit pathological changes in structure in schizophrenia, bipolar disorder, some forms 
of autism and rs1344706 risk allele carriers. 
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Finally, ZNF804A knockdown using an RNA interference technique in hiPSC-derived NPCs 
was found to alter expression of a wide variety of genes, of which those involved in interferon signalling 
were particularly enriched among the genes reduced in expression following knockdown. Furthermore, 
ZNF804A knockdown particularly affected the expression of genes mediated by interferon-alpha 2 
(IFNA2), a key component of immune response pathways (Chen et al., 2015). This is particularly of 
note given the vast body of research suggesting that immune responses may in part contribute to the 
risk of developing schizophrenia (Müller et al., 1999). 
Upstream of these effects, a number of mechanisms have been proposed as regulators of 
ZNF804A activity, and further acting as potential mediators of the effect of the rs1344706 SNP on the 
risk of developing psychosis. Although (as described previously) rs1344706 is unlikely to directly 
influence ZNF804A expression several indirect mechanisms have been suggested, including alterations 
in pre-mRNA splicing, allele-specific alterations in transcription factor binding efficiency and epigenetic 
modifications which alter the site’s affinity for DNA binding proteins (Hess et al., 2015; Hill et al., 2011; 
Voineskos et al., 2011). One such proposed epigenetic mechanism is histone 3 lysine 9 trimethylation 
(H3K9me3), which is specifically enriched at rs1344706 in the fetal and adult cortex (Hess et al., 2015). 
This alteration is particularly noteworthy as it has been implicated in gene repression and alternate 
splicing (Saint-André et al., 2011), though the full effect of all the potential epigenetic changes at the 
rs1344706 locus on ZNF804A activity is not yet fully understood. 
ZNF804A is known to be a target of miR-137, a non-coding RNA that acts as a regulator of 
gene expression (Kim et al., 2012). A SNP in the gene for this microRNA has been found to be 
associated with schizophrenia in a previous GWA study (Ripke et al., 2011). Indeed, expression of miR-
137 has recently been found to inversely correlate with ZNF804A expression in the primary motor cortex 
of first trimester fetuses and the ventrolateral and dorsolateral PFC and ACC of adult subjects (Hess et 
al., 2015). ZNF804A expression has also been found to be modulated by treatment with glutamate in 
and NMDA receptor-dependent mechanism as well as exposure to heat shock (Chang et al., 2015; Lin 
et al., 2014).  
ZNF804A is also predicted to possess binding sites for a number of transcription factors at an 
intronic region which are implicated in neurodevelopmental processes and schizophrenia-associated 
pathology as well as cytokine-influenced pathways involved in synaptic plasticity and behaviour (Hess 
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et al., 2015; J. Chen et al., 2015). Taken together with the literature implicating ZNF804A’s involvement 
in heat shock pathways, NMDA receptor-mediated signalling pathways, TGF-β signalling, IFNA2-
mediated gene expression, and expression of multiple psychosis-relevant genes involved in 
neurotransmission, this suggests that the ZNF804A protein may be a common factor in multiple 
immune-related and neurotransmission-related pathways underlying psychosis. 
Several studies have further attempted to determine the subcellular localisation of both the 
ZNF804A and Zfp804A proteins, a common method for identifying prospective functions of a given 
protein. The first study to investigate the localisation of ZNF804A in neural cells found that endogenous 
and exogenous Zfp804A is expressed predominately within the nucleus of rat NPCs (Girgenti et al., 
2012). In rat primary cortical neuron cultures, Zfp804A is initially expressed predominately within the 
perinuclear cytoplasm, and then during differentiation it is redistributed throughout the neuron, with 
particularly strong immunostaining being seen in the growth cones of neurites. Finally, in mature rat 
primary cortical neurons it re-adopts the predominately cytoplasmic distribution, though expression can 
still be seen along the dendrites and within the nuclei (Hinna et al., 2015). 
Further studies have determined that in humans the ZNF804A protein is expressed in layer III 
pyramidal neurons and interneurons in the temporal and parietal cortex, in granule and purkinje cells in 
the cerebellum and in fetal neuroblasts during the 19th week of gestation (Bernstein et al., 2014; Tao et 
al., 2014). Taken together, these studies appear to support a putative role for ZNF804A and Zfp804A 
as transcription factors due to the localisation of these proteins within the cell nucleus, particularly in 
NPCs. The data also appears to be suggestive of a potential extra-nuclear role given the prominent 
cytoplasmic, dendritic and growth cone staining for these proteins in developing and mature neurons in 
humans and rodents. Despite these interesting findings however, it should be noted that many of these 
findings are not consistent across studies even using the same anti-ZNF804A antibody, and 
characterisation of the antibodies used is either limited or missing entirely (Bernstein et al., 2014; 
Umeda-Yano et al., 2013; Anitha et al., 2014; Tao et al., 2014). Thus, for the purposes of future 
experiments a thorough characterisation of the currently available anti-ZNF804A antibodies and a 
subsequent employment of one of these antibodies in the study of subcellular localisation of 




In contrast to the growing number of in vitro studies assessing the impact of ZNF804A/Zfp804A 
manipulation on gene expression, very few investigations have attempted to assess the impact of these 
proteins on the morphological and functional characteristics of neurons and other neural cell types. A 
preliminary study conducted in hiPSC-derived NPCs found that knockdown of ZNF804A using RNA 
interference resulted in a trend towards an increase in proliferation that did not reach significance (Chen 
et al., 2015). However, no studies have yet attempted to determine whether the alterations in the 
expression of genes relevant to neurite outgrowth and synapse formation and maintenance following 
ZNF804A overexpression/knockdown actually impact these parameters. Clearly, this is a critical area 
for further exploration in future studies in order to link previous work at the genetic and molecular level 
with that at the neuroanatomical level. 
1.6 CELLULAR MODELS OF NEUROPSYCHIATRIC DISEASE 
GWA studies have provided an invaluable tool for identifying novel candidate genes which may 
contribute to psychiatric disease. However, many of the genes marked as potentially contributing to 
disease pathways underlying psychiatric disease by GWAS have not yet been fully characterised and 
thus little is currently known about their biological functions. Animal models involving the conditional or 
unconditional knockout of a given gene offer one method of studying that gene’s impact on brain 
function and development, though such studies are limited by differences in neuronal biology between 
the commonly used model species and human cells. Neuronal cultures generated from human stem 
cell sources offer a means of bypassing this issue.  
Recent advances in stem cell technology have resulted in an unprecedented variety of 
experimental paradigms in which neurodevelopmental and neuropsychiatric disease mechanisms can 
be studied in human neurons. Human neurons can now be generated from several sources, including 
immortalised lines such as tumour-derived neural cell lines, neural stem cell (NSC) and neural 
progenitor cell (NPC) lines; as well as patient-derived lines such as induced pluripotent stem cells 
(iPSCs) and cells taken from the olfactory neuroepithelium.1 The advantages and disadvantages of 
these differing platforms will now be discussed in the following section. 
                                                     
1 It is worth noting that NPC and NSC are terms which are often used interchangeably in the literature. 
However, typically NSC is used to refer to neural cells which are able to renew themselves indefinitely 
and differentiate into a variety of neural cell types, while NPC usually refers to cells which only 
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1.6.1 IMMORTALISED NEURAL STEM CELL LINES 
Certain populations of neurons can be obtained directly from human brain tissue during 
biopsies, surgery, or from post-mortem brains and grown as primary cultures (Gibbons and Dragunow, 
2010). However, such sources are limited by ethical and practical considerations, rendering them 
unsuitable for research purposes in the vast majority of cases. In contrast to this, immortalised stem 
cell lines offer a method for generating cultures of human neurons from a standardised and continually 
proliferating source. Tumour-derived lines have long been used in such a manner, though 
developments in stem cell biology over the past two decades have provided an alternative in the form 
of immortalised ESC, NSC and NPC lines. 
1.6.1.1 TUMOUR-DERIVED CELL LINES 
Tumour-derived lines such as the SH-SY5Y line, derived from a metastatic neuroblastoma, can 
provide a renewable source of cells which display neuronal properties such as neurite outgrowth, 
synthesis of neurotransmitters, receptor expression and even electrophysiological phenomena such as 
action potentials after differentiation with retinoic acid (Johansson, 1994). The SH-SY5Y line in 
particular has been used in a several studies investigating the mechanisms of anti-depressant and anti-
psychotic drug activity (Arun et al., 2008; Park et al., 2011; Sanchez-Wandelmer et al., 2009). Due to 
its ability to express key neuronal proteins this line also represents a useful model for investigating 
psychiatric disease-associated gene functions and the impact of genetic variants on those functions 
(Biedler et al., 1978; Bray et al., 2012).  However, there remain a number of drawbacks to the use of 
tumour-derived cell lines in the generation of neuronal cultures. These lines typically have low 
phenotypic potential and thus the variety of experimental avenues which may be explored using this 
paradigm is limited. Furthermore, care must be taken to ensure that the SH-SY5Y cells under 
experimental study adopt the appropriate neuronal characteristics as SH-SY5Y cultures may remain 
heterogeneous even after differentiation, and neuroblastoma lines in general are predisposed to 
chromosomal abnormalities (Bray et al., 2012; Encinas et al., 2000). In contrast to this, immortalised 
                                                     
(continued) possess a transient ability to proliferate and which tend to be unipotent or only able to 
differentiate into a handful of cell types (Seaberg & van der Kooy, 2003). For the purposes of the 
present discussion, NSC and NPC will be used according the nomenclature applied by the relevant 




lines derived from embryonic and fetal brain tissue offer a method for generating multiple neuronal cell 
types while simultaneously avoiding these pitfalls. 
1.6.1.2 EMBRYONIC STEM CELL LINES 
Embryonic stem cell (ESC), immortalised neural stem cell (NSC) and neural progenitor cell 
(NPC) lines offer a means of bypassing several of the limitations of neuroblastoma lines: these cells 
typically lack the chromosomal abnormalities seen in tumour-derived lines, they are multipotent and 
thus capable of differentiating into multiple neuronal cell types, and differentiation of neurons from these 
lines resembles differentiation in vivo more closely (Bray et al., 2012). ESCs are obtained from the inner 
mass of the initial blastocyst and possess the potential to differentiate into all the tissues of the 
developing fetus (Thomson et al., 1998). The first paper to describe the derivation of these cells from a 
human blastocyte was conducted by Thomson et al. in 1998; these cells demonstrated continual 
proliferative capabilities and were shown to form derivatives of all three germ layers including neural 
epithelium from the ectodermal layer via spontaneous differentiation. However, this method is inefficient 
in producing neural cells and subsequent techniques have attempted to direct differentiation more 
specifically towards neural lineages using media supplements such as RA or BMP-inhibitors in adherent 
cultures, and FGF-2 for cultures in suspension (Dhara and Stice, 2008). Adherent cultures can be grown 
with or without MEF feeder layers, and progressively generate radial structures resembling a transverse 
section of the developing neural tube in vivo, known as ‘neural rosettes’. These rosettes give rise to 
nestin-positive neural progenitor cells which can be manually picked and passaged into media 
containing high levels of FGF-2 and maintained or frozen down into seed stocks (Dhara and Stice, 
2008). Depending on the differentiation protocol used, these NPCs can adopt multiple regional 
characteristics including those consistent with progenitors from the midbrain, spinal cord and forebrain 
(Johnson et al., 2007; Li et al., 2005; Singh Roy et al., 2005; Yan et al., 2005), and can be further 
differentiated into neurons, astrocytes and oligodendrocytes (Carpenter et al., 2001; Wilson and Stice, 
2006). Additionally, neurons differentiated from these NPCs can demonstrate the hallmarks of 
functional neurons including neuronal morphology, synaptic protein expression and electrophysiological 
properties such as action potentials (Johnson et al., 2007). These neurons also develop the 
characteristics of specific neuronal subpopulations, including midbrain dopaminergic neurons and 
cortical glutamatergic and GABAergic neurons, though again via specific differentiation protocols 
(Carpenter et al., 2001; Ma et al., 2012; Zhang, 2006). For example, a combination of retinoic acid and 
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SHH can push neuroepithelial cells towards a motor neuron identity while SHH and FGF8 drives these 
cells towards a dopaminergic fate (Singh Roy et al., 2005; Zhang, 2006).  
ESCs offer an advantage over tumour-derived cell lines as a model of human neurons in that 
they faithfully recapitulate the stages of neuronal development during differentiation, from initial 
neutralisation to terminal differentiation of neurons. Furthermore, they provide greater experimental 
flexibility in contrast to tumour-derived lines due to the wide variety of cell types which can be generated 
from a single ESC source (Bray et al., 2012; Gaspard et al., 2008). However, there also exists several 
drawbacks to their use: strong controversy exists over the source of these cells, and as a result the 
number of the available lines is relatively limited. Furthermore, there is also a risk of contamination from 
non-neuronal cells in cultures derived from ESCs, and generation of neuronal cells from ESCs requires 
a considerable increase in culture times relative to tumour-derived lines, raising the susceptibility of 
cultures to infection (Jakel et al., 2004). NPC and NSC lines offer a way of avoiding the risks of long 
term culture by eliminating the initial neutralisation step required with ESCs. Additionally, these lines 
avoid the risk of contamination with other, non-neural cell types, being directly obtained from the 
developing fetal brain. 
1.6.1.3 NEURAL STEM CELLS AND NEURAL PROGENITOR CELLS 
The earliest NSC and NPC lines to be derived from human fetal brain tissue were first described 
in a series of papers published in the late 1990s. These lines could differentiate into both neurons and 
astrocytes, though they initially lacked the ability to produce oligodendrocytes (Sah et al., 1997). 
Subsequent studies have demonstrated full multipotentiality however, both in vitro and in vivo following 
grafting experiments (Carpenter et al., 1999a; Flax et al., 1998). The primary samples obtained from 
fetal brain tissue often contain a mixture of cells, both pluripotent and terminally differentiated cells such 
as neurons or oligodendrocytes. This mixture will depend on the gestational age of the fetal brain and 
the region from which the tissue is extracted from, however for the purposes of experimental, 
therapeutic and screening use it is critical that any NPC and NSC lines arising from these primary 
samples are homogenous to reduce variability between cultures (Hook et al., 2011). To address this, 
typically clonal populations are isolated from a single NPC or NSC within the primary sample. However, 
such clonal lines often lose their ability to proliferate and gradually alter their karyotype following 
prolonged periods in culture (Villa et al., 2004). To target the former problem, NSC and NPC clonal lines 
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are commonly conditionally immortalised using the insertion of a transgene into the cell’s genome to 
drive regulated proliferation and thus permit greater control over expansion and differentiation of 
cultures from the line in question (Pollock et al., 2006) and to counter problems arising from any limited 
potential for renewal possessed by unedited cells. Despite this, several studies have also demonstrated 
that certain NSCs are able to proliferate indefinitely in culture in the presence of EGF and FGF2 (Hook 
et al., 2011; Sun et al., 2008). 
NSCs can be derived from embryonic neural tissue following the closure of the neural tube 
during development, though other populations of NSCs are known to exist in the adult brain in 
subgranular zone of the dentate gyrus of the hippocampus and the subventricular zone of the lateral 
ventricles (Fuentealba et al., 2012; Price and Williams, 2001). NPCs subsequently arise from NSCs in 
later development and possess distinct regional identities determined by their position within the 
germinal zones of the developing brain, which in turn impacts the genes they express and ultimately 
the potential cellular fates they can adopt during terminal differentiation (Price and Williams, 2001). 
NPC lines have previously been generated from a wide variety of fetal tissues, including spinal cord, 
mesencephalon, dorsal and ventral telencephalon (Cocks et al., 2013; Horowitz et al., 2015; Lin et al., 
2015; Pollock et al., 2006; Storch et al., 2001). As isolated hNPCs retain their regional identity these 
lines produce neurons specific to their origin within the fetal brain. For example, NPCs derived from the 
mesencephalon can adopt a dopaminergic neuronal identity following differentiation, while those from 
the ventral telencephalon adopt the features of GABAergic interneurons (Storch et al., 2001; Zhang et 
al., 2008).  
These lines can be employed in similar research to that of SH-SY5Y cells – studying 
mechanisms of drug action, neuronal development, neuronal function and disease processes – though 
these lines have also previously been utilised as a therapeutic treatment in an animal model of stroke 
(Pollock et al., 2006; Stevanato et al., 2009). Previous research has shown NSC and NPC lines to be 
capable of generating cultures of cells staining positive for markers of neuronal fate and negative for 
markers of stem cell identity and proliferation. Subsequent to this, neurons expressing markers of 
distinct regional and functional identity have also been observed, including GABAergic interneurons, 
glutamatergic cortical neurons, midbrain dopaminaergic neurons (De Filippis et al., 2007; Storch et al., 
2001; Zhang et al., 2008), Neurons derived from NPC and NSC lines have also been shown to develop 
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morphological features consistent with neurons in vivo, which are plastic in response to activity-inducing 
stimuli. Calcium responses have been demonstrated in neurons derived from these lines as a proxy 
marker of neuronal activity, while the expression of synaptic markers and electrophysiological features 
consistent with neurons in vivo and in other in vitro models has also been shown (Cacci et al., 2007; 
Carpenter et al., 1999a; Cocks et al., 2013; De Filippis et al., 2007; Gaspard et al., 2008; Lin et al., 
2015; Nunes et al., 2003; Zhang et al., 2008). Such features place these cell lines in an ideal position 
to study mechanisms of brain development and disorder at the cellular level. However, there are also 
several drawbacks to the use of immortalised NSC and NPC lines. As with embryonic cells, there is 
considerable controversy over the use of embryonic and fetal tissue as a source for experimental lines. 
In addition to this, neural stem and progenitor cell lines can also be relatively restricted in their neuronal 
progeny, limiting their experimental flexibility within a single line (Jakel et al., 2004). Moreover, the use 
of fetal tissue as a source precludes some of their uses in the study of heritable disease-related 
phenotypes which are only detectable in post-natal individuals, like psychiatric disorders. Patient-
derived cell lines provide one method of bypassing some of these difficulties. 
1.6.2 PATIENT DERIVED LINES 
1.6.2.1 ADULT STEM CELL LINES 
Patient-derived stem cell lines offer a valuable tool for investigating the impact of certain genetic 
variants and genotypes on known clinical syndromes which only emerge following birth, and would 
otherwise be unpredictable in cell lines derived from fetal tissue. As previously described, olfactory 
mucosa tissue provides one useful source of NSC and NPC lines. In addition to this, other sources of 
these lines exist within two key regions in the adult brain: the granular layer of the dentate gyrus and 
the subventricular zone of the lateral ventricles (Price and Williams, 2001). These cells can be accessed 
via post-mortem tissue, biopsies and surgical specimens, though NSCs and NPCs derived from these 
sources are typically limited in their fate specification, are difficult to expand into large populations in 
vitro and also tend to senesce after relatively few passages (Akiyama et al., 2001; Jakel et al., 2004; 
Schwartz et al., 2003). However, adult stem cells can also be obtained from the olfactory mucosa via 
biopsies which are considerably less invasive. These cells can be subsequently grown in culture as 
neurospheres: clustered cultures of NSCs and NPCs undergoing differentiation (Borgmann-Winter et 
al., 2009). NSCs and NPCs from these cultures can be further differentiated into cells which express a 
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wide variety of neuronal markers, adopt neuronal morphologies and even express key synaptic proteins 
and respond to treatment with neurotransmitters (Borgmann-Winter et al., 2009; Wang et al., 2011a). 
Olfactory neuroepithelium-derived cells have previously been used to show altered cell cycle dynamics 
in schizophrenia patient-derived cells relative to controls, and demonstrate changes in the expression 
of genes implicated in axonal guidance (Fan et al., 2012; Matigian et al., 2010).  
Olfactory neuroepithelium cell lines offer an advantage over immortalised neural cell lines in 
that they can be directly obtained from patients known to be diagnosed with a given psychiatric disorder 
and thus mechanisms and phenotypes differing between psychiatric patient-derived cells and those of 
healthy controls can be studied. However, like NSCs and NPCs obtained from the dentate gyrus and 
subventricular zone of the lateral ventricles, neuronal cells derived from such sources are typically 
limited in their regional and functional identity, and thus other cellular models must be adopted in studies 
where olfactory neuroepithelium-derived cells are unable to adopt the relevant neuronal identity (Wang 
et al., 2011a). Additionally, despite being less drastic than the surgery required for biopsies taken from 
other sources of adult NSCs, biopsies of the olfactory mucosa are still relatively invasive for the subject 
involved (Roisen et al., 2001). HiPSC lines and other related technologies offer a novel means of 
circumventing both of these issues. 
1.6.2.2 HIPSC LINES 
The recent development of iPSC technology has provided a highly flexible new tool for 
investigating disease and developmental mechanisms in a vast array of neural tissues and cell types 
that would not be available using olfactory neuroepithelium sources. This technique was first described 
in a 2006 study by Takahashi & Yamanaka, who reprogrammed dermal fibroblasts from adult mice into 
pluripotent cells using retroviral transduction of just four transcription factors: Oct3/4, Klf4, Sox2, and c-
Myc. Similarly to ESCs, these induced pluripotent stem cells (iPSCs) possessed the ability to 
differentiate into the cellular identities of all three germ layers, and additionally exhibited similar 
morphology, proliferative capabilities, gene expression and surface antigens to embryonic stem cells, 
though some studies have also noted key phenotypic differences in epigenetic modifications and gene 
expression between these cell types (Puri and Nagy, 2012). Since this initial discovery, integrative and 
non-integrative iPSC transduction methods have now been successfully applied to a wide range of 
human somatic cells including dermal fibroblasts, blood cells, amniotic fluid and hair cells, opening the 
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path to the generation of lines derived from patients with psychiatric diseases (Aasen et al., 2008; C. Li 
et al., 2009; Loh et al., 2009; Takahashi et al., 2007).  
A critical aspect of hiPSC technology as it relates to the study of psychiatric disease is the 
ability to produce neurons and other neural cell types following the application of directed differentiation 
protocols. Numerous neuronal cell types can now be generated from hiPSC lines, including basal 
forebrain cholinergic neurons, spinal motor neurons, pyramidal glutamatergic neurons, GABAergic 
interneurons and midbrain dopaminergic neurons, as well as astrocytes and oligodendrocytes, though 
it should be noted that typically such protocols usually result in heterogeneous populations of multiple 
neuronal cell types (Liu et al., 2013; Ogawa et al., 2011; Ring et al., 2012; Sareen et al., 2013; Shi et 
al., 2012a; Swistowski et al., 2010). hiPSC-derived neurons have been found to display similar 
properties to neurons in fetal tissue including expression of neuronal markers, the progressive 
development of neuronal morphology (including dendritic spines), the expression of a wide variety of 
key synaptic proteins, functional responses to neurotransmitters and even the generation of action 
potentials and other key electrophysiological phenomena (Maroof et al., 2013; Nicholas et al., 2013; 
Pedrosa et al., 2011; Verpelli et al., 2013).  
Several studies have employed patient-derived hiPSC lines in the study of disease mechanisms 
underlying schizophrenia, autism and even bipolar disorder. Neurons generated from schizophrenia 
patient hiPSCs have previously been found to exhibit reduced neuronal connectivity and alterations in 
gene expression relative to controls, including reduced expression of ZNF804A in two out of four patient 
lines; these deficits were found to be attenuated following treatment with loxapine, an antipsychotic 
(Brennand et al., 2011a). Schizophrenic patient hiPSC-derived NPCs have also demonstrated 
pathological elevations in intracellular zinc and potassium which are reversed by valproate treatment 
as well as increases in reactive oxygen species (ROS) (Paulsen et al., 2014). Additionally, impairments 
in synaptic maturation and alterations in mitochondrial function have been seen in schizophrenia patient 
hiPSC-neurons (Robicsek et al., 2013). For bipolar disorder, hiPSC lines have demonstrated 
proliferative deficits in bipolar patient NPCs and abnormalities in the expression of genes involved in 
neurodevelopment and neurogenesis (Madison et al., 2015). Finally, hiPSC-based studies of autism 
have previously tended to focus on hiPSC lines derived from patients with clinical syndromes 
characterised by autistic features, including Rett syndrome, Timothy syndrome, Fragile X syndrome, 
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Prader-Willi/Angelman syndrome and Phelan- McDermid syndrome. It is worth noting that hiPSC-
neurons derived from patients within these cohorts have demonstrated variously alterations in synaptic 
density and calcium signalling; reductions in neurite complexity and electrophysiological dysfunction; 
and changes in gene expression (Chamberlain et al., 2010; Liu et al., 2012; Marchetto et al., 2010a; 
Paşca et al., 2011; Shcheglovitov et al., 2013). Although these studies typically use hiPSC lines 
generated from only a handful of patients and controls, the advent of high-throughput automated 
techniques in cell culture studies may greatly improve the power of these investigations in the future by 
exponentially increasing the number of feasible lines in a given study. 
As with other patient-derived lines, hiPSCs offer an advantage over immortalised cell lines in 
modelling late-emerging, genetically heterogeneous diseases such as psychiatric disorders as they 
permit assessments of neuronal function and development in a system with a genetic background 
known to ultimately result in disease. Additionally, hiPSC cultures offer similar benefits to ESCs as a 
model system in that they also recapitulate the cellular stages of human neural development, crucial 
for studies of brain development or diseases thought to feature early developmental pathology (see 
Figure 1.4). However, caution must be ascribed in attempting to model disease processes which may 
only occur in the adult human brain (particularly in the case of certain psychiatric and neurological 
disorders), as iPSC-derived neurons most closely match the gene expression patterns seen in neurons 
within the developing fetal brain 8-24 weeks post-conception (Brennand et al., 2014). One possible 
method of sidestepping this problem is to specifically focus studies on mechanisms and signalling 
pathways in isolation without attempting to model the disease etiology as a whole. Furthermore, iPSCs 
may also be used to focus instead on early pathological mechanisms which are thought to contribute 




Figure 1.4: Schematic of neuronal differentiation from ESCs (A) and iPSCs (B). A: ES cells are obtained 
from the inner mass of a blastocyst then expanded in culture. ESCs are neuralised using RA and BMP 
inhibitors until the formation of neural rosettes. NPCs are picked and expanded. Finally cells are 
terminally differentiated using a protocol specific to the intended lineage. B: IPSCs are transduced from 
somatic cells using viral vectors or other methods including microRNAs and protein transduction. IPSC 
cultures are then commonly neutralised using dual SMAD inhibition until the formation of neural 
rosettes. NPCs are picked from the rosettes and expanded. NPC cultures are then terminally 
differentiated according to defined protocols. 
Despite these advantages, there are several caveats in the use of hiPSC lines which may limit 
their use in certain forms of experimental inquiry. Genetic lesions associated with particular diseases 
may impede or halt entirely the process of hiPSC derivation from patient samples due to interference 
with the reprogramming technique itself – previous attempts to model Fanconi anaemia using hiPSCs 
reprogrammed from fibroblasts were stymied by the causative mutation for the disorder impacting a 
DNA repair pathway involved in the reprogramming process (Raya et al., 2009). In addition to this, 
diseases involving aberrant epigenetic modification of particular genes may not be well suited to study 
using hiPSCs as typically the reprogramming of somatic cells results in the loss of epigenetic signatures 
due to chromatin remodelling and competitive growth selection during the expansion of hiPSC colonies 
(Mertens et al., 2016).  
The heterogeneity of hiPSC cultures also poses a challenge for experimental design in several 
ways. hiPSC lines derived from different somatic tissues within the same individual, or even from the 
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same tissue but with different reprogramming techniques, have been reported as exhibiting differences 
in global gene expression, raising the question of whether these cells partially retain elements of their 
initial identity (Rouhani et al., 2014). However, intra-individual heterogeneity in this regard is still less 
than inter-individual heterogeneity in gene expression, suggesting that differences between cell lines 
are predominately driven by genetic differences rather than induction techniques or source tissue and 
highlighting the priority of using iPSC lines from multiple patients and/or controls rather than within a 
single individual (Rouhani et al., 2014). The majority of existing techniques for iPSC and neural 
induction result in diverse cultures populated with multiple cell types, further contributing to the intra- 
and inter-individual heterogeneity of cell lines. This variability necessitates the generation of multiple 
lines (typically 3 per patient or control) from multiple individuals in each clinical group in a given study 
(Brennand et al., 2014). Due to the wide degree of clinical variation typically seen in psychiatric 
disorders such as schizophrenia, studies focusing on cohorts sharing a clinical phenotype or that are 
genetically homogenous have been proposed as experimental designs which would bypass the 
problems caused by the heterogeneity of these diseases (Brennand et al., 2014). However, even 
limiting an experimental paradigm in this way requires the generation of a large number of patient and 
control lines, each of which requires culturing and validation for multiple months prior to 
experimentation. The generation of large quantities of iPSC lines is highly time consuming and 
expensive, and for the purposes of some studies these may be prohibitive factors. However, recent 
developments in stem cell technology have produced two new experimental systems which can greatly 
reduce the time required to generate neuronal cells by reprogramming somatic tissue: induced NPCs 
(iNPCs) and induced neurons (iNs). 
1.6.2.3 INPCS AND INS 
Induced neurons were initially reported by Vierbuchen et al. (2010), who found that inducing 
expression of Ascl1, Brn2 and Myt1l in rodent fibroblasts using lentiviral transduction resulted in the 
generation of populations of cells expressing markers of neurons, exhibiting action potentials and 
demonstrating functional synapses. Similar techniques have been subsequently applied to human 
fibroblasts to generate cultures of glutamatergic and dopaminergic iNs with similar neuronal properties 
(Pang et al., 2011; Pfisterer et al., 2011). The production of iNPCs from mammalian cells was first 
demonstrated by Tian et al. (2012), using retroviral induction of just five transgenes (Pou3f2, Nr2e1, 
Sox2, c-Myc and Bmi1) to convert mouse epidermal fibroblasts. iNPCs have been subsequently derived 
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from human somatic cells and possess the proliferative, differentiation, self renewal and gene 
expression properties consistent with NPCs in vivo (Ring et al., 2012). These cells can be later used to 
generate cultures of glutamatergic or dopaminergic neurons which express the neuronal and synaptic 
markers and electrophysiological properties of functional neurons in the developing mammalian brain 
(Lim et al., 2015; Ring et al., 2012).  
iNs and iNPCs possess several advantages over iPSC models. The time required to generate 
these lines from somatic cells is greatly reduced in comparison to iPSC reprogramming, thus also 
reducing cell culture costs and the risk of contamination. In addition to this, iN cultures have been found 
to retain age-related transcriptomic and functional signatures, raising the possibility that they may be 
suitable for the study of biological phenomena which only occur in the mature or aged brain. The 
preservation status of these signatures in iNPCs is currently unknown. iNPCs offer an additional 
advantage over iN techniques in that they overcome the experimental limitations arising from the 
restricted numbers of cells arising from iN induction while still retaining the advantage of skipping the 
iPSC stage and the related problems in culture heterogeneity, inefficiency of differentiation and residual 
pluripotency (Mertens et al., 2016). 
Despite the crucial advantage of reducing culture time relative to iPSC-based paradigms, iNs 
and iNPCs have several drawbacks. While iPSCs can proliferate indefinitely in vitro, iNs are limited by 
the expandibility of the initial somatic cell cultures and the efficiency of conversion and iNPCs eventually 
lose their ability to proliferate, ultimately limiting the number of neurons which may be generated using 
these techniques. Furthermore, while the generation of neurons from iPSCs permits an approximation 
of the development of neurons from embryonic stem cells in vivo, it should be noted that iNPCs and iNs 
do not go through some of these analogous developmental stages and thus may preclude investigations 
of disease mechanisms which may occur during neural induction or neuronal maturation (Mertens et 
al., 2016). Regional patterning of iNPCs has not yet been demonstrated (Brennand et al., 2014) and 
further refinement of these techniques will be required before they can be employed in studies of all the 
functional neuron subtypes of the brain. As a result iNPCs have not yet been utilised in studies of 
psychiatric disease. iN cultures and some iNPC cultures also exhibit mosaicism due to the genetic 
diversity of the donor tissue, an issue which may increase the variability of differentiated cultures but 
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may also be useful as a means of modelling the natural genetic diversity seen in mature somatic tissue 
(Mertens et al., 2016).  
1.7 ASSESSMENTS OF SNP FUNCTION USING CELLULAR SYSTEMS 
As has been outlined here, human stem cells represent a flexible model system for the study 
of human disease-relevant genes, and the wide variety of stem cell models now available permits 
depending on the requirements of the line of experimental inquiry. However, these advances in stem 
cell technology, coupled with breakthroughs in genome editing techniques, have now additionally 
produced a means through which individual disease-associated SNPs can be studied in human cells. 
The generation of hiPSC lines from human patients possessing the disease-associated allele of a 
GWAS-identified SNP permits detailed evaluations of the impact of this SNP on a wide range of 
biological attributes, including the binding affinity of transcription factors, splicing factors and/or 
microRNAs and the transcription and splicing of genes (Merkle and Eggan, 2013). In the case of SNPs 
occurring outwith the coding regions of the genome, such techniques may also assist in the identification 
of the candidate gene affected by the SNP which conveys the increased risk of disease. Moreover, as 
multiple SNPs often occur in linkage disequilibrium with one another, hiPSC lines provide a useful tool 
for studying haplotypes consisting of several SNPs which are associated with a particular disease 
(Merkle and Eggan, 2013). The impact of haplotypes or single SNPs on cellular and molecular 
mechanisms in hiPSC-derived somatic cells may then be further used to identify potential mechanisms 
linking genetic variants to the associated disorder. 
As described in Section 1.4, previous GWA studies have found the rs1006737 SNP within an 
intron of the CACNA1C gene (coding for the CaV1.2 voltage gated calcium channel) to be associated 
with both bipolar disorder and schizophrenia (Green et al., 2010). A subsequent study compared iNs 
derived from individuals possessing the risk allele for this SNP in comparison to iNs derived from 
individuals homozygous for the nonrisk allele. Possession of both copies of the risk allele was found to 
result in a significant increase in CACNA1C mRNA relative to heterozygous and homozygous carriers 
of the nonrisk allele, a finding previously observed in studies of post-mortem brain tissue and suggested 
to be mediated by multiple cis-elements within the intronic region containing rs1006737 (Yoshimizu et 
al., 2015). In addition to this, possession of both copies of the risk allele was found to be correlated with 
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an increase in the density of CaV1.2-mediated currents in these iNs relative to iNs derived from nonrisk 
allele carriers, indicating that the rs1006737 SNP has downstream functional consequences. 
hiPSC lines have also been used to study the impact of disease-associated SNPs on diseases 
outwith the field of psychiatry. In a study of hiPSC-neurons derived from patients possessing 
polymorphisms associated with sporadic Alzheimer’s disease within the SORL1 gene exhibited reduced 
SORL1 expression and APP processing responses to treatment with BDNF relative to control hiPSC-
neurons (Young et al., 2015). Highly penetrant SNPs have similarly been investigated in the case of 
hiPSC lines derived from patients with Parkinson’s disease (PD). In one such study the LRRK2 mutation 
G2019S - known to cause an autosomal dominant form of PD – was found to result in deficits in neurite 
outgrowth and hypersensitivity to treatment with 6-Hydroxydopamine in neurons derived from PD 
patient hiPSC lines (Reinhardt et al., 2013). These effects were found to be mediated in part by 
increased ERK phosphorylation and alterations in gene expression in the G2019S lines, highlighting 
how hiPSCs can ultimately be used as a tool in identifying novel mechanisms underlying disease. 
In addition to the use of hiPSC lines derived directly from individuals possessing specific 
disease-associated polymorphisms, genome editing represents a valuable technique to not only induce 
these disease-associated polymorphisms in unaffected lines, but also to generate ‘rescue’ lines 
whereby the variants known to be associated with disease are ‘corrected’ in isogenic lines (Wen et al., 
2016). In the previously described hiPSC study of the G2019S variant known to cause PD, hiPSC lines 
carrying the disease-causing mutation were genome edited using zinc finger nucleases to correct this 
mutation; these genome-edited lines exhibited an amelioration of the disease-related cellular 
phenotypes seen in hiPSC-neurons derived from PD patient cells. This experimental paradigm permits 
an assessment of SNP function with much greater specificity than is possible with hiPSC lines alone, 
as it eliminates the possibility of phenotypic differences between risk allele carrier and noncarrier lines 
arising from other genomic variation. Recently, a new approach combining both TALENs and the 
CRISPR/Cas system, termed iCRISPR, has been developed to rapidly and efficiently edit the genome 
of hiPSC lines (González et al., 2014). This approach permits the generation of biallelic knockout lines 
and homozygous knockin lines with stage-specific control during differentiation and the potential for 
double- and triple gene knockouts in a single line. Critically, alterations of single nucleotides can be 
performed using this technique, thus establishing a highly useful method to study the impact of 
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individual SNPs - in this study, an Alzheimer’s disease-associated SNP located within APOE exon 4 
was successfully inserted into the genome of hiPSC lines (González et al., 2014).  
The functionality of SNPs located within genes coding for microRNAs can also be tested using 
human stem cell models without the requirement for genome editing. In a study of a SNP at 
rs147061479 within piR-598, a PIWI-interacting, noncoding RNA linked to glioma formation, 
immortalised human astrocytes and cells from two human glioma lines were independently transfected 
with wild type and variant piR-598 mimics (Jacobs et al., 2016). In all cell lines transfection with wild 
type piR-598 sharply reduced cell proliferation relative to a control RNA, an effect that was ameliorated 
in the SNP-containing piR-598 transfection condition. Such an experimental system may be useful in 
future studies of psychiatric disease-associated SNPs located within microRNAs. Moreover, if a 
particular disease-associated SNP within a given gene is known to be associated with an upregulation 
or downregulation of that gene’s expression, cellular models such as immortalised stem cell lines or 
hiPSCs may be similarly combined with transfection techniques to either knock down or overexpress 
the disease-relevant gene as an approximation of the effects of the risk SNP. 
Finally, genetic variants linked to a specific disease may exert their effects through non-cell-
autonomous pathways which can be investigated through the use of different cell types differentiated 
through isogenic hiPSC lines. For example, mouse motor neurons carrying the ALS-causing G93A 
SOD1 point mutation exhibit cell-autonomous death in vitro, but control motor neurons also exhibit non-
cell-autonomous apoptosis when co-cultured with astrocytes carrying the disease-causing mutation (Di 
Giorgio et al., 2007; Nagai et al., 2007); such mechanisms could similarly be explored in hiPSC lines 
carrying disease-associated SNPs. The combination of hiPSC lines with techniques to produce pure 
populations of specific cells, such as fluorescence-assisted cell sorting (FACS) (Schöndorf et al., 2014), 
will in future aid the development of new experimental systems which can be used to identify the cellular 
populations contributing to the pathology of a particular disease. In the case of pathological alterations 
of neuronal function, these may even manifest on the level of brain circuitry; purifying distinct 
populations of hiPSC-derived neuronal cells for co-culture will in future provide a useful method for 
investigating SNP-associated pathology at specific circuits. 
In the context of the current investigation it is particularly worth noting that a conditionally 
immortalised, cortically derived human NPC line, CTX0E03, has been previously used to study the 
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impact of ZNF804A on gene expression (Hill et al., 2012). This line expresses a modified c-mycERTAM 
transgene, which causes these cells to continually proliferate and maintain an NPC identity when 
cultured in media supplemented with a synthetic drug, 4-hydroxytamoxifen (4-OHT) (Pollock et al., 
2006). Recently, a sister cell line to CTX0E03, CTX0E16, has become commercially available and, due 
to the cortical abnormalities associated with variants at the ZNF804A locus, may represent a highly 
useful model in which key aspects of ZNF804A-mediated cortical dysfunction can be studied at the 
cellular level. However, this cell line has not yet been thoroughly characterised, and thus it is critical to 
establish whether NPCs from this line are capable of generating cultures of cells which exhibit all the 
key hallmarks of mature, functional neurons. Previous characterisation studies of hNSC and hNPC lines 
have established neuronal identity by assessing a number of attributes including expression of 
functional and regional neuronal markers; the progressive development of key morphological features 
of neurons including an axon, dendrites and dendritic spines; the expression of a range of pre- and 
post-synaptic markers in a manner consistent with in vivo observations; functional responses to 
physiologically-relevant stimuli; electrophysiological properties consistent with mature neurons such as 
action potentials; and morphological plasticity (Cacci et al., 2007; Carpenter et al., 1999a; Cocks et al., 
2013; De Filippis et al., 2007; Gaspard et al., 2008; Lin et al., 2015; Nunes et al., 2003; Zhang et al., 
2008). A similar characterisation is thus necessary for the CTX0E16 cell line before it can be used in 
conjunction with other cellular models to study ZNF804A expression and function. 
1.8 AIMS AND HYPOTHESES 
In light of the previous literature on neurons generated from immortalised hNSC and hNPC 
lines, I hypothesise that cells from the CTX0E16 hNPC line will be capable of differentiating into 
glutamatergic neurons which exhibit the characteristic phenotypes of functional pyramidal 
neurons and thus represents an ideal cellular model in which to understand the biological 
functions of disease risk genes. With this in mind, the first aim of the present investigation is to 
characterise the CTX0E16 hNPC line to determine whether a well defined neuralisation protocol that 
favours the production of glutamatergic neurons from ESCs and other immortalised cells will have 
similar results in this line. In particular, this study will examine key cellular phenotypes of neurons that 
have been previously observed in other immortalised ESC, NSC and NPC studies by assessing 
markers of cell fate, neuronal morphology, functional responses, synaptic expression and 
electrophysiological characteristics in these cells. These investigations will therefore demonstrate the 
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CTX0E16 NPC line as a valuable platform from which studies of the mechanisms of human cortical 
development and disease can be carried out. 
 Previous research has suggested that ZNF804A acts as a transcription factor that mediates the 
expression of genes coding for proteins involved in neurite outgrowth and synapse formation and 
maintenance (Chen et al., 2015; Hill et al., 2011). In addition to this, while early studies suggested this 
protein was localised to the nucleus, subsequent investigations have demonstrated extra-nuclear 
expression though the precise distribution of ZNF804A at the subcellular level is currently unresolved 
(Girgenti et al., 2012; Tao et al., 2014). Finally, expression of ZNF804A is thought to be high during 
early fetal development and a psychosis-associated genetic variant at the ZNF804A locus is known to 
reduce mRNA expression at this point, suggesting a role for this protein in neural development (Hill and 
Bray, 2012; Tao et al., 2014). Therefore, I hypothesise that ZNF80A plays a role in early neural 
development and is critical in the formation of neuron morphology; that it is expressed outwith 
the nucleus and along the dendrites of developing and mature cortical neurons; and that it plays 
a role in the maintenance of dendritic spines. I aim to investigate these characteristics of ZNF804A 
using a combinatorial approach integrating multiple cellular models including neurons derived from 
CTX0E16 NPCs, hiPSCs and rat primary cortical neuron cultures, investigating the expression and 
localisation of these proteins as well as evaluating the impact of manipulations of ZNF804A on the 
morphological characteristics of these cells. These experiments will thus provide a more thorough 








CHAPTER 2: MATERIALS AND 
METHODS 
2.1 CELL CULTURE 
2.1.1 PROLIFERATIVE CTX0E16 CELLS 
 Use of the CTX0E16 cell line was kindly granted by ReNeuron Group plc. (Guildford, UK) under 
a Material Transfer Agreement. The CTX0E16 cell line is a conditionally immortalised, cortically derived, 
human neural progenitor cell line. This line was derived from first trimester foetal brain tissue using c-
mycER transgene technology; this transgene was inserted into the genome of the cell line using a 
pLNCX-2 (Clontech) MMLV retroviral vector. The c-mycER transgene codes for a protein consisting of a 
c-myc cell division-promoting region and a modified hormone receptor which responds to binding of a 
synthetic drug, 4-hydroxytamoxifen (4-OHT) (Pollock et al., 2006). Ectopically expressed within the cell 
cytoplasm, the monomeric protein undergoes dimerisation upon binding of 4-OHT and subsequently 
translocates to the nucleus, where the c-myc portion of the protein acts as a transcription factor driving 
cell proliferation (see Figure 2.1).  
 CTX0E16 hNPCs were maintained in a proliferative state by culturing in Reduced Modified 
Medium (RMM+++);  DMEM:F12 with 15 mM HEPES and sodium bicarbonate (Sigma) supplemented 
with 0.03% human serum albumin (PAA), 100 μgml-1 apo-transferrin (Scipac), 16.2 µgml-1 putrescine 
(Sigma), 5 µgml-1 human insulin (Sigma), 60 ngml-1 progesterone (Sigma), 2 mM L-glutamine (Sigma) 
and 40 ngml-1 sodium selenite (Sigma)). To maintain proliferation 10 ngml-1 human FGF2 (PeproTec), 
20 ngml-1 human EGF (PeproTech) and 100 nM 4-OHT (Sigma) were also added to RMM. CTX0E16 
hNPCs were seeded onto Poly-D-lysine (PDL, 5 μgcm-²; Sigma) and laminin-coated (1 μgcm-²; Sigma) 
tissue culture flasks, with full media changes occurring every 2-3 days. Cells were passaged once 70 – 
80% confluent using Accutase (Sigma) and maintained for between 25-30 passages; all experiments 
were carried out using cells from passages 12 to 30.  
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Figure 2.1.1: Schematic of c-mycER transgene in a CTX0E16 NPC. A: The transgene codes for a 
modified form of the estrogen receptor, which remains in a monomeric form within the cytoplasm when 
inactive. B: 4-OHT diffuses across the cell membrane from the surrounding media, and binds 
specifically to the monomeric receptor. C: Upon binding, the receptor dimerises and translocates to the 
nucleus. D: The dimerised receptor binds to the c-Myc promoter and drives NPC proliferation. Upon 
removal of 4-OHT from the media, mitosis will cease and the NPC will begin terminal differentiation. 
2.1.2 DIFFERENTIATION OF CTX0E16 CELLS 
 CTX0E16 cultures were maintained under proliferative conditions until 70 – 90% confluent, then 
washed once with prewarmed RMM+++ and passaged onto Poly-D-lysine (PDL, 5 μgcm-²) and laminin-
coated (1 μgcm-²) Nunc tissue culture plastic or No. 1.5 coverglass (The Paul Marienfeld GmbH & Co. 
KG) at a density of 12,500 cells per ml. Cells were then washed in warm Dulbecco's Phosphate-Buffered 
Saline (DPBS; Life Technologies) and maintained in Neuronal Differentiation Media (NDM: Neurobasal 
Medium (Life Technologies) supplemented with 0.03% human serum albumin (PAA), 100 μgml-1 apo-
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transferrin (Scipac), 16.2 µgml-1 putrescine (Sigma), 5 µgml-1 human insulin (Sigma), 60 ngml-1 
progesterone (Sigma), 2 mM L-glutamine (Sigma), 40 ngml-1 sodium selenite (Sigma) and 1 x B27 
serum-free supplement (Life Technologies)). Half medium changes were performed every 2-3 days and 
cultures were differentiated for up to 61 days (days differentiated (DD) 61). 
2.1.3 MOUSE EMBRYONIC FIBROBLASTS 
Feeder cultures of Embryomax primary mouse embryo fibroblasts (strain CF1, Millipore) were 
cultured in MEF media: Advanced DMEM (Sigma) supplemented with Glutamax and Fetal Bovine 
Serum (FBS) in tissue culture flasks precoated in 0.1% gelatin. Half media changes were performed 
every 3-4 days and cells were passaged once ~80% confluent with Trypsin to maintain the cultures. 
MEFs were maintained for up to 5 passages with all experiments being carried out with cells from 
passages 1-5. In experiments requiring inactivated MEFs, MEF media was aspirated and replaced with 
fresh media containing 10 µg ml−1 Mitomycin C and incubated for 2 hours at 37C to arrest mitosis. 
Flasks of arrested MEFs were washed 3 times with prewarmed PBS before being passaged to generate 
monolayer support cultures. 
2.1.4 HUMAN EMBRYONIC KIDNEY CELLS 
Human Embryonic Kidney (HEK293) Cells were cultured in Advanced DMEM supplemented 
with Glutamax and FBS. HEK293 cells were seeded onto tissue culture flasks, with media changes 
occurring every 3-4 days. Cells were passaged 70 – 80% confluent using Accutase and maintained for 
between 10-15 passages; all experiments were carried out using cells from passages 5-20.  
2.1.5 HUMAN INDUCED PLURIPOTENT STEM CELLS (HIPSCS) 
 HiPSCs were generated from keratinocytes of apparently healthy individuals using 
nonintegrating approaches. Keratinocyte cultures were maintained in Epilife (Invitrogen) supplemented 
with 10 µM Rock inhibitor (Sigma) on matrigel-coated plastic. 2 µg ml−1 of hexadimethrine bromide was 
added to the cultures to reduce the charge of the keratinocytes and thus facilitate viral transduction. 
Cultures were transduced using polycistronic excisable lentiviral vectors expressing the Yamanaka 
transcription factors (C-MYC, KLF4, OCT4 and SOX-2). Transduced keratinocytes were plated onto 
monolayers of mitotically arrested MEFs cultured as described previously. These MEF-supported 
cultures were maintained for 4-5 days and passaged onto fresh MEF monolayers. Epilife media was 
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gradually replaced with Knock out serum replacement (KOSR) media (ThermoFisher) from day 10 to 
day 14 of transduction. These cultures were maintained until the emergence of hiPSC colonies, which 
were picked and transferred to fresh wells containing mTeSR supplemented with 10 µM Rock inhibitor. 
Full medium changes were performed every day until proceeding to neuralisation at day 16 following 
transduction. 
HiPSCs were differentiated into neurons using an established protocol that favors the 
generation of cortical forebrain neurons (Cocks et al., 2014; Shum et al., 2015). Neuronal differentiation 
of hiPSCs was by achieved by the addition of N2- and B27-containing medium supplemented with 5 µg 
ml−1 insulin, 1 mM l-glutamine, 100 µM non-essential amino acids, 100 µM 2-mercaptoethanol and 
SMAD inhibitors 1 µM Dorsomorphin (Sigma) and 10 µM SB431542 (Cambridge Bioscience). HiPSCs 
adopted an NPC fate at day 8 of neuralisation, at which point SMAD inhibitors were withdrawn from the 
culture medium. HiPSC-derived NPCs were continually passaged and maintained in this medium until 
day 23 of neural induction. Terminal differentiation (day 23) was achieved by culturing plated NPCs with 
medium containing Neurobasal + B27 and supplemented with 10 µM DAPT for 5 days (day 30); hiPSC-
neurons were grown in Neurobasal + B27 medium up to day 35 (see figure 2.1.2 for a schematic of the 
hiPSC transduction and neuralisation timelines). 
 
Figure 2.1.2: Schematic of hiPSC transduction and neuralisation timeline. A: Days 0-16 of transduction 
from keratinocyte cultures to hiPSC colonies. B: Days 0-35 of hiPSC neuralisation. 
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2.1.6 RAT PRIMARY CORTICAL NEURONS 
Dissociated high-density cultures of primary cortical neurons were prepared from the dissected 
cortices of E18 Sprague-Dawley rat embryos, plated on glass coverslips coated in PDL (0.2 mgml-1) at 
a density of 3 x 105 cells per well and cultured in Neurobasal media (Life Technologies) containing 2% 
B27 supplement, 1% penicillin/streptomycin and 0.5 mM glutamine. On day in vitro (DIV) 4, 200 µM of 
APV, an NMDA receptor inhibitor (also known as AP-5) (Tocris) was introduced to the feeding medium 
until DIV21 in order to reduce cell death arising from excitotoxicity. Half media changes were performed 
twice a week until fixation. 
2.2 GENOME EDITING OF CTX0E16 CELLS 
2.2.1 NUCLEOFECTION 
A flask of proliferative CTX0E16 cells at 80% confluency was nucleofected using Custom 
CompoZr Zinc Finger Nucleases (ZFNs) designed to excise the full length ZNF804A gene from the 
CTX0E16 genome. Cells were initially detached from the flask using acutase before being spun down 
at 200g for 5 minutes and washed twice with 20ml of prewarmed HBSS. Cells were then resuspended 
in 400ul of Nucleofection Solution V (Lonza) containing the appropriate supplement according to the 
manufacturer’s instructions. 100 µl of this solution was then added to each of four tubes containing 
either 2.5 µg of a GFP control plasmid, 5 µl of the supplied ZFN mRNA, 2.5 µg of a 1:1 mix of the two 
supplied ZFN DNA plasmids or a blank control. These mixtures were transferred to 2 mm 
electroporation cuvettes and nucleofected on a nucleofector using programme T-030. Immediately 
following nucleofection these mixtures were transferred to each of four wells in a 6 well Nunc tissue 
culture plate precoated with PDL and laminin (as described in Section 2.1.1) and containing 2ml of 
prewarmed RMM+++. These were then coldshocked to increase the efficiency of nucleofection (as 
described in Doyon et al., 2010) by incubation at 30°C for 3 days, changing media at day 1 and day 3 
to remove dead cells before returning cells to 37°C. Cultures were then grown as normal until confluent, 
and during passaging half of cells were retained for continuation of the cell line with the other half being 





2.2.2 CEL-1 ASSAY 
Chromosomal DNA was prepared from the harvested cells by adding Lysis Solution for Blood 
(Sigma) and incubated at 75°C for 15 minutes. Neutralisation Solution for Blood (Sigma) was added 
and the solution was mixed to neutralise the lysis buffer. The concentration of the chromosomal DNA 
in each sample was quantified using a DNA spectrophotometer and an RT-PCR was performed on the 
samples using the primers provided with the ZFN kit in order to determine the efficiency of the knockout 
in the nucleofected cells (see RT-PCR section for full protocol). 
2.2.3 DILUTION CLONING 
To establish a pure population of ZNF804A knockout CTX0E16 cells, the nucleofected cultures 
were plated on PDL and laminin-coated terasaki plates at a density of 1-5 cells per well. Two hours 
prior to passaging an apoptosis inhibitor (Y-27632, Cambridge Biosciences) was added to the RMM+++ 
culture media at a final concentration of 10µM; cells were maintained in this media until confluent. 
Individual wells were then passaged and plated onto PDL and laminin-coated 24 well Nunc cell culture 
plates containing a monolayer of mitotically arrested mouse embryonic fibroblasts (MEFs). These 
individual cultures were subsequently expanded and retested for the efficiency of knockout using the 
CEL-1 assay. 
2.2.4 EXPANDING NUCLEOFECTED POPULATIONS 
 MEFs were employed to aid the growth of very small populations of CTX0E16 cells (1-5 cells). 
Flasks of arrested MEFs were washed 3 times with prewarmed PBS, trypsinised and the detached cells 
were spun down. The cells were then resuspended in fresh MEF media and plated on 24 well Nunc 
tissue culture plates precoated in 0.1% gelatine at a density of 50,000 cells per well. Whole media 
changes were performed the following day to RMM+++ supplemented with Y-27632 in preparation for 
seeding of the nucleofected CTX0E16 populations. Mitotically arrested MEFs do not survive 
subsequent passages after the initial plating; this permits a pure population of nucleofected CTX0E16 






2.3.1 LIPOFECTAMINE TRANSFECTION 
 CTX0E16 cells, HEK293 cells, hiPSC-derived neurons and rat primary cortical neurons were 
transfected at the desired age using Lipofectamine 2000 (Life Technologies) using a modified form of 
the manufacturer’s protocol, where Optimem was substituted for DMEM (Srivastava et al., 2011). An 
assay-determined concentration of the desired plasmid was mixed with Lipofectamine 2000 in DMEM 
pH balanced using HEPES and incubated for 20 minutes in a humidified atmosphere of 95% air/5% 
CO2 at 37°C with open caps. The DNA:Lipofectamine 2000 mixture was added dropwise to the cells to 
be transfected, and cells were incubated for 4 hours (CTX0E16 or hiPSC cells) or overnight (HEK293 
cells or rat primary cortical neurons) at 37°C, before being transferred to new wells containing fresh 
media to enhance viability. Transfections were allowed to proceed for 1 or 2 days before either 
treatment or fixation and subsequent immunocytochemistry. 
2.3.2 VIRAL TRANSFECTION 
DD28 CTX0E16 neurons were treated with a recombinant AAV vector driving eGFP expression 
under the control of a CamKII promoter at a concentration of 5.23x1010 GC/ml 
(AAV1.CamK110.4.eGFP.WPRE.rBG, Penn Vector Core). Neurons were fixed, immunostained and 
imaged 7 days later (see Section 2.7 for immunocytochemistry and imaging protocols). 
2.4 SIRNA SILENCING OF ZNF804A AND ZFP804A  
2.4.1 N-TER TRANSFECTION 
 CTX0E16 cells, hiPSC-derived NPCs and rat primary cortical neurons were transfected using 
the N-TER Nanoparticle siRNA Transfection System. SiRNAs targeting full length ZNF804a mRNA 
sequence at exon 4 (siRNA#1, Thermo Fisher: HSS150612) and exon 2 (siRNA#2, Thermo Fisher: 
HSS150613) (see Table 2.2 and Hill et al., 2011) were used along with Stealth RNAi siRNA negative 
control med GC duplex (Invitrogen: 465372) that has no significant sequence similarity to human or rat 
gene sequences. These siRNAs have been previously validated in a sister cell line to the CTX0E16 
NPCs, CTX0E03 (Hill et al., 2011). Cells were transfected with both siRNAs (hiPSC-neurons and 
CTX0E16 neurons) or siRNA#2 only (rat primary cortical neurons) using the N-Ter Nanoparticle siRNA 
Transfection System (Sigma: N2913) at DD0 (CTX0E16 cells), DD23 (hiPSC-derived neurons) and 
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DIV21 (rat neurons) in accordance to manufacturer’s instructions, along with an N-Ter only blank control 
condition. Rat primary cortical neurons were SiRNAs in dilution buffer were mixed with N-TER 
transfection reagent, vortexed, incubated at room temperature in a darkened container for 20 minutes 
and added to the appropriate culture media. Cells were then washed with prewarmed HBSS or culture 
media before adding the media containing the siRNA transfection reagents. In the case of CTX0E16 
and hiPSC-derived neurons, cells were differentiated for 7 days, with a half media change occurring at 
day 4. Cells were assessed for transfection efficiency in the fluorescent control condition the day after 
transfection; all other conditions were fixed or harvested at day 7 of differentiation. In the case of the 
rat primary cortical neurons, cells remained in the siRNA media for 5 days after which they were 
processed for western blotting. Rat neurons were transfected with GFP under the control of a synapsin 
1 promotor (synGFP) three days after siRNA transfection using Lipofectamine 2000 (see Section 2.3.1 
above), double fixed at day 5 and processed for immunocytochemistry. 
2.4.2 TRANSFECTION EFFICIENCY 
 Transfection efficiency in all three cellular systems was assessed the day following siRNA 
transfection via live cell imaging using an inverted epifluorescence microscope with a 10x objective and 
manually performing cell counts of the number of cells expressing the fluorescent oligonucleotide 
relative to the total number of cells using the multi-point tool in ImageJ, with 3-5 FOV being imaged per 
well. In each cellular system three independent experiments were carried out, with two technical 
replicates per biological replicate for each experimental condition. 
2.5 COLLECTION OF CELL LYSATES AND WESTERN BLOTTING 
2.5.1 CELL LYSATES 
To collect protein samples, cells grown on 6 well Nunc plates were washed once with PBS and 
lysed with 150 µl of lysis buffer (see Table 2.4) containing the protease inhibitors 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF), leupeptin, pepstatin A, phosphatase inhibitor cocktail 
3 (Sigma), aprotinin and NaF. Protein samples were sonicated and spun at 15,000 rpm at 4°C for 15 
minutes to disrupt cell membranes. Supernatants were collected and the protein concentration of each 




2.5.2 SYNAPTOSOMAL PREPARATIONS 
Neurons treated were collected in ice cold RIPA buffer (75 µl/well): 10mM Tris pH 7.2; 150 mM NaCl; 
1% Triton x-100; 0.1% SDS; 1% Deoxycholate and 5mM EDTA pH8 containing protease and 
phosphatase inhibitors. Samples collected were sonicated with 2 pulses every few second for a total of 
approximately 8 to 10 pulses on ice, left on ice for 30 min and finally centrifuged at 15’000 rpm for 15 
min at 4°C. Neurons processed for crude synaptosomal preparation were collected at DIV25 in ice cold 
homogenisation buffer (300 µL/well): 320mM sucrose; 5mM Na4P2O7; 1mM EDTA; 10mM HEPES 
pH7.4 with freshly added protease and phosphatase inhibitors. Homogenates were centrifuged at 2000 
rpm for 5 min at 4°C to obtain the P1 (nuclear) and S1 (extra-nuclear) fractions. 100ul was removed 
from the S1 fraction and centrifuged at 13,000 rpm for 15 min at 4°C to obtain the P2 (crude 
synaptosome) and S2 (crude cytosol) fractions. P2 was dissolved in 300 µl homogenisation buffer. 
2.5.3 WESTERN BLOTTING 
For western blotting, samples (either cell lysates or synaptosomal preparations) were then 
mixed with 2x lamelli sample buffer in a 1:1 ratio; protein samples were then run on a 4% polyacrylamide 
gel (Biorad) for one hour at 110 mV to separate proteins according to size via electrophoresis. Proteins 
were then electrophoretically transferred to a polyvinylidine fluoride (PVDF) membrane at 100 mV for 
one hour at 4°C. Membranes were stained using Ponceau solution to assess the efficacy of protein 
transfer, before being washed twice in TBS-T (see Table 2.4 for composition), blocked for one hour in 
5% BSA in TBS-T and incubated with primary antibody (see Table 2.1) in 5% BSA TBS-T overnight at 
4°C on a rocker (unless otherwise indicated). Membranes were then washed a further 3 times with TBS-
T before being incubated with secondary antibody (see Table 2.1) in 5% BSA TBS-T for one hour at 
room temperature then washed in TBS-T a final 3 times. Finally, membranes were incubated in Pierce 
ECL Western Blotting Substrate (Thermo Scientific) for five minutes and then developed and processed 
for detection using exposure films in a dark room for varying exposure times. For the purposes of 
quantification, staining intensities were normalised against a β-Actin staining control to account for 





2.6 RNA PREPARATION, CDNA SYNTHESIS, RT-PCR AND Q-PCR 
2.6.1 RNA EXTRACTION AND CDNA SYNTHESIS 
Proliferative and differentiated CTX0E16 cells and hiPSC-derived neurons were pelleted and 
lysed using TRIzol reagent (Life Technologies) and total RNA extracted according to the manufacturer’s 
instructions. Each sample was lysed in 500 µl of TRIzol, frozen and stored immediately at -80°C. For 
RNA extraction, pellets were thawed at RT and left on ice for 5 minutes. 200 µl of 1-bromo-3-
chloropropane was added to each sample and the resulting mixture was spun at 20,000 rpm at 4°C for 
15 minutes. Supernatants were extracted and added to 500 µl of isopropanol to precipitate the RNA, 
and spun down as before. RNA pellets were washed twice with 70% ethanol and a final time with 100% 
ethanol, and dissolved in 20 µl of nuclease-free water. Residual genomic DNA was removed from each 
replicate using the TURBO DNA-free Kit (Life Technologies) according to published protocols. RNA 
concentrations were then measured in the purified samples using a NanoDrop ND1000 
spectrophotometer (Thermo Scientific). CDNA was synthesised from 750 ng of total RNA from each 
extraction using random hexamers and SuperScript III (Life Technologies), according to the 
manufacturer’s instructions. 
2.6.2 RT-PCR 
To determine the expression of specific genes, primer sequences from previously established 
amplicons were designed to target all known RefSeq transcripts of genes of interest, sourced from the 
UCSC Genome Browser website (http://genome.ucsc.edu) (see Table 2.3). Primer pairs producing 
amplicons of 80-120 bp were chosen to ensure compatibility with q-PCR experiments. Reactions were 
carried out in a total volume of 20 µl containing diluted cDNA, 1 X HOT FIREPol Blend Master Mix (Solis 
Biodyne) and primers at 200 nM, using a GS4 thermal cycler. Samples were separated and visualised 
via polyacrylamide gel electrophoresis. 
2.6.3 Q-PCR 
For quantitative expression analysis, 20 µl cDNA samples from SuperScript III reactions were 
diluted with a further 100 µl of nuclease-free H2O. Reactions were carried out in a total volume of 20 µl, 
containing diluted cDNA, 1× HOT FIREPol® EvaGreen® q-PCR Mix (Solis Biodyne) and primers at 200 
nM, using an MJ Research Chromo 4 (Bio-Rad) and MJ Opticon Monitor analytic software (Bio-Rad).  
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Triplicate q-PCR reactions were performed and averaged to measure each gene in each cDNA 
sample. For samples taken from siRNA knockdown experiments, normalised q-PCR target gene 
expression values were compared between siRNA-treated conditions and control conditions. Mean 
measures of target genes were normalised against a geometric mean determined from 3 control 
housekeeping genes for each cDNA sample to yield a relative target gene expression value for all 
samples. The Pfaffl method was used to calculate the relative difference in the normalised expression 
values of full-length ZNF804A across experimental conditions. In this method, the real time PCR 
efficiency calculated by the Opticon Monitor analytic software is used to control for any differences in 
reaction efficiency across samples which may over- or underestimate the relative expression of the 
target gene (Pfaffl, 2001). Housekeeping genes for CTX0E16 samples were identified as suitable 
internal controls on the basis of previously conducted whole-genome microarray data of CTX0E16 cells, 
where they showed the least variability (in terms of standard deviation) across conditions (Anderson et 
al., 2015). The amplification efficiency of each set of primers was also measured using a standard curve 
constructed by serial dilution of pooled cDNA from all assayed samples; only primer sets with 
efficiencies between 1.8 and 2.2 were used in order to ensure reproducibility of results. An efficiency 
value outside of these parameters indicates either an inefficient amplification reaction, or the 
amplification of non-specific products. A Kruskall-Wallis test with posthoc Dunn’s multiple comparisons 
test was performed on the normalised q-PCR data for relative expression of the full length ZNF804A 
transcript using Graphpad Prism. 
For assessments of relative gene expression in the CTX0E16 line in Chapter 4, the CT values 
for each gene was measured against a standard curve constructed by serial dilution of pooled cDNA 
from all assayed samples. A relative value was thus obtained for each of the three triplicate reactions 
for each cDNA sample. Mean measures of target genes were then normalised against a geometric 
mean determined from three internal control genes (GAPDH, HPRT1 and RPL13A) for each cDNA 
sample to yield a relative target gene expression value for all samples. These control genes were 
identified on the basis of previous whole-genome microarray data of CTX0E16 cells as described 
above. Normalised q-PCR target gene expression values were compared between proliferative (DD 0) 
or DD28 CTX0E16 cells. Student’s paired t tests were performed on the normalised q-PCR data for 
expression of each mRNA transcript in DD0 and DD28 cells using Graphpad Prism. 
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To determine relative expression values of ZNF804A transcripts in each cell line, normalised 
q-PCR target gene expression values were compared between proliferative (DD0) and DD28 CTX0E16 
cells, or between hiPSC-derived NPCS and DD35 hiPSC-neurons. Calculations of relative mRNA 
expression in these experiments were carried out using the 2^-dCT method (Livak and Schmittgen, 2001), 
as all probes showed similar PCR efficiencies (average efficiency ± SD: 1.95 ± 0.10 for CTX0E16 and 
1.87 ± 0.09 for probes for hiPSC-derived cells). dCT was calculated by dividing the difference between 
the average CT of the target transcripts in each maturation stage by the geometric mean from the best 
housekeepers for each cell line. A Kruskall-Wallis test with posthoc Dunn’s multiple comparisons test 
was performed on the normalised q-PCR data for relative expression of the full length ZNF804A 
transcript using Graphpad Prism. 
2.7 IMMUNOCYTOCHEMISTRY AND MICROSCOPY 
2.7.1 IMMUNOCYTOCHEMISTRY 
Prior to fixing, cells were washed once in warm PBS. Cells were then fixed in either 4% 
formaldehyde/4% sucrose in PBS at room temperature for 10 minutes, or in 4% formaldehyde/4% 
sucrose in PBS at room temperature for 10 minutes followed by two washes with PBS and incubation 
with pre-chilled (-20°C) methanol for 10 minutes 4°C. Methanol fixation was used to unmask proteins 
in lipid rich structures, such as the post-synaptic density (Glynn and McAllister, 2006). Cells were 
washed a further two times in PBS; where indicated, 50 mM of ammonium hydrochloride was added to 
the second of these washes to quench autofluorescence. Cells were blocked in PBS containing 2% 
normal animal serum (NAS; either goat or donkey serum being used depending on the antibody) with 
0.1% Triton X-100 (Sigma) for two hours at room temperature. Primary antibodies were added in PBS 
containing 2% NAS overnight at 4°C, followed by 3 x 15 minute washes in PBS. Cells were then 
incubated for a further hour in 2% NAS, before incubation with Alexa, 488, 568 or 633 secondary 
antibody (Life Technologies) diluted in PBS with 2% NAS for one hour at room temperature. Two further 
washes (15 minutes each) were performed before coverslips were washed once with PBS containing 
0.1% DAPI, and then mounted using ProLong antifade reagent (Life Technologies). A list of antibodies 




2.7.2 IMAGING OF ZFP804A IN MOUSE CORTICAL SECTIONS 
For in vivo assessment of Zfp804A expression in the mouse cortex, mice were anesthetised 
with sodium pentobarbital at 50 mg per gram of body weight, and fixed by transcardial perfusion of 4% 
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) at postnatal day 28 (P28). Brains were 
dissected out and sectioned into 50 mm coronal sections and immunostained with DAPI and a mouse 
anti-bassoon and a rabbit anti-ZNF804A (C2C3) antibody (see Table 2.1) as floating sections, before 
being mounted onto glass slides and covered with glass coverslips. Cells exhibiting Zfp804A staining 
were imaged by taking 1 mm serial optical sections, 35–45 optical sections per cell, using a Leica 
confocal microscope with a 40x objective (N.A. 1.3). Following acquisition, images were Z-projected 
and background subtracted using Metamorph. 3-4 images were taken of each cortical slice. 
2.7.2 EPILUORESCENCE AND CONFOCAL MICROSCOPY 
 For epifluorescent imaging, representative images were taken on a Zeiss Axio Imager Z1, 
equipped with an ApoTome and an AxioCam MR3 camera running AxioVision 4.7.1 imaging software 
(Carl Zeiss). Images were acquired using 10x, 20x and 40x objectives (N.A. 0.3, 0.8 and 0.75 
respectively). Images of double and triple labelled neurons were also obtained using a Leica SP5 
confocal microscope with 40x, 63x or 100x oil-immersion objectives (N.A. 1.25, 1.4 and 1.4 
respectively). Images were taken as a Z-series (Z-step = 0.5 µm for 40x images; 0.35 µm for 63x and 
100x images). All epifluorescence images were exported to ImageJ (http://imagej.nih.gov/ij/) where 
maximum intensity projections and background subtracted images were generated (Srivastava et al., 
2011). All confocal images were processed using MetaMorph software (Universal Imaging Corporation); 
Z-projections and background subtraction (via a statistical correction) were generated using a journal. 
In the green/purple and the green/red color schemes, colocalisation is indicated by white. Images were 
taken in the linear range, to allow an accurate representation. Some channels are shown individually in 
grey scale, or were pseudocoloured to emphasise areas of high staining intensity. Scale bars are 
described for each individual figure panel within figure legends. 
2.7.3 STRUCTURED ILLUMINATION MICROSCOPY 
 SIM imaging was carried out on primary rat cortical neurons transfected with GFP and co-
immunostained for ZNF804A (Genetex, C2C3) and either PSD-95 or GluN1. Images were acquired 
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with a Nikon N-SIM super-resolution microscope. Acquisition was performed in a 3D SIM mode using 
the 100X N.A. 1.49TIRF objective lens with 13-25 z-steps per stack at a step interval of 0.12 µm. Raw 
images were acquired on an Andor DU897 EMCCD camera at 512 x 512 pixels (62 nm pixel size in the 
image). Reconstructed images are displayed with 1024 x 1024 pixels (32 nm pixel size in the image). 
Image reconstructions were performed with Nikon N-SIM software. Final images, including z-projections 
and brightness and contrast adjustments were reconstructed in ImageJ and MetaMorph. 
2.7.4 ANALYSIS OF CELL IDENTITY MARKERS 
 Cell counts were performed using images acquired with either a Zeiss Axioimager or Olympus 
IX70 with a 20x objective (N.A. 0.8), with at least four fields of view (FOV) imaged per biological replicate 
per condition. Three biological replicates were imaged for each staining condition at each of the time 
points assessed, with 1-2 technical replicates for each. Z-stacks of 4 slices at 1 µm between each slice 
were Z-projected and the resulting projections were background subtracted. In all conditions, the DAPI 
channel was thresholded and regions of interest (ROI) were created around each nucleus and used to 
assess expression of MAP2 along with the various markers of cell identity via the average intensity of 
each area in the respective channels. The percentage of cells expressing each marker in each biological 
replicate was calculated relative to the total number of cells (DAPI positive cells) and the number of 
MAP2-positive cells. These percentages for each biological replicate were then averaged and the 
standard errors calculated. All image processing for the quantification of cell counts was performed 
using ImageJ, and all subsequent analysis of this data was performed using Microsoft Excel.  
2.7.5 ANALYSIS OF PUNCTA COLOCALISATION 
 Z-projected and background subtracted confocal stacks were acquired for DD28 CTX0E16 
cultures, DD35 hiPSC-neurons and DIV25 rat primary cortical cultures stained for MAP2, 
ZNF804A/Zfp804a and the postsynaptic markers PSD-95 or GluN1. For CTX0E16 and hiPSC-derived 
neurons, images in the ZNF804A and synaptic protein staining channels were thresholded and particle 
analysis was performed on 50 µm sections of MAP2-positive dendrites. Regions of interest were 
generated around the subsequent synaptic or ZNF804A-positive puncta, and average staining intensity 
for all other channels was measured within these regions. For rat primary cortical neurons, dendritic 
spines along 50 µm sections of dendrite were traced using MetaMorph software. Regions of interest 
were generated around each spine, and staining intensity of ZNF804A and synaptic markers was 
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recorded. Expression of a given protein within a region of interest was determined by whether staining 
intensity was greater than 20% of the maximum staining intensity recorded for all regions; this threshold 
was determined via qualitative assessment of the staining intensity of puncta deemed to be colocalising 
with other proteins. 
2.7.6 QUANTITATIVE ANALYSIS OF SPINE MORPHOLOGIES AND 
IMMUNOFLUORESCENCE 
 Confocal images of double-stained neurons were acquired with a Leica SP-5 confocal 
microscope using a 63x objective as a z-series as described previously. Two-dimensional maximum 
projection reconstructions of images were generated and morphometric analysis (spine number, area 
and breadth) was conducted using MetaMorph software (Srivastava et al., 2011). Morphometric 
analysis was performed on spines from at least two dendrites (secondary or tertiary branches), totaling 
100 µm, from each neuron. Linear density and total gray value of each synaptic protein cluster was 
measured automatically using MetaMorph (Srivastava et al., 2011). Cultures directly compared were 
stained simultaneously and imaged with the same acquisition parameters. For each condition, 9-
12 neurons from at least 3 separate experiments were used. Experiments were carried out blind to 
condition and on sister cultures. 
2.7.7 RELATIVE EXPRESSION OF ZNF804A 
 To determine the relative subcellular expression of ZNF804A using immunocytochemistry, DD0 
and DD28 CTX0E16 cultures were fixed, immunostained for ZNF804A and βIII-Tubulin and imaged 
using confocal microscopy with a 63x objective as described previously. 3-5 fields of view per technical 
replicate were imaged, with 1-2 technical replicates per biological replicate and 3 biological replicates 
overall being sampled. Regions of interest were traced around DAPI-positive cell nuclei as well as the 
cytoplasm of each cell used in analysis using ImageJ. Regions of interest were transferred to the 
ZNF804A staining channel and average staining intensities were measured for each ROI. For each cell, 
relative expression of ZNF804A in both the nuclear and cytoplasmic regions was normalised to an 
overall expression value for the whole cell. Values were averaged within each technical replicate and 
for all technical replicates within each biological replicate. Averages for each subcellular compartment 
were calculated for both DD0 and DD28 CTX0E16 cells. 
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2.8 CALCIUM IMAGING  
For experiments assessing the responsiveness of CTX0E16 cells to treatment with 
neurotransmitter ligands, cells were differentiated to DD28 on PDL (5 μg/ml) and laminin- coated (1 
μg/cm2) glass coverslips, then incubated with HEPES-buffered physiological saline solution (140 mM 
NaCl, 5 mM KCl, 2 mM CaCl2,1 mM MgCl2,10mM HEPES and 10 mM glucose, buffered to pH 7.4 
using 5 M NaOH) supplemented with 2.5 μM Fura-2AM and 1 mM probenecid (loading buffer) at 37°C 
for 60 minutes. This solution was then replaced with assay buffer (loading buffer minus Fura-2 AM and 
probenecid). Images of groups of cells were taken every 2 seconds using fluorescence microscopy with 
a 10x objective. Fluorescent signal was detected at the 520 nm emission wavelength following 
excitation at 340 and 380 nm using a microscope-based imaging system (Photon Technology 
International). Each experiment began with 2 minutes of baseline readings to allow cells to settle before 
the addition of the neurotransmitter ligand (dopamine, glutamate or acetylcholine; Sigma) at 1 mM, 
diluted in HEPES-buffered physiological saline solution. Cells were exposed to these compounds for 
one minute. Image analysis of individual cells by emission intensity ratios from 340 nm/380 nm 
excitation were performed using ImageMaster software (Photon Technology International).  
To investigate spontaneous Ca2+ transients in CTX0E16 neurons, cells were differentiated for 
42 days on coverslips, then loaded with 2 μM Fluo-4-AM dye (Life Technologies, Paisley, UK) in 
HEPES-buffered physiological saline solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl2,1 mM MgCl2, 10 
mM HEPES, 10 mM glucose and buffered to pH 7.4 using 5 M NaOH) supplemented with 0.02% 
Pluronic-F27 (Life Technologies) for 15 minutes at 37 °C. This was followed by washing in HEPES-
buffered physiological saline solution for a further 15 minutes at 37 °C. Fluo-4 fluorescence was time-
lapse-recorded at 1 second intervals with MetaMorph (Molecular Devices) on an Axiovert S100 
microscope (Carl Zeiss) equipped with appropriate filter sets (Chroma Technology), with a 40x (N.A. 
1.3) PlanNeofluar objective (Carl Zeiss) and a Photometrics Cascade-II 512B EMCCD. KCl (50 mM) 
and Tetrodotoxin (TTX; 1 μM), were diluted in HEPES-buffer and added to cells to give the final 
concentration. In all experiments, 10 μM ionomycin was added as a second stimulation for the dye 
loading control. Offline analysis of the intensity pattern of the Fluo-4 signal was performed in ImageJ. 
ROI were drawn around the soma of cells with clear dendritic processes. Spontaneous activity was 
categorised when at least one clear neuronal Ca2+ event was detected on an individual soma. Neuronal 
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calcium events were defined as a sharp transient increase in fluorescence intensity: Fluo-4, ΔF/F0 >5%, 
with a fast riseand slower decay. 
2.9 ELECTROPHYSIOLOGY  
 Electrophysiological recordings were obtained from CTX0E16 neurons, differentiated for 
between 29 and 61 days. Patch pipettes (4-7.5 MΩ) were pulled from borosilicate glass capillary tubes 
using a P97 Flaming/Brown Micropipette Puller (Sutter Instruments). The internal patch solution 
contained (in mM): 135 KGluconate, 10 KCl, 1 MgCl2, 10 HEPES, 2 Na2-ATP and 0.4 Na3-GTP. All 
recordings were conducted at room temperature. The external recording solution contained (in mM): 
139 NaCl, 2.5 KCl, 10 HEPES, 10 Glucose, 2 CaCl2, 1.3 MgCl2. For recordings in older cells (DD55-
DD61) electrophysiological recordings were conducted in neuronal differentiation medium. Whole cell 
voltage clamp recordings were conducted at a holding potential of -70mV in order to monitor 
predominantly α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor mediated 
spontaneous excitatory post synaptic currents (EPSCs) and at +40 mV to monitor EPSCs mediated by 
N-methyl-D-aspartate (NMDA) receptors. A stable access resistance was maintained between 20-35 
MΩ for the duration of these recordings with no series resistance compensation. In some cases, tight-
seal cell-attached recordings were conducted in order to monitor spontaneous action potential firing. In 
all experiments, corrections were made for liquid junction potentials offline. Data was generated and 
acquired using an EPC10 amplifier (Heka Instruments) and the software PatchMaster. Data was 
sampled at 15 kHz and filtered at 3 kHz. 
2.10 NEURONAL TREATMENT; CHRONIC NEURONAL DEPOLARISATION  
 Differentiation day (DD) 13 CTX0E16 neurons were transfected with eGFP using Lipofectamine 
2000 as described previously. At DD15, media was replaced with warm experimental media for each 
of the three experimental conditions: NDM supplemented with pure water, NDM supplemented with 30 
mM NaCl as an osmotic control or NDM supplemented with 30 mM KCl. Following 7 hours of exposure 
to the experimental media cultures were fixed and immunostained. Cells were imaged using a Zeiss 
fluorescence microscope with a 63x objective (N.A. 1.4) as described previously. Only cells with a 
neuronal morphology and more than one neurite were imaged for the purpose of assessing neurite 
length. 3-12 cells were imaged per condition per biological replicate, and 6 experiments were carried 
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out in total. Images were processed using ImageJ and neurites were traced using the NeuronJ plugin. 
Imaging and neurite tracing was carried out with the experimenter blinded to experimental condition.  
2.11 TREATMENT OF RAT PRIMARY CORTICAL NEURONS WITH CLTP 
Rat primary cortical neuron cultures were plated and cultured as described in Section 2.1.6 
until DIV25, then treated with ACSF supplemented with APV or ACSF supplemented with 10 µM glycine, 
100mM picrotoxin and 1 µM strychnine (inducing chemical LTP (cLTP)) (Xie et al., 2007) 30 minutes 
prior to fixation. Cultures were then double fixed in 4% FA and methanol and immunostained for DAPI, 
Genetex ZNF804A/Zfp804A and PSD-95 as a marker of mature neuronal cells (see Table 2.1). PSD-
95-positive neurons were imaged using confocal microscopy with a 100x objective to maximise Zfp804A 
staining quality. Of these image stacks, a single Z-plane which bisects the nuclei of the neurons to be 
assessed was selected and background subtracted for further analysis. ROI were then drawn around 
the nuclei and corresponding cytoplasmic regions for each PSD-95-positive neuron in these images 
and average Zfp804A staining intensity was recorded within each region.   
2.12 STATISTICS 
 For all graphs, bars represent means, and error bars as either standard deviations (S.D.) or 
standard error mean (S.E.M). To identify differences among means, statistical analyses (Student’s 
unpaired t-test, analysis of variance for parametric data, Kruskall-Wallis test for non-parametric data) 
were performed in either Excel or GraphPad Prism 5. Tukey post hoc analysis was used for multiple 










ANTIBODY COMPANY CATALOGUE 
NO. 
DILUTION 
chicken α GFP  Abcam ab13970 1:10000 
chicken α MAP2  Abcam AB104896 1:1000 
goat α ZNF804A (D-
14) 
Santa Cruz sc-241170 1:200 
mouse α Bassoon  Assay Design SAP7F407 1:300 
mouse α CaMKII  Abcam ab52476 1:500 
mouse α GluA2  NeuroMab/Antibody 
Inc 
L21/32 1:500 
mouse α GluN1  NeuroMab/Antibody 
Inc 
N308/48 1:500 
mouse α GM130  BD Biosciences 610823 1:250 
mouse α Nestin  Millipore MAB5326 1:500 
mouse α O4  Sigma O7139 1:1000 
mouse α PSD-95  NeuroMab/Antibody 
Inc 
K28/43 1:1000 
mouse α SAP97  NeuroMab/Antibody 
Inc 
K64/15 1:250 





mouse α SNAP-25  Synaptic-Systems 111 011 1:1000 
mouse α VAMP2  Synaptic-Systems 104 211 1:2000 
mouse α VGlut1  Millipore MAB5502 1:250 
mouse α ZNF804A Millipore MABN706 1:200 
mouse α βIII Tubulin  Millipore MAB1637 1:1000 
rabbit α Ankyrin G Abcam ab104896 1:500 
rabbit α Calbindin D-
28k  
SWant CB-38a 1:20000 
rabbit α Calretinin  SWant 7699/4 1:10000 
rabbit α Cux1  Santa Cruz sc-13024 1:500 
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Table 2.1: List of antibodies used in immunostaining experiments. 
 
rabbit α DISC1 (440) Custom N/A 1:200 
rabbit α Doublecortin  Abcam ab18723 1:500 
rabbit α GABA  Sigma A2052 1:1000 
rabbit α GAD65/67  Millipore AB1511 1:250 
rabbit α Gephyrin  Millipore AB5725 1:500 
rabbit α GluA1  Millipore AB1504 1:500 
rabbit α Glutamate  Sigma G6642 1:500 
rabbit α KI-67  Abcam ab15580  1:500 
rabbit α Neuroligin 3 Santa Cruz sc-50395 1:250 
rabbit α PSD-95 Cell Signalling 25075 1:1000 
rabbit α S100β  Dako M7221 1:500 
rabbit α SOX2 Millipore AB5603 1:100 
rabbit α Synapsin-1  Cell Signalling 5297 1:200 
rabbit α Tau  Dako A0024 1:500 
rabbit α Tbr1  Abcam ab31940 1:200 
rabbit α VGAT  Millipore AB5062P 1:300 
rabbit α VGlut2  Abcam ab101756  1:500 
rabbit α ZNF804A 
(C2C3) 
Genetex GTX130124 1:200 


















SIRNA ID  ZNF804A SIRNA#   SENSE SEQUENCE  
HSS150612 1 CCUAUAGCUGUAAUCCUCUAUGUUU 
HSS150613 2 CCAGGAGUUUGACAAUCACAUUAAU 
 Table 2.2: Sequence of siRNAs against ZNF804A.  
 
  
OLIGO SEQUENCE  
  
FORWARD (5'-3')  REVERSE (5'-3')  
Full length 
ZNF804A 
GAT TTG TCC CCA GTG 
CTT GT 
GCC TCT GGT GGA TGA 
AAA GA 
E3/E4 variant 
CAA GCC AAA ATG CGA 
GAA AAT ATT 
CCT TGT CGA GAG GTA 
AAC ACA ACA 
Variant 2.2 
GAA TGA GGC AGC ATG 
CAG TA 
TGG GAT CAA AGA CTG 
GGT TC 
HPRT1 
TGA CAC TGG CAA AAC 
AAT GCA 
GGT CCT TTT CAC CAG 
CAA GCT 
RPL13A 
CCT GGA GGA GAA GAG 
GAA AGA GA 
TTG AGG ACC TCT GTG 
TAT TTG TC 
RPL30 
ACA GCA TGC GGA AAA 
TAC TAC 
AAA GGA AAA TTT TGC 
AGG TTT 
SDHA 
TGG GAA CAA GAG GGC 
ATC TG 
CCA CCA CTG CAT CAA 
ATT CAT G 
B2M 
TAT CCA GCG TAC TCC 
AAA GA 
GAC AAG TCT GAA TGC 
TCC AC 
UBC 
ATT TGG GTC GCG GTT 
CTT G 
TGC CTT GAC ATT CTC 
GAT GGT 
GAPDH 
ATG GCA AGT TCA AAG 
GCA CAG TCA 
TGG GGG CAT CAG CAG 
AAG G 
GRIN1 
AGA TGG CTC TGT CGG 
TGT G 
GTG GGA GTG AAG TGG 
TCG TT 
GRIA2 
TTC AGA TGA GAC CCG 
ACC TC 
GCA CAG CTT GCA GTG 
TTG AT 
GRM1 CTA GCT GGC ATC TT 





TGG TTA TGA CAA TCG 
CCT GA 
CCG AAA CTG GTG ACG 
AAG AT 
DRD2 
ATC TCC TGC CCA CTC 
CTC TT 
TGA CAA TGA AGG GCA 
CGT AG 
CACNA1C 
CCT GAG AAT GAG GAC 
GAA GG 
GTT TTC GGT GTT GAC 
GGA CT 
DLG4 
TAT CCA GCG TAC TCC 
AAA GA 
GAC AAG TCT GAA TGC 
TCC AC 
CAMK2A 
GAG CCA TTC TCA CCA 
CGA TGC T 
TGG TGT TGG TGC TCT 
CTG AGG A 
PPP1R1B 
CTA CAC ACC ACC TTC 
GCT GA 
CTG AGG CCT GGT TCT 
CAT TC 
GSK3B 
AAA CTA CCA AAT GGG 
CGA GA 
CCG AGC ATG AGG AGG 
AAT AA 
SLC6A4 
GTG ATT GGC TAT GCT 
GTG GA 
GGT GTA GGG GAG GAG 
GAA TG 
DLX1 
GGA AGG GCT CAG GAG 
GAA AC 
TAG CTT CTT GGT GCG 
CTG AA 
EMX1 
CAG GAG AAA CAG GCT 
AGA CAT AG 
CCT GAT TCC CAC CTC 
TCA ATA C 
FOXG1 
AGA AGA ACG GCA AGT 
ACG AGA 
TGT TGA GGG ACA GAT 
TGT GGC 
GBX2 
GGC AAG GGA AAG ACG 
AGT CA 
GGG TCT TCC TCC TTG 
TGA GC 
ISL1 
AAG GAG GAC CGG GCT 
CTA AT 
GGA CTG GCT ACC ATG 
CTG TT 
NKX2.1 
GCA AAG AGG ACT CGC 
TTG TA 
AGT GAC AAG TGG GTT 
ATG TTG A 
OTX2 
GCA GAG GTC CTA TCC 
CAT GA 
GGT GAT GCA TAG GGG 
TCA AA 
PAX6 
TGT CCA ACG GAT GTG 
TGA GT 
TTT CCC AAG CAA AGA 
TGG AC 
TBR1 
GTG ATG GGT TTC CCA 
CTT CT 
GGG TGG ATT CTC CTT 
AGC TAT TT 
GAD1 
CCA ACA GCC TGG AAG 
AGA AG 
TCG CTG TTT TCA CAG 
GAA AG 




SOLUTION REAGENTS AND CONCENTRATIONS  
TBS-T 50 mM Tris, 150 mM NaCl, 0.05% Tween 20 
PBS 
137mM NaCl, 2.7mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4  
Lysis Buffer 
20mM Tris pH 7.2, 150mM   NaCl, 1.0% Triton X-100, 
5mM EDTA pH8. 
ACSF 
125 mM NaCl, 2.5 mM KCl, 26.2 mM NaHCO3, 1 mM 
NaH2PO4, 11 mM Glucose, 5 mM HEPES  
Homogenisation 
buffer 
320mM Sucrose, 5mM Sodium pyrophosphate, 1mM 
EDTA, 10mM HEPES pH7.4, 200nM Okadaic Acid, 1mM 
PMSF, 5mg/ml Aprotinin, 1µg/ml Pepstatin A, 10µg/ml 
Leupeptin, 1M NaF, 1:100Ser/Thr phosphatase inhibitor 
cocktail 3  














CHAPTER 3: DIFFERENTIATION OF 
EXCITATORY CORTICAL NEURONS 
FROM THE CTX0E16 NPC LINE 
3.1 SUMMARY  
This chapter describes the characterisation of a conditionally immortalised, cortically derived 
human NPC line, CTX0E16. CTX0E16 NPCs were assessed for expression of markers of functional 
and regional identity, as well as the potential to generate neurons following several weeks of 
differentiation. This chapter also describes the expression of markers of specific neuronal subtype 
and function in differentiated cultures, and key stages in the development of neuronal morphology in 
CTX0E16 cells. 
3.2 INTRODUCTION 
Recent advances in stem cell biology have led to the emergence of several powerful new 
paradigms for investigating both physiological and pathological processes in vitro (Bray et al., 2012). 
Specifically, the establishment of novel methods for the generation of human neuronal cultures has 
greatly facilitated our ability to study cellular and molecular mechanisms that may be unique to the 
human brain. This has provided a particular advantage in research into neuropsychiatric disorders such 
as schizophrenia, bipolar disorder and autism as these diseases present with several clinical features 
that can only be observed in humans (Gould and Einat, 2007; Nestler and Hyman, 2010; Powell and 
Miyakawa, 2006). Several studies have noted  alterations in the structure and function of glutamatergic 
and GABAergic neurons within the prefrontal cortex of patients with these disorders, particularly 
(Beneyto and Meador-Woodruff, 2008; Harrison, 1999; Howes et al., 2015; Rajkowska et al., 2001; Rao 
et al., 2012; Stone et al., 2016), a region of the brain that is particularly well developed in humans (Teffer 
and Semendeferi, 2012). Thus, a system using human cortical neurons may be optimal for modelling 
the mechanisms underlying these characteristic features. This chapter will focus on the use of hNPCs 
in particular as a platform for generating neuronal cultures for experimentation. 
Recently several clonal hNPC lines have been isolated from first trimester human foetal tissue 
and conditionally immortalised using retroviral integration of a c-mycERTAM construct (Pollock et al., 
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2006; Smith et al., 2011; Stroemer et al., 2009). One such line, CTX0E03, has been generated and 
subsequently utilised in several studies investigating the efficacy of NPC transplant in treating a rodent-
based model of ischaemic stroke (middle cerebral artery occlusion) (Pollock et al., 2006; Smith et al., 
2011; Stevanato et al., 2009; Stroemer et al., 2009), as well as in an investigation of the function of 
ZNF804A, a gene implicated in the pathophysiology of schizophrenia and bipolar disorder (Hill et al., 
2011). A sister cell line to CTX0E03, CTX0E16, has been generated from the same first trimester foetus 
using the same technique, and has been identified as a potential candidate for investigating similar 
mechanisms of neuropsychiatric disease (Anderson et al., 2015). This cell line is the focus of the 
present chapter. 
In order to determine the suitability of the CTX0E16 hNPCs for use in studying the mechanisms 
underlying the alterations in neuronal structure and function seen in neuropsychiatric disease, these 
cultures must first be characterised to establish whether they are capable of generating cells with key 
neuronal phenotypes. It is thus critical to determine whether these cell cultures can 1) robustly 
differentiate into glutamatergic neurons in vitro; 2) display functional responses to activation of 
neurotransmitter signalling systems; 3) form putative synapses; and 4) are able to respond to activity-
dependent stimulations in the anticipated manner. This chapter will discuss the characterisation of the 
first of these phenotypes in the CTX0E16 cell line. 
Previous studies have established whether comparable cell lines are capable of generating 
functional neurons by testing for several phenotypes following differentiation. These include determining 
whether differentiated cells express neuronal markers such as Tau, MAP2 or βIII-Tubulin (Tuj1) and 
are negative for markers of proliferation (BrdU, ki67) or stem cell identity (Sox2, nestin) (Cacci et al., 
2007; Cocks et al., 2013; Donato et al., 2007; Pollock et al., 2006; Zhang et al., 2008). Once positive 
expression of neuronal markers can be established, markers of regional and functional identity were 
also assessed. These included determinants of excitatory/inhibitory identity, markers specific to 
neurons derived from subregions of the central nervous system, and markers of astrocytic and 
oligodendrocytic identity to determine whether differentiated cultures contained pure or mixed 
populations of cells (Cacci et al., 2007; Cocks et al., 2013; Donato et al., 2007; Pollock et al., 2006; 
Zhang et al., 2008). The development of neuronal morphology has also been used as an indicator of 
cell identity, with the polarisation of the cell, outgrowth of axons and dendrites and establishment of 
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putative synapses being cited as critical aspects of neuronal differentiation and identifiers of neuronal 
identity in vitro (Barnes and Polleux, 2009; Dotti et al., 1988; Gaspard et al., 2008; Marchetto et al., 
2010; Pollock et al., 2006; Verpelli et al., 2013). 
This chapter details a characterisation of the cellular identity of CTX0E16 NPCs and neurons. 
Proliferative and differentiated (DD28) cultures of CTX0E16 cells were assessed for expression of 
proliferation, stem cell identity and neuronal identity markers in order to determine whether NPCs adopt 
a neuronal fate after four weeks of culturing with differentiation media. NPCs and differentiated cells 
were also assessed for relative expression of glial markers to determine the proportion of differentiated 
cultures made up by neurons and astrocytes. Following this, cells positive for neuronal markers were 
further characterised by investigating co-expression of markers of excitatory and inhibitory neurons, 
superficial- and deep-layer cortical neurons, and various synaptic proteins to determine their regional 
and functional identity. Finally, cells were qualitatively assessed at several stages throughout 
differentiation to determine whether they recapitulated critical aspects of the development of cortical 
neuron morphology, including neurite outgrowth, polarisation of the cell, a pyramidal cell soma, 
specialisation of dendrites and axons and the establishment of putative synaptic structures. 
3.3 RESULTS 
3.3.1 OPTIMISATION OF DIFFERENTIATION PROTOCOL FOR CTX0E16 NPCS 
Neurons derived from human stem cell sources can typically take several weeks to display the 
key aspects of neuronal function, such as neuronal morphology, expression of synaptic proteins, and 
the development of functional synapses (Donato et al., 2007; Verpelli et al., 2013). Thus, it is critical to 
establish whether pre-existing protocols for the differentiation of CTX0E16 cells are capable of 
maintaining cultures for several weeks without significant deterioration or cell death.  
Modified plating and differentiation protocols were assessed for their viability in producing long term 
neuronal cultures without excessive proliferation thought to contribute to overcrowding and subsequent 
culture death. Overcrowding of neuronal cultures also renders evaluation via immunocytochemistry 
problematic due to the difficulty of resolving individual cells among overconfluent cultures. Thus, 
cultures generated using several modified forms of this differentiation protocol were assessed for 
markers of proliferation following 5 days of differentiation in order to develop a differentiation protocol 
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which minimises the risk of overcrowding and cell death in CTX0E16 cultures. Six culture conditions 
were assessed for expression of the proliferative marker ki67 and the early neuronal marker MAP2 5 
days after exposure to differentiation media (DD5): 
1. Cells were plated in RMM+++ and media was switched to NDM three days later. 
2. Cells were plated in RMM+++ and media was switched to NDM one day later. 
3. Cells were plated in RMM+++ and media was switched to NDM one hour later. 
4. Cells were washed in HBSS and plated in NDM as in the original protocol. 
5. As condition 4, but with a complete media change one hour after plating. 
6. As condition 4, but with a complete media change one day after plating. 
(see Figure 3.3.1, A-F). Of the six conditions assessed, condition 2 was found to have the lowest 
proportion of ki67-positive cells in comparison to the other five conditions (mean ± SEM: 31.48 ± 2.24% 
of cells vs 52.71 ± 5.27%, 36.19 ± 2.38%, 40.20 ± 3.43%, 35.06 ± 2.31% and 32.79 ± 1.90% for 
conditions 1, 3, 4, 5 and 6 respectively). Very little difference was seen in the relative proportion of 
MAP2-positive cells in each condition (83.84 ± 4.18%, 84.69 ± 4.04%, 85.31 ± 2.09%, 84.12 ± 2.59%, 
83.73 ± 2.37% and 85.83 ± 3.02% for conditions 1, 2, 3, 4, 5 and 6 respectively) (see Figure 3.3.1, G). 
Condition 2 was also found to produce the lowest density cultures, with an average of 53.00 ± 5.60 cells 
per FOV compared to 56.00 ± 8.90, 101.25 ± 10.37, 85.75 ± 6.92, 64.38 ± 4.02 and 63.29 ± 5.78 cells 
per FOV for conditions 1, 3, 4, 5 and 6 respectively (see Figure 3.3.1, H). Taken together, these findings 
suggest that differentiation protocol 2 is the most optimal condition to generate long term cultures of 
differentiating CTX0E16 cells. The lower density of the cultures at DD5 in this condition indicates that 
these cultures will be easier to assess via experimental methods using immunofluorescence techniques 
at later stages of differentiation. The lower proportion of ki67-positive cells indicates that cells cultured 
using this protocol exit the mitotic cycle sooner than those cultured under other conditions; this suggests 
that these cultures are less likely to become overcrowded at later time points. As a further measure to 
reduce cell density in mature cultures of CTX0E16 cells, all subsequent experiments were plated at a 
quarter of the initial density used (12,500 cells per well of a 24 well plate). This did not appear to 
negatively impact long term culture viability. 
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Figure 3.3.1: Optimisation of CTX0E16 plating protocol. A-F: CTX0E16 cells were plated according to 
one of six different plating conditions as detailed in Section 3.3.1, differentiated for 5 days and stained 
for DAPI, MAP2 and ki67. Yellow arrows indicate ki67-positive cells, white arrowheads indicate MAP2-
positive cells. G: Quantification of proportion of CTX0E16 cells staining positive for each marker in each 
plating condition. Condition 2 resulted in the lowest proportion of ki67-positive cells after 5 days of 
differentiation. H: Average number of DAPI-positive nuclei per FOV in each plating condition. Condition 
2 resulted in the lowest cell density after five days of differentiation. Scale bar = 20 µm, bar graphs show 
mean ± SD. 
3.3.2 CHARACTERISATION OF DIFFERENTIATION IN THE CTX0E16 CELL LINE 
Following the initial establishment of optimal conditions for prolonged culturing of the cell line, 
a characterisation of markers of cellular identity was carried out on cultures of proliferative (DD0) and 
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differentiated (DD5 or DD28) CTX0E16 cells. Previous studies have focused on the downregulation of 
proliferative and stem cell markers and the upregulation of postmitotic neuronal and astrocytic markers 
as a means of assessing the efficiency of differentiation of neurons from proliferative hNPC lines (Cacci 
et al., 2007; Donato et al., 2007; Zhang et al., 2008). To investigate this in the CTX0E16 cell line, 
proliferative (DD0) and differentiated (DD28) CTX0E16 cells were fixed and immunostained for DAPI, 
the NPC marker Nestin, the astrocytic marker S100β and the neuronal markers MAP2 and Tau. DD0 
and DD5 CTX0E16 cells were additionally stained for the proliferative marker ki67, to determine whether 
proliferation is rapidly reduced following the switch to differentiation media. These cultures were 
assessed for expression of each marker according to the method detailed in Section 2.7.4. In DD0 
cultures, 91.41 ± 5.22% of cells were positive for the proliferative marker ki67 while only 52.82 ± 3.28% 
of cells were ki67 positive by DD5; analysis of this data with a Student’s unpaired t test revealed this 
difference to be significant (p<0.001) (see Figure 3.3.2, A, B & K). Thus, CTX0E16 proliferation is 
rapidly reduced following the introduction of differentiation media. 
Analysis of expression of the neural progenitor cell marker nestin in DD0 and DD28 CTX0E16 
cultures indicated that 39.04 ± 9.54% of proliferative cells and 63.75 ± 5.58% of differentiated cells were 
positive for this marker (see Figure 3.3.2, C, D & L). This finding was surprising in that it seemed to 
imply that a greater proportion of cells in the differentiated cultures were positive for a marker of neural 
stem cell identity. However, further assessment of the pictures taken of nestin staining in these cultures 
suggested that analysis using nuclear regions of interest is susceptible to an overestimation of the 
number of nestin-postive cells in later stage cultures due to 1) the higher density of the cultures and 2) 
large processes from nestin-positive cells overlapping nestin-negative cells. This would compound an 
underestimation of the number of nestin-positive cells in proliferative cultures due to nestin staining 
being primarily localised to non-nuclear regions of the CTX0E16 NPCs (see Figure 3.3.2, C & D).  
S100β-positive cells accounted for only a subset of both proliferative and differentiated 
CTX0E16 cultures, with 2.77 ± 0.38% of DD0 cultures and 8.46 ± 2.08 of DD28 cultures staining positive 
for the marker (see Figure 3.3.2, E, F & L). Analysis of this data with a Student’s unpaired t test did not 
find this difference to be significant (p>0.05). This finding suggests that only a small subset of cells in 
proliferative and differentiated cultures are astrocytes. 
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MAP2-positive cells accounted for 2.92 ± 0.24% of the DD0 cultures and by DD28 this had 
increased to 68.21 ± 6.66% of all cells; this increase was also reflected in the number of Tau-positive 
cells, with 8.05 ± 1.07% of DD0 cells increasing to 65.28 ± 5.61% of DD28 cells staining positive for 
Tau. Analysis of this data with two Student’s unpaired t tests did found both of these differences to be 
significant (p<0.001, see Figure 3.3.2, G-L). Taken together, these data indicate that neuronal cells 
make up the majority of CTX0E16 cultures by day 28 of differentiation. 
Taken together, these findings suggest that CTX0E16 NPCs represent a robust source from 
which cultures of neurons can be continually differentiated, with the majority of cells ceasing proliferation 
soon after being switched to differentiation media. Interestingly, a small subset of these differentiated 
cultures is comprised of astrocytes; attempts at varying culture conditions for the cell line to attempt to 
minimise or increase the proportion of astrocytes in differentiated cultures may be a fascinating avenue 






Figure 3.3.2 (overleaf): Differentiation of CTX0E16 cells. A-J: Representative images of 
immunostaining for the proliferative marker ki67 (A & B), the neural stem cell marker Nestin (C & D), 
the astrocytic marker S100β (E & F), and the neuronal markers Tau (G & H) and MAP2 (I & J) in 
proliferative (left columns) and differentiated (right columns) CTX0E16 cultures. K: Quantification of 
the number of ki67-positive cells as a percentage of total cells; n = approximately 1,500 cells from three 
independent experiments carried out in triplicate; error bars represent SD; ***p <0.001 (Student’s 
unpaired t test). L: Number of proliferative (DD 0) or differentiated (DD 28) cells positive for Nestin, 
S100β, Tau or MAP2; N = approximately 1,500 cells from three independent experiments carried out in 
triplicate; error bars represent SD; ***p <0.001 (unpaired t tests). 
3.3.3 CHARACTERISATION OF NEURONAL SUBTYPES AND FUNCTIONAL MARKERS 
IN DIFFERENTIATED CTX0E16 CULTURES 
Following the preliminary finding that a majority of CTX0E16 cells are neuronal in four-week-
differentiated cultures, a similar investigation was undertaken into the functional and regional identity of 
these neurons. Previous characterisations of human NPC lines have assessed the relative expression 
of excitatory and inhibitory markers, as well as various neurotransmitters, cortical region markers and 
markers of various synaptic proteins to determine whether these cell lines are suitable models of 
specific neuronal subtypes (Cacci et al., 2007; Donato et al., 2007; Verpelli et al., 2013; Zhang et al., 
2008). As the CTX0E16 cell line has been cortically-derived and proposed as a platform to conduct 
studies of mechanisms of glutamatergic dysfunction in neuropsychiatric disease (Anderson et al., 
2015), it is therefore critical to establish whether the neurons generated from this cell line have a specific 
cortical identity, whether they are glutamatergic and whether they produce excitatory synapses. DD28 
CTX0E16 cultures were and immunostained for DAPI, MAP2 and one of several neuronal subtype 
markers. These included the excitatory, glutamatergic markers VGlut1 and CaMKIIα and the inhibitory, 
GABAergic markers Calretinin, Calbindin-D28k, VGAT and GAD65/67 (see Table 3.3.5 for a list of 
these markers and their biological functions). 75.25 ± 8.74% of DD28 CTX0E16 neurons were found to 
also co-express the glutamatergic neuron marker VGlut1, while 67.09 ± 10.15% of these neurons co-
expressed CaMKIIα (see Figure 3.3.3, A, B & G). Both of these markers exhibited a punctate pattern 
of staining in both the cell bodies and along neurites of MAP2-positive neurons (see Figure 3.3.3, A & 
B) suggesting the presence of functional excitatory synapses (Herzog et al., 2006). In contrast to this, 
only 44.58 ± 11.09% of neurons expressed VGAT and 39.30 ± 11.51% of neurons were positive for 
GAD65/67 (see Figure 3.3.3, C, D & G). Moreover, only a fraction of the neuronal population of DD28 
CTX0E16 cultures expressed calretinin or calbindin (1.03 ± 0.18% and 2.13 ± 0.40% of neurons 
79 
 
respectively; see Figure 3.3.3, E-G). However, the distribution of calretinin and calbindin in these 
neurons reflects the pattern of localisation seen in previous research (DeFelipe, 1997; Rogers, 1992). 
VGAT and GAD65/67 were expressed in a punctate pattern around the cell soma of MAP2-positive 
neurons, consistent with previous studies (Schwab et al., 2013). Taken together, these data indicate 
that CTX0E16 cultures predominately produce excitatory, glutamatergic neurons following 28 days of 




Figure 3.3.3 (overleaf): Differentiation of CTX0E16 cells generates glutamatergic and GABAergic 
neurons. A-F: Representative images of differentiated (DD28) CTX0E16 neurons stained with the 
neuronal marker MAP2 and the glutamatergic markers VGlut1 (A) and CaMKII (B) and the GABAergic 
interneuron markers GAD65/67 (C), VGAT (D), Calretinin (E) and Calbindin (F). Yellow arrows indicate 
neurons staining positive for these markers. G: Quantification of A-F revealed that over 65 % of MAP2-
positive neurons also expressed VGlut1 or CaMKIIα, whereas less than 45 % of MAP2-neurons were 
also positive for either GAD65/67 or VGAT, and less than 10% of MAP2-positive neurons were positive 
for Calretinin or Calbindin; n = approximately 1,500 cells per condition from three independent 
experiments carried out in triplicate; error bars represent SD. Scale bars = 20 µm. 
triplicate; error bars represent SD; ***p <0.001 (unpaired t tests). 
3.3.4 EXPRESSION OF REGIONAL MARKERS IN CTX0E16 CULTURES 
The expression of both GABAergic and glutamatergic markers in differentiated cultures of 
CTX0E16 cells was perhaps surprising given that in the human brain these neurons typically originate 
from different regions of the developing telencephalon: glutamatergic neurons in the cortex are 
generated by progenitors located within the ventricular zone of the dorsal telencephalon (Hansen et al., 
2010; Stiles and Jernigan, 2010) while GABAergic cortical neurons derive from ventral telencephalic 
regions known as the medial, lateral and caudal ganglionic eminences (Ma et al., 2013; Radonjić et al., 
2014). Although the CTX0E16 cell line is reported to be a clonal population, the heterogeneity of 
neurons within the differentiated cultures may be indicative of a mixed population of progenitors derived 
from both dorsal and ventral regions of the developing telencephalon. Thus, to identify the lineage of 
the CTX0E16 line RNA samples were taken from proliferative (DD0) and differentiated (DD28) cultures 
and assessed for expression of several regional NPC and neuronal markers using semi-quantitative 
RT-PCR. The markers included genes expressed in the dorsal telencephalon during development: 
EMX1, OTX2 and PAX6; genes expressed in the ventral telencephalon: DLX1, NKX2.1 and GBX2; and 
neuronal markers: FOXG1, TBR1, GAD1 and ISL1 (see Table 3.3.4 for a list of these markers and their 
biological functions). Interestingly, markers of both dorsal and ventral telencephalic identity could be 
detected in proliferative and differentiated CTX0E16 cultures, suggesting that the CTX0E16 line may 
indeed be comprised of a mixed population of progenitors with different regional identities (see Figure 
3.3.4, A & B). Moreover, markers of both GABAergic and glutamatergic cortical neuron identity were 
detected in differentiated CTX0E16 cultures, further supporting the possibility of multiple lineages being 
present within the CTX0E16 line (Figure 3.3.4, A & B). Semi-quantitative analysis of the normalised 
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RT-PCR bands for each gene of interest suggested that relative expression of dorsal telencephalon 
markers increased in differentiated CTX0E16 cultures relative to proliferative cultures; Student’s t tests 
with posthoc Bonferonni-Sidak correction for multiple comparisons revealed that these increases in 
expression were significant (p<0.05). 
EMX1 and TBR1 were not found to be significantly upregulated following several weeks of 
differentiation, an unexpected result given that typically these genes are highly expressed in terminally 
differentiated cortical projection neurons. However, semi-quantitative analysis of RT-PCR results may 
not be sensitive enough to detect changes in expression across multiple time points; such techniques 
are typically better suited to determine the presence rather than level of expression of a given gene. To 
more accurately evaluate the pattern of expression of these two genes in CTX0E16 NPCs and neurons, 
RNA samples were again taken from DD0 and DD28 CTX0E16 cultures and assessed via q-PCR to 
determine whether expression of these genes was significantly altered following several weeks of 
differentiation. q-PCR analysis revealed a significant increase in the dorsal forebrain marker EMX1, and 
the cortical marker TBR1 28 days after differentiation (Figure 3.3.4, C), indicating that a significant 
proportion of CTX0E16 NPCs were differentiating into neurons with a cortical identity. 
Following this initial assessment of regional marker expression, a previously-conducted 
microarray of proliferative (DD0) and differentiated (DD28) CTX0E16 RNA samples was re-analysed to 
confirm the findings of the RT-PCR and to expand the number of markers assessed as a means of 
better identifying the putative regional identity of CTX0E16 progenitors. To improve the reliability of 
analysis, data for probes which did not detect expression of a given gene in all samples were removed 
from the overall dataset. Student’s t tests were conducted on the data for each individual gene to 
determine whether expression had significantly altered following several weeks of differentiation, with 
subsequent FDR correction to account for multiple comparisons. Not all of the regional markers 
assessed using RT-PCR could be observed in the microarray data; this may be due to one or more of 
the biological replicates exhibiting insufficient expression at a given time point.  
Of the genes present in both analyses, PAX6 exhibited a significant increase in expression after 
four weeks of differentiation (FDR-corrected p<0.05), reflecting the trend seen in the RT-PCR data 
(Figure 3.3.4, D). DLX5 exhibited a significant increase in expression following four weeks of 
differentiation (FDR-corrected p<0.05) as assessed by microarray, reflecting the previous findings via 
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RT-PCR. NKX2.1 showed no significant changes in expression after differentiation, in contrast to the 
RT-PCR data which demonstrated a significant increase in expression in the neuronal cultures relative 
to CTX0E16 NPCs. FOXG1 expression did not differ in differentiated cultures as compared to NPC 
cultures, similarly to the findings of the RT-PCR. Surprisingly, ISL1 expression decreased significantly 
in the differentiated CTX0E16 cultures relative to the NPC stage (FDR-corrected p<0.05), in contrast to 
the RT-PCR data which did not demonstrate any significant alterations in expression. Finally, GAD1 
expression significantly increased in CTX0E16 cultures after four weeks of differentiation, as assessed 
by microarray (FDR-corrected p<0.05); again this was in contrast to the RT-PCR data, which did not 
detect any significant changes in expression. Overall, despite some discrepancies in the findings of the 
microarray relative to semi-quantitative analysis of RT-PCR data, both investigations found expression 
of dorsally- and ventrally expressed telencephalic markers, as well as markers of excitatory and 
inhibitory cortical neurons. This further supports the conclusion that the CTX0E16 cell line represents a 
heterogenous population of NPCs comprised of both dorsal and ventral telencephalic progenitors. 
The expression of several other markers of regional and functional identity was further explored 
in the microarray dataset (see Table 3.3.4 for a list of these markers and their biological functions) 
(Figure 3.3.4, D). Differentiation of CTX0E16 cells for several weeks was accompanied with a 
significant upregulation of DCX, a marker of newborn cortical neurons, and GFAP, expressed in neural 
progenitor cells and astrocytes (FDR-corrected p<0.05 for both genes). This upregulation was 
accompanied with a concommittant downregulation of the proliferative marker MKI67 and the neural 
stem cell marker NES (FDR-corrected p<0.05 for both genes). Surprisingly, the neural progenitor 
marker SOX2 was found to significantly increase expression in CTX0E16 cultures after four weeks of 
differentiation (FDR-corrected p<0.05). Expression of SP8, a marker of cortical interneurons, was found 
to be significantly upregulated in differentiated CTX0E16 cultures relative to CTX0E16 NPCs (FDR-
corrected p<0.05). Other genes expressed in cortical interneurons including MASH1 and CTIP1 were 
similarly upregulated after four weeks of differentiation (FDR-corrected p<0.05 for both genes). BRN2, 
a gene expressed in upper layer neurons of the cortex, was further found to be significantly upregulated 
in CTX0E16 neuronal cultures relative to the NPC stage (FDR-corrected p<0.05), though this was not 
similarly seen with CUX1 expression, another marker of upper layer cortical neurons. Overall, these 
additional markers support the findings of Section 3.3.2 and the previous RT-PCR, indicating that not 
only do CTX0E16 cultures lose their stem cell identity and differentiate into mixed cultures of neuronal 
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and non-neuronal cells, but also that this NPC line is comprised of a mixed population of NPCs from 
both the dorsal and ventral telencephalon. 
 
Figure 3.3.4: Expression of markers of regional identity in proliferative and differentiated CTX0E16 
cultures. A: RT-PCR of markers expressed in defined regions of the developing forebrain, including the 
dorsally-expressed telencephalic markers EMX1, OTX2 and PAX6, the ventrally-expressed 
telencephalic markers DLX1, GBX2 and NKX2.1 and the neuronally-expressed genes FOXG1, TBR1, 
GAD1 and ISL1. Expression of all markers was seen in both proliferative and differentiated CTX0E16 
cultures. B: Quantification of RT-PCR bands seen in A, with the mean intensity of each band normalised 
to intensity values for two housekeeping genes obtained from the same RNA sample. N = 3 biological 
replicates per time point; error bars represent SD; *p<0.05, Student’s t test. C: Quantitative PCR (q-
PCR) analysis revealed an increase in the expression of dorsal forebrain marker, EMX1 and cortical 
neuron marker TBR1 in DD 28 CTX0E16 neurons compared to DD 0 cells; n = 4 independent 
experiments carried out in triplicate; error bars represent SD; ***p <0.001 (Student’s unpaired t test). D: 
Heat map of relative expression of selected markers derived from a microarray of samples taken from 
proliferative (DD0) and differentiated (DD28) CTX0E16 cultures. Green = higher relative expression, 
red = lower relative expression. N = 3 biological replicates per time point, *FDR-corrected p<0.05, 
Student’s unpaired t test. Previous microarray data was generated by Rodrigo R. Duarte and analysed 




3.3.5 DIFFERENTIATION OF CTX0E16 CULTURES PREDOMINATELY PRODUCES 
CORTICAL NEURONS WITH A LOWER CORTICAL LAYER IDENTITY 
The upregulation of BRN2 expression in differentiated CTX0E16 cultures is suggestive of the 
production of upper layer cortical neurons (Shi et al., 2012b). To further investigate whether CTX0E16 
cultures produced neurons with layer-specific identities, DD28 CTX0E16 cultures were immunostained 
for markers expressed in both deep and superficial cortical layer neurons: Tbr1, Cux1 and Ctip2 (see 
Table 3.3.4 for a list of these markers and their biological functions). Analysis of regional neuronal 
markers in the DD28 neurons determined that 41.58 ± 6.45% of MAP2-positive cells costained for the 
marker of deep-layer cortical neurons, Ctip2. In contrast to this, only 3.57 ± 1.32% of MAP2-positive 
neurons were also positive for Cux1, a marker of upper-layer cortical neurons (Molyneaux et al., 2007) 
(See Figure 3.2.5, D), reflecting the low expression of CUX1 seen in the previous microarray. 
Assessment of the pattern of staining with these markers indicated that expression was restricted to the 
nucleus of CTX0E16 cells, consistent with previous in vivo studies (Shi et al., 2012a) (see Figure 3.2.5, 
A & B). 77.82 ± 12.23% of MAP2-positive cells were also positive for Tbr1 staining, another marker of 
deep-layer cortical neurons (Molyneaux et al., 2007) (see Figure 3.2.5, D). However, further qualitative 
assessment of images of Tbr1-stained cultures indicated that this finding may have been due to non-
specific binding of the Tbr1 antibody, as the pattern of Tbr1 staining did not match that observed in 
previous studies (Shi et al., 2012a). The Tbr1 protein acts as a transcription factor, and thus expression 
of this protein would typically be restricted to the nuclei of positive neurons. However, the antibody used 
in the present study appeared to stain nuclei, cytoplasm and neurites evenly, indicating that analysis 
using this antibody may not be reliable (see Figure 3.2.5, C). Despite this, the data obtained using the 
Ctip2 and Cux1 antibodies indicates that the majority of neurons differentiated from the CTX0E16 cell 
line have a deep cortical layer identity, with a subset adopting a superficial-layer fate.  
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Figure 3.3.5: Differentiation of CTX0E16 cultures predominately produces cortical neurons with a lower 
cortical layer identity. A-C: Representative images of differentiated CTX0E16 cultures stained for the 
neuronal marker MAP2 and the deep layer cortical neuron markers Ctip2 (A) and Tbr1 (C) and the 
upper layer cortical neuron marker Cux1 (B). Yellow arrows indicate neurons staining positive for these 
markers. D: Quantification revealed that 41.6 % of MAP2-positive neurons expressed Ctip2, whereas 
less than 10 % of MAP2-labelled neurons were positive for Cux1. Note: although ~75% of MAP2-
positive neurons appeared to also costain for Tbr1, closer assessment of the immunostaining images 
revealed non-specific staining in the neurites of CTX0E16 cells (C, yellow arrows). N = approximately 
1,500 cells per condition from three independent experiments carried out in triplicate; error bars 
represent SD. Scale bars = 20 µm. 
3.3.6 EXPRESSION OF EXCITATORY SYNAPTIC MARKERS IN CTX0E16 NEURONS 
In light of the evidence indicating that differentiated CTX0E16 cultures generated excitatory 
cortical neurons, the expression of excitatory synaptic proteins was assessed in these cells to determine 
whether they produce key components of glutamatergic synapses, a hallmark of mature excitatory 
neurons. DD28 CTX0E16 cultures were immunostained for the postsynaptic proteins PSD-95, SAP97, 
GluN1 and GluA2 (see Table 3.3.4). Analysis of synaptic protein immunostaining revealed that PSD-
95 and SAP97 expression occurred in 50.30 ± 8.46% and 55.59 ± 8.22% of DD28 MAP2 positive cells 
respectively (see Figure 3.3.6, E). However, further assessment of the pattern of SAP97 staining in 
high magnification confocal images revealed that this staining was non-specific, indicating that the 
findings for this marker were not reliable (Figure 3.3.6, B). The glutamatergic receptor subunit proteins 
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GluN1 and GluA2 were expressed in 49.33 ± 8.51% and 37.95 ± 8.61% of neurons in DD28 CTX0E16 
cultures respectively. PSD-95, GluN1 and GluA2 exhibited punctate staining within the cell bodies and 
along the MAP2-positive dendrites of CTX0E16 neurons, reflecting the pattern of localisation seen in 
previous research (see Figure 3.3.6, C-E). These data indicate that even after only 28 days of 
differentiation, CTX0E16 neurons are already expressing key components of the glutamatergic 
postsynaptic density, in addition to the presynaptic glutamatergic protein VGlut1 and GABAergic 
proteins GAD65/67 and VGAT, described previously. 
Taken together, these data demonstrate that CTX0E16 cultures predominately produce 
excitatory, glutamatergic neurons expressing both pre- and post-synaptic components of excitatory 
synapses, with a subset of neurons adopting a GABAergic interneuron identity. Generally, neurons also 
expressed the deep-layer cortical marker Ctip2, reflecting the relatively immature stage of cortical 




Figure 3.3.6 (overleaf): Differentiated (DD28) CTX0E16 cells express postsynaptic markers and 
glutamatergic receptor proteins. A-D: Representative images of differentiated CTX0E16 cultures 
stained for the neuronal marker MAP2 and the postsynaptic density proteins PSD-95 (A) and SAP97 
(B) and the glutamatergic receptor proteins GluN1 (C) and GluA2 (D). Note: SAP97 immunostaining 
appeared to be non-specific and so quantification with this marker is unlikely to be representative of 
actual expression levels. E: Quantification revealed that ~50 % of MAP2-positive neurons expressed 
the synaptic markers PSD-95, GluN1 or GluA2. N = approximately 1,500 cells per condition from three 
independent experiments carried out in triplicate; error bars represent SD. Scale bars = 20 µm. 
3.3.7 DEVELOPMENT OF NEURONAL MORPHOLOGY IN DIFFERENTIATING 
CTX0E16 CULTURES 
Following these promising early results, an investigation was then conducted into whether 
CTX0E16 cells recapitulate key stages in the development of neuronal morphology during 
differentiation. Previous in vitro studies have found that primary rodent neuronal cultures are capable 
of generating unipolar neurons, with distinct primary and secondary dendrites akin to the apical and 
basal dendrites seen in vivo (Dotti et al., 1988; Horton et al., 2005; Threadgill et al., 1997). The 
development of a polarised neuronal morphology in vitro can be subdivided into four phases: the initial 
outgrowth of several processes; the specification of an axonal process; the specification of the other 
processes into dendrites; and the maturation of both axon and dendrites and subsequent 
synaptogenesis (Dotti et al., 1988; Fukata et al., 2002). This section will detail the investigation of the 
progressive development of key stages of neuronal morphology in CTX0E16 cells during differentiation. 
To investigate the development of early development of neuronal morphological characteristics, 
DD0, DD2 and DD4 CTX0E16 cultures were immunostained for the marker of immature neurons and 
hNPCs, βIII-Tubulin (Tuj1). To assess later-stage neuronal morphology, CTX0E16 cultures were also 
transfected at DD13, DD18 and DD33 with a CMV-driven pEGFP construct. A qualitative examination 
of the transfected cells at each time point revealed that DD15 CTX0E16 cells were capable of 
developing the triangular somatic morphology consistent with that of cortical pyramidal neurons in vivo 
(see Figure 3.2.7, D) (Dichter, 1978; Kriegstein and Dichter, 1983). These cells also possessed neurites 
with multiple branch points at this stage. By DD20 neurites with distinct dendritic and axonal 
characteristics could be observed (Figure 3.2.7, E); a single long, thin process with a relatively uniform 
diameter extending from the soma (consistent with axonal morphology) and multiple shorter tapering 
processes reminiscent of early-stage dendrites (Fukata et al., 2002). Typically one of these dendrites 
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would extend from the apex of the cell soma much further than the others, similar to the polarisation of 
apical and basal dendrites seen on cortical pyramidal neurons in vivo (McAllister, 2000). By DD35 these 
dendrites had developed complex arbors and even some small filopodial protrusions protruding from 
the dendritic shaft, similar to the morphology of immature dendritic spines in vivo and in vitro (García-
López et al., 2010; Irwin et al., 2001) (see Figure 3.2.7, F-H).  
Figure 3.3.7: Differentiated CTX0E16 neurons display morphological features of pyramidal neurons. A-
C: Generation of small neurites in βIII Tubulin (Tuj1)-positive CTX0E16 cells after 2 or 4 days of 
differentiation. D-F: Expression of green fluorescent protein (GFP) in young CTX0E16 neurons, reveals 
the development of neuronal morphology; at DD15, neurite processes extend from the cell’s soma (D). 
By DD20, a single long and thin process can be seen emerging from the cell soma with a thicker single 
process also emerging from the opposite side. Note the pyramidal shape of the cell soma. F: By DD35, 
the dendritic process displays some level of arborisation; additional smaller processes protruding from 
the cell soma are also evident. G & H: Representative confocal images of a distal dendrite of GFP-
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expressing CTX0E16 neurons (DD35). Examination of dendrites revealed the presence of filopodia 
(white arrow heads) and dendritic spine-like structures (red arrows), indicative of ongoing 
synaptogenesis. Yellow boxes indicate region used in high magnification in inset. Scale bars = 20 μm 
(A-F), 5 μm (G & H) & 1 μm (G & H, inset). 
Taken together, these observations suggest that cells from the CTX0E16 line are capable of 
developing several key features of cortical neuron morphology after several weeks of differentiation. 
Crucially, these cells also develop filopodial protrusions consistent with early dendritic spine 
morphology, suggesting that CTX0E16 neurons may be capable of producing functional synapses. This 
avenue of inquiry is expanded on and discussed in Chapter 4. 
3.3.8 POLARISATION OF SUBCELLULAR STRUCTURES IN CTX0E16 NEURONS 
Following the initial findings of a polarised morphology in GFP-transfected CTX0E16 cultures, 
an investigation was conducted into the polarisation of the trans-Golgi apparatus in differentiated 
CTX0E16 neurons, another hallmark of the development of cortical neuron morphology in vivo and in 
vitro (Horton et al., 2006, 2005). Typically the trans-Golgi network localises to the apical dendrite of 
pyramidal neurons in vivo (Horton et al., 2005; Srivastava et al., 2012); interestingly, this phenomenon 
is also recapitulated in the primary dendrites of primary neuronal cultures (Jones et al., 2014; Srivastava 
et al., 2012). To confirm whether this polarisation also occurred in differentiated CTX0E16 neurons, 
DD35 CTX0E16 cultures were immunostained for the dendritic marker MAP2 and the cis-Golgi network 
protein GM130. The majority (83.89±4.55%) of MAP2-positive cells were found to have GM130 staining 
within the cell soma (see Figure 3.2.8, A). Notably, in the majority (81.96±4.96%) of these cells this 
staining was oriented towards a single MAP2-positive dendrite, typically the longest of the dendrites, 
consistent with a polarised neuronal morphology. Moreover, GM130 staining occasionally extended into 
this dendrite, consistent with the formation of primary dendrites and secretory networks seen in 
functional neurons in vivo and in vitro (Figure 3.2.8, B) (Horton et al., 2005). These findings further 
indicate that after several weeks of differentiation, CTX0E16 cultures are capable of generating neurons 
with a polarised morphology consistent with that of cortical pyramidal neurons in vivo. 
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Figure 3.3.8: Differentiated CTX0E16 neurons exhibit polarisation of intracellular organelles. A: Double 
immunostaining of DD 35 CTX0E16 neurons for the trans-Golgi marker, GM130 and MAP2. In MAP2-
positive neurons, GM130 is clearly seen orientated towards a single, typically the longest, dendrite (red 
arrows). This indicates the primary dendrite, and the formation of a polarised morphology). B: High-
magnification images reveal that the Golgi-network is present along the primary dendrites (red arrow). 
Scale bars = 20 μm (A) & 5 μm (B). 
3.4 DISCUSSION 
This chapter has provided data on the optimisation of several protocols using the CTX0E16 cell 
line, and subsequently has shown the application of these protocols in the characterisation of the cell 
line at various time points during differentiation, via assessments of the expression of markers of cellular 
identity and synaptic proteins and an evaluation of the progressive development of key aspects of 
neuronal morphology. Taken together, these experiments have demonstrated that differentiation of the 
CTX0E16 cell line successfully produces pyramidal glutamatergic neurons and GABAergic 
interneurons, and these cells recapitulate the critical phases in the development of neuronal morphology 
that may be further studied in the context of neuropsychiatric disease-relevant mechanisms at the 
cellular level. 
As a significant number of the experiments in this body of work involved the use of the CTX0E16 
cell line, it was crucial to establish the optimal culture conditions to differentiate these NPCs for long 
periods of time without excessive cell density or cell death impacting the viability of this line as a tool 
for studying cellular phenomena. To this end, the optimisation of transfection and immunocytochemistry 
protocols was also of critical importance as a large proportion of the subsequent experiments in this 
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thesis rely on both of these techniques to investigate the cell line in later chapters. The successful 
application of transfection protocols to neurons of the CTX0E16 line proved highly valuable in the 
assessment of CTX0E16 morphology in this chapter, and this protocol may be a useful method for 
assessing the function of psychiatric disease-associated proteins via overexpression in further 
experiments. 
Evidence has been presented indicating that CTX0E16 NPCs are multipotent, being capable 
of differentiating into mixed cultures primarily consisting of glutamatergic and GABAergic neurons, but 
also possessing a subset of astrocytes. The heterogeneity of differentiated CTX0E16 cultures was 
particularly interesting given that this line is reportedly derived from just a single NPC and therefore 
ostensibly a clonal population. During the development of the human forebrain glutamatergic neurons 
are generated by neural progenitors located within the ventricular zone of the pallium and migrate 
radially to form the cortical plate. In contrast to this, GABAergic interneurons are derived from separate 
populations of progenitors located within the subpallium: the medial, lateral and caudal ganglionic 
eminences as well as the preoptic area (Hansen et al., 2013; Ma et al., 2013). Newborn interneurons 
migrate along tangential routes into the neocortex, then switch to radial migration as they move to 
specific layers of the developing cortex (Ma et al., 2013). Each of these progenitor populations 
expresses a distinct set of regional markers; thus the putative lineage of NPCs from the CTX0E16 line 
may be determined on the basis of whether or not these cultures express dorsal or ventral telencephalic 
markers, and subsequently whether differentiated CTX0E16 neurons express markers of the neuronal 
populations known to arise from specific regions of the developing telencephalon.  
Surprisingly, proliferative CTX0E16 cultures were shown to express not only markers seen in 
dorsal telencephalon progenitors such as EMX1, OTX2 and PAX6, they were also demonstrated to 
express ventral markers including NKX2.1, GBX2 and DLX1. Moreover, differentiated CTX0E16 
cultures also simultaneously expressed ISL1, a marker typically expressed in lateral ganglionic 
eminence progenitors and striatal projection neurons (Stenman et al., 2003); and TBR1, expressed in 
cortical projection neurons (Englund et al., 2005). These findings were further reflected in data collated 
from a microarray of proliferative and differentiated (DD28) CTX0E16 cultures showing expression of 
markers of both the dorsal and ventral telencephalon, including several additional markers not included 
in the RT-PCR experiment. Taken together, these data suggest that rather than being a clonal 
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population derived from a single cell from a specific region of the developing telencephalon, the 
CTX0E16 line may instead be comprised of a mixed population of both dorsal and ventral telencephalic 
progenitors, which later differentiate into glutamatergic and GABAergic cortical neurons respectively. 
However, the simultaneous expression of dorsal and ventral telencephalic markers in a reportedly clonal 
line may also be an artefact of an in vitro culture system wherein these progenitors are not subjected 
to the influence of the same extracellular milieu as would be seen in human telencephalic development 
in vivo. Moreover, the simultaneous expression of markers indicative of multiple regional NPC identities 
may also be a consequence of the reprogramming process whereby the CTX0E16 cell line is 
conditionally immortalised following integration of the c-mycERTAM transgene into the host genome. 
Neural progenitor cells in the developing human forebrain can be further sub-divided into 
separate classes with distinct temporal and functional properties. Neuroepithelial progenitors are the 
first of these populations in the cerebral cortex, and give rise to radial glial cells (RGCs), a class of 
progenitors which subsequently produces all the excitatory neurons of the cortex (Otani et al., 2016). 
RGCs can produce neurons either directly via mitosis or indirectly via the generation of one of two 
further classes of progenitor cells: intermediate/basal progenitor cells (IPCs) or outer radial glial cells 
(oRGCs) (Otani et al., 2016). Each of these classes of progenitor can be distinguished from each other 
via the expression of distinct combinations of transcription factors, their morphology, their localisation 
within the developing cortical plate and the presence or absence of inter kinetic nuclear migration 
(IKNM) during mitosis. RGCs are found within the ventricular zone of the developing primate cortex, 
express neural stem cell and astroglial markers, exhibit both apical and basal processes and, unlike 
IPCs and oRGCs, display IKNM during mitosis (Ladran et al., 2013). IPCs are found primarily (but not 
exclusively) within the inner subventricular zone of the developing cortex, are typically PAX6-and TBR2-
positive and typically exhibit no apical or basal processes (Betizeau et al., 2013; Englund et al., 2005; 
Otani et al., 2016). In contrast to this, oRGCs are found within the outer subventricular zone of the 
developing cortex, are typically PAX6-positive but TBR2-negative and can be further subclassified 
according to the exhibition of apical and/or basal processes (Betizeau et al., 2013). oRGCs have 
previously been suggested to contribute to the differences in cortical size between humans and other 
primates (Betizeau et al., 2013; Otani et al., 2016), and thus may be of particular interest in the study 
of cortical mechanisms underlying human psychiatric diseases. However, the identification of each of 
the above NPC populations in CTX0E16 cultures is problematic for several reasons: as the CTX0E16 
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cultures do not form neural rosettes, as in the case of 2D hiPSC cultures undergoing neuralisation, it is 
not possible to establish NPC identity via an assessment of localisation to a particular region of the 
cortex or any other analogous structure. Moreover, the lack of polarity in the NPC cultures may preclude 
the identification of directional processes in the CTX0E16 cells as an indicator of NPC subtypes. Finally, 
although TBR2 and PAX6 expression can be used generally to distinguish between IPC and oRGC 
populations in vivo and in polarised cultures, these markers are not specific enough to determine the 
identity of progenitor populations in non-polarised cultures in vitro (Betizeau et al., 2013; Otani et al., 
2016; Shi et al., 2012a). In addition to this, analysis of the CTX0E16 microarray in Section 3.3.4 did 
not produce any data on TBR2 expression in this line. Future investigations utilising the CTX0E16 cell 
line may therefore benefit from the identification of markers specific to the oRGC and IPC populations. 
Among the glutamatergic neurons within the differentiated CTX0E16 cultures, VGlut1 was 
observed in the cell soma of a large proportion of these cells. Although typically VGlut1 is not found in 
the cell soma of excitatory neurons, instead being limited to the presynaptic bouton (Herzog et al., 2006; 
Real et al., 2006), previous studies have found VGlut2 to be expressed within the cytoplasm of immature 
mouse neurons derived from embryonic stem cells and in vivo (Illes et al., 2009; Real et al., 2006). One 
possible explanation for this may be that the somatic localisation is due to an accumulation of synaptic 
proteins during early development and immediately prior to axogenesis and synaptogenesis. Thus, the 
presence of VGlut2 within the cell body of immature neurons may have arisen from the accumulation 
of synaptic proteins which are to be subsequently transported into the developing axon to facilitate 
synaptogenesis. This may also be the reason for the somatic localisation of VGlut1 seen in the relatively 
immature CTX0E16 neurons used in the present investigation.  
Interestingly, MAP2-positive neurons in the differentiated CTX0E16 cultures were found to 
predominately express Ctip2, a marker expressed in deep layer neurons (Shi et al., 2012b). In contrast 
to this, the upper layer marker Cux1 was not found to be expressed at high levels in DD28 CTX0E16 
neurons via ICC and microarray, though surprisingly expression of BRN2, another marker of upper layer 
neurons, was found to be upregulated after several weeks of differentiation in this microarray. A 
previous investigation conducted by Gaspard et al. (2008) using neural progenitor cells generated from 
mouse ESCs found that neurons expressing markers of specific cortical layers differentiated 
sequentially from these NPCs in a manner that mimicked the stages of cortical development in vivo. 
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Neurons expressing markers of deep cortical layers differentiated first, with superficial-layer markers 
being expressed by neurons that differentiated from the NPCs at a later time point. This has also been 
demonstrated in neurons differentiated from human iPSC lines (Paşca et al., 2011; Shi et al., 2012b). 
Given the relatively early developmental time point being assessed in the CTX0E16 cell line, neurons 
generated from these NPCs at later stages of differentiation may therefore preferentially express 
markers of upper layer neurons such as Cux1 rather than the lower layer markers seen in the present 
experiment, though time constraints precluded this experiment during the confines of the current study. 
If the sequential generation of cortical neurons with distinct layer-specific expression profiles is 
demonstrated in the CTX0E16 line in future experiments then this will indicate that these cells provide 
a useful model of the mechanisms of cortical development, similarly to ESC and iPSC methods but 
bypassing the ethical concerns and lengthy transduction process associated with these paradigms 
respectively (Brennand et al., 2014; Jakel et al., 2004). However, despite these interesting results it 
should be noted that Ctip2 expression has also been previously observed in GABAergic interneurons 
of the striatum, which in the human brain are derived from neural progenitors within the lateral ganglionic 
eminence of the ventral telencephalon (Arlotta et al., 2008). Given that CTX0E16 NPCs were found to 
express markers of the lateral ganglionic eminence (see Section 3.3.4), and that a relatively large 
proportion of differentiated CTX0E16 cells also express GABAergic markers, this may alternately 
account for why the number of Ctip2-positive neurons is comparatively high. 
The development of key aspects of neuronal morphology during differentiation was also 
assessed using several experimental paradigms. Ultimately, CTX0E16 cultures were shown to be 
capable of generating cells which recapitulated several key phases in the establishment of neuronal 
morphology, including the initial outgrowth of several neurites, the specialisation of a single axon and 
multiple dendrites, an increase in dendritic arbour complexity and even the development of filopodia 
reminiscent of immature dendritic spines, further supporting the evidence suggesting that cells from the 
CTX0E16 cell line may be capable of generating functional synapses. Early neurite outgrowth is a 
critical stage in the development of neuronal morphology, and a wide range of proteins implicated in 
psychiatric disease are known to influence this process including Shank3 and Disc1 (Durand et al., 
2012; Hattori et al., 2010). The early stages of CTX0E16 differentiation may therefore be a useful target 
for genetic and molecular manipulations in order to determine the role of other psychiatric disease-
associated proteins in modulating this crucial developmental process. This experimental paradigm is 
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further explored in Chapter 6, where the impact of the siRNA-mediated knockdown of a protein linked 
to autism, schizophrenia and bipolar disorder, ZNF804A, on early neurite outgrowth in CTX0E16 
neurons is assessed. 
Dendritic spines are the primary site of excitatory glutamatergic neurotransmission within the 
mammalian forebrain. Alterations in the number and morphology of these spines within certain regions 
of the cortex are known to feature in autism spectrum disorders, bipolar disorder and schizophrenia 
(Hutsler and Zhang, 2010; Konopaske et al., 2014; Marchetto et al., 2010a; Sweet et al., 2009a), These 
changes are thought to underlie the altered connectivity demonstrated in these disorders, and ultimately 
may be a significant component of their overall etiology (Penzes et al., 2011). The demonstration of 
putative dendritic spines in neurons differentiated from the CTX0E16 line suggests that this line may be 
of use in studies of the genetic and molecular underpinnings of this spine pathology. However, the 
relative paucity of spines in DD35 CTX0E16 neurons currently precludes their use in such experiments 
at this developmental stage, and further differentiation may be required before spines are expressed in 
sufficient numbers to permit quantification. However, the punctate staining of several excitatory and 
inhibitory synaptic proteins seen along the MAP2-positive neurons in this study suggests that immature 
synapses may yet still be present on these neurons, and assessments of puncta density may therefore 
be a useful approximate marker of synapses in the CTX0E16 line in future studies. Dendritic spines 
have previously been demonstrated in neurons derived from human ESC and iPSC sources (Espuny-
Camacho et al., 2013; Marchetto et al., 2010b), though neurons derived from these cells typically 
require multiple months of differentiation before the first of these spines appear. Clearly, optimisation 
of differentiation protocols for these lines and CTX0E16 cells to promote more rapid spinogenesis will 
be a critical area for further study in order to maximise their potential in future investigations of the 
cellular pathology underlying neuropsychiatric diseases. 
 Taken together, these data suggest that CTX0E16 cultures offer a useful platform for 
generating cultures of excitatory cortical neurons from a human source. This cell line provides a reliable 
method of continually generating mixed cultures comprised predominately of glutamateric and 
GABAergic cortical neurons and therefore may be of considerable use in studies of excitatory and 
inhibitory dysfunction underlying severe psychiatric disease. However, further work is first required to 
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determine whether these neurons are capable of producing physiological responses to chemical and 
pharmacological stimuli, as well as generating functional synapses, key hallmarks of neuronal identity. 
To address these issues, Chapter 4 will focus on characterising the functional responses to a 
variety of chemical stimuli in neurons from the CTX0E16 cell line, as well as the development of critical 
features of synaptic structure and function in these cells. This chapter will also discuss the relevance of 
these findings in relation to the study of psychiatric disease pathology, specifically that of schizophrenia 


















MARKER CELL TYPE LABELLED FUNCTION 
VGlut1 Canonical glutamatergic 
neurons; excitatory synapses 
Vesicular glutamate transporter 1; key 
component of glutamatergic 
neurotransmission apparatus. 
CaMKIIα Excitatory pyramidal neurons Ca2+/calmodulin-dependent protein kinase II; 
key component of several intracellular 
signalling cascades and involved in long term 
potentiation. 
VGAT Inhibitory GABAergic and 
glycinergic neurons; inhibitory 
synapses 
Vesicular GABA transporter; key component 
of GABAergic neurotransmission apparatus. 
GAD65/67 GABAergic interneurons Glutamate decarboxylase; responsible for 
synthesis of GABA in inhibitory interneurons. 
Calretinin Cortical interneurons Calcium binding protein involved in calcium 
signalling. 
Calbindin-D28k Cortical interneurons Calcium binding protein involved in calcium 
signalling. 
Tbr1 Deep layer cortical neurons Transcription factor involved in the regulation 
of neuron differentiation and migration. 
Cux1 Superficial layer cortical neurons DNA binding protein involved in the regulation 
of gene expression, morphogenesis and 
differentiation. 
Ctip2 Deep layer cortical neurons Regulates neuronal differentiation. 
PSD-95 Post-synaptic density marker of 
neurons 
Post-synaptic density scaffolding protein 95; 
core component of synapses 
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SAP97 Post-synaptic density marker of 
neurons 
Synapse-associated protein 97; involved in 
neurotransmitter receptor trafficking in 
neurons. 
GluN1 Glutamatergic synapses in 
neurons. 
NMDA receptor subunit 1; key component of 
glutamatergic neurotransmission. 
GluA2 Glutamatergic synapses in 
neurons. 
AMPA receptor subunit 2; key component of 
glutamatergic neurotransmission. 
Emx1 Cortical neurons and dorsal 
telencephalon progenitor cells 
Transcription factor regulating telencephalic 
development. 
Foxg1 Telencephalic progenitor cells 
and neurons 
Transcription factor regulating telencephalic 
development. 
Otx2  Neural progenitor cells in the 
forebrain and midbrain 
Transcription factor regulating patterning of 
the forebrain/midbrain during development. 
Pax6  Neural progenitor cells in the 
dorsal forebrain 
Transcription factor involved in several 
developmental processes in the CNS. 
Gad1 Cortical interneurons Enzyme involved in the production of GABA 
from glutamate. 
Dlx1 Lateral ganglionic eminence 
progenitor cells 
Transcription factor regulating interneuron 
differentiation. 
Isl1 Lateral ganglionic eminence 
progenitors and early striatal 
projection neurons 
Transcription factor regulating cholinergic 
neuron identity 
Nkx2.1 Progenitor cells within the medial 
ganglionic eminence 




Dcx Newborn cortical neurons Microtubule-associated protein involved in 
cytoskeletal stabilisation during early 
neuronal maturation. 
GFAP Neural progenitor cells and 
astrocytes 
Intermediate filament protein regulating cell 
shape. 
Gbx2 Progenitor cells in the hindbrain Transcription factor involved in hindbrain 
development. 
Nestin Neural stem cells Intermediate filament protein regulating 
cytoskeletal remodelling. 
MASH1 Cortical interneurons Transcription factor involved in medial and 
lateral ganglionic eminence patterning and 
differentiation. 
SP8  Cortical interneurons from the 
lateral and caudal ganglionic 
eminences 
Transcription factor regulating patterning of 
the telencephalon. 
Brn2 Upper layer neurons of the cortex Transcription factor involved in the production 
of neocortical neurons. 









CHAPTER 4: DEVELOPMENT OF 
SYNAPSES AND FUNCTIONAL 
CHARACTERISTICS IN CTX0E16 
NEURONS 
4.1 SUMMARY 
This chapter details the further functional characterisation of differentiated neurons from the 
CTX0E16 cell line, in particular the development of functional synapses and physiological attributes 
consistent with mature neurons in vivo. The expression of numerous synaptic proteins, including several 
which have been strongly implicated in the pathological mechanisms underlying neuropsychiatric 
disorders, is shown in differentiated CTX0E16 neurons. The pattern of synaptic protein expression in 
these neurons was consistent with previous findings showing that neurons diiferentiated from the 
CTX0E16 line adopt a predominately glutamatergic fate. This chapter also describes spontaneous and 
evoked physiological phenomena in CTX0E16 neurons: these cells are found to exhibit morphological 
plasticity in response to prolonged depolarisation, adopt functional Ca2+ responses to several 
neurotransmitters, exhibit spontaneous fluctuations in intracellular Ca2+ concentrations and produce key 
electrophysiological events including action potentials. 
4.2 INTRODUCTION 
The characterisation of neural lineages and the development of neuronal morphology in the 
CTX0E16 cell line in the previous chapter provided a valuable insight into the composition and function 
of CTX0E16 cultures, both during proliferation and after several weeks of differentiation. However, in 
order to determine whether differentiated CTX0E16 cells adopt the features of mature, cortical neurons 
it is critical to establish whether these cells develop functional synapses as well as the specific 
electrophysiological properties and responses to physiologically relevant stimuli consistent with those 
observed in previous in vivo research and in neuronal cultures derived from comparable cell lines. 
The generation of synapses is a critical step in the differentiation of neurons during the 
development of the cerebral cortex (Huttenlocher and Dabholkar, 1997). The formation of synapses 
involves the recruitment and functional integration of a wide variety of scaffolding, intracellular signaling 
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and neurotransmitter receptor proteins at the presynaptic bouton and postsynaptic density (Tada and 
Sheng, 2006). The expression of synaptic proteins in a discrete “punctate” immunostaining pattern has 
been commonly used as a marker of putative synapses in previous in vitro and in vivo studies (Johnson 
et al., 2007; Pinches and Cline, 1998; Silver and Stryker, 1999; Washbourne et al., 2004; Woolfrey et 
al., 2009). Research into the properties of neurons differentiated from cortically-derived hNPCs have 
attempted to investigate the expression of synaptic proteins as markers of neuronal subtypes, including 
those corresponding to specific regions of the brain; or as markers of specific categories of synapses 
(Carpenter et al., 1999b; Lin et al., 2015; Zhang et al., 2008). 
A characterisation of the expression and distribution of synaptic proteins in neurons derived 
from the CTX0E16 hNPC line will similarly be a critical experiment to assess neuronal identity and 
functionality in this line as well as highlighting the suitability of the cell line as a platform for investigating 
synaptogenesis and synaptic mechanisms in human neurons. As several proteins expressed at the 
synapse have been implicated in disease pathways in neuropsychiatric disorders (Penzes et al., 2011), 
establishing whether these proteins are expressed in the CTX0E16 cell line would be an important step 
in ascertaining the suitability of the CTX0E16 cell line in studies of neuropsychiatric disease 
mechanisms at the cellular and molecular level.  
Morphological plasticity in response to neuronal activity or depolarising stimuli is another well 
characterised feature of mature neurons in vitro; neurite outgrowth and growth cone assays in particular 
have been used in a number of studies to assess this plasticity (Cohan and Kater, 1970; Fields et al., 
1990; Krey et al., 2013; Schilling et al., 1991). Assessing this phenomenon in the CTX0E16 cell line 
would ideally require an experimental paradigm which has previously been successfully employed in a 
comparable human cell line.  
Calcium responses have previously been used in numerous studies as a proxy marker of 
neuronal activity in response to treatment with neurotransmitters and depolarising stimuli (Nunes et al., 
2003; Zhang et al., 2008). Calcium imaging can also be used as a means of investigating oscillations 
in intracellular calcium concentration in neurons. These oscillations are reflective of calcium influx via 
voltage-gated calcium channels following spontaneous neuronal activity and are a hallmark of 
functional, mature neurons (Cocks et al., 2013; Murphy et al., 1992). This method of assessing neuronal 
activity has been employed in previous studies of neuronal cultures differentiated from immortalised 
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human NPC lines (Cocks et al., 2013), and may therefore provide additional valuable information about 
the functional properties of differentiated CTX0E16 neurons. However, an electrophysiological 
assessment is likely to produce a more direct and detailed profile of these properties. Several facets of 
the electrophysiological makeup of the mature neuron have been used in previous studies as an 
indicator of neuronal and synaptic maturity in neuronal cultures generated from hNPC, hES and hiPSC 
lines, specifically postsynaptic currents, action potentials and the development of a mature resting 
potential (Gaspard et al., 2008; Johnson et al., 2007; Nunes et al., 2003; Paşca et al., 2011; Pedrosa 
et al., 2011). Taken together, an assessment of these features in CTX0E16 neurons would provide 
critical information on whether these cells are able to replicate key neuronal phenomena necessary for 
their regular functioning in vivo. 
This chapter describes the further characterisation of neuronal cultures generated from the 
CTX0E16 cell line, in particular focusing on the development of synapses, electrophysiological 
characteristics and functional responses to neuronal activity-inducing stimuli. To investigate the 
development of synapses, DD28 CTX0E16 neurons were qualitatively assessed for the expression of 
a wide variety of inhibitory and excitatory synaptic proteins (as well as several neuropsychiatric disease-
relevant proteins) in discrete puncta consistent with synaptic immunostaining in vivo. Colocalisation of 
pre- and postsynaptic protein puncta was also assessed in these neurons as a putative marker of fully 
formed synapses. Expression of several genes coding for key synaptic and intracellular signalling 
proteins was also quantified in proliferative and differentiated CTX0E16 cultures via q-PCR. 
morphological plasticity of differentiating CTX0E16 cells in response to depolarising stimuli was 
Intracellular fluctuations in calcium concentration in response to treatment with activity-inducing or –
blocking stimuli as well as spontaneous calcium oscillations were also assessed in differentiated 
cultures as a means of determining whether CTX0E16 neurons exhibited Finally, the 
electrophysiological characteristics of CTX0E16 neurons were assessed at several time points of 
differentiation. Taken together, these lines of inquiry provided a more thorough understanding of the 
neuronal cells generated from the hNPC line, the synaptic and electrophysiological properties of these 
neurons, and ultimately showed that this cell line provides an ideal platform from which to launch 





4.3.1 DIFFERENTIATED CTX0E16 NEURONS EXPRESS KEY PRESYNAPTIC AND 
POSTSYNAPTIC PROTEINS 
Glutamatergic synapses comprise the majority of inter-neuronal connections between 
pyramidal cells in the mammalian forebrain (Robinson, 1998). A key feature of mature, functional 
glutamatergic neurons is the presence of pre- and post-synaptic structures containing a wide range of 
key synapse-specific proteins including neurotransmitter receptor proteins (McAllister, 2007). Previous 
studies have utilised the expression of synaptic proteins as a marker of neuronal maturity in vitro. 
However, in cultures derived from hNPCs characterisation of synaptic protein expression has 
historically been superficial or entirely lacking from characterisation studies (Carpenter et al., 1999b; 
Lin et al., 2015; Zhang et al., 2008). Thus, a thorough assessment of synaptic protein expression in the 
CTX0E16 cell line would provide valuable insights into the characteristics of the synapses generated 
during differentiation, and subsequently would produce a useful platform from which to launch 
investigations into synaptic mechanisms in human neurons. 
CTX0E16 cell cultures were differentiated up to DD35 then immunostained for the dendritic 
marker MAP2 as well as markers of the presynaptic and postsynaptic components of excitatory and 
inhibitory synapses. These included the postsynaptic density scaffolding protein PSD-95, excitatory 
postsynaptic markers such as the AMPA receptor subunits GluA1 and GluA2, the NMDA receptor 
subunit GluN1, the inhibitory postsynaptic marker gephyrin, the excitatory presynaptic markers 
Synapsin, bassoon and VGlut1 and the inhibitory presynaptic markers GAD65/67 and VGAT. Cultures 
were qualitatively assessed for the presence of punctate staining, a key characteristic of 
immunostaining for synaptic proteins in mature cortical neurons. Interestingly, discrete puncta could be 
observed along MAP2-positive dendrites for all synaptic proteins investigated in the DD35 neurons. The 
postsynaptic density protein PSD-95, the NMDA receptor subunit GluN1, and the AMPA receptor 
subunits GluA1 and GluA2 could all be found in discrete points along the dendrites of CTX0E16 
neurons, strongly suggesting the presence of the postsynaptic densities of excitatory synapses (see 
Figure 4.3.1, A-D). Furthermore, gephyrin, a scaffolding protein typically present at the postsynaptic 
densities of inhibitory synapses, was also found along MAP2-positive dendrites in a pattern consistent 
with the established literature (Budreck and Scheiffele, 2007) (Figure 4.3.1, E).  
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In addition to this, several presynaptic proteins could be observed in punctate structures along 
MAP2-positive CTX0E16 dendrites, including excitatory markers such as the active zone protein 
bassoon and the vesicular proteins Synapsin and VGlut1 (Figure 4.3.1, F-H). Furthermore, inhibitory 
markers including the vesicular GABA transporter VGAT and the enzyme responsible for the production 
of GABA at inhibitory synapses, GAD65/67, were also observed, suggesting the potential for expression 
of functional GABAergic synapses in differentiated CTX0E16 cultures (Figure 4.3.1, I & J). Although 
these proteins would not typically be present within dendrites the juxtaposition with MAP2-positive 
processes is likely to be reflective of the close proximity of these presynaptic structures to the post-
synaptic densities located on the adjacent dendrites. These findings are altogether highly suggestive of 
the development of both excitatory and inhibitory synapses in CTX0E16 neurons. 
 
Figure 4.3.1: CTX0E16 neurons express key pre- and post-synaptic proteins. A-E: DD35 CTX0E16 
neurons express puncta for the post-synaptic proteins PSD-95 (A), GluA1 (B), GluA2 (C), GluN1 (D) 
and gephyrin (E) along MAP2-positive dendrites (red arrows). F-J: CTX0E16 neurons also expressed 
the excitatory pre-synaptic proteins bassoon (F), synapsin1 (G) and VGlut1 (H) and the inhibitory pre-
synaptic proteins VGAT (I) and GAD65/67 (J) in punctate structures juxtaposed along MAP2-positive 
dendrites. Scale bars = 5 μm. 
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In addition to these qualitative findings, PSD-95 and GluN1 were chosen as markers of putative 
synapses for the purposes of quantification due to the consistent high quality of the staining observed 
in the previous images. These images were assessed for synaptic density along MAP2-positive 
dendrites to determine whether CTX0E16 neurons produce comparable synaptic densities to those 
observed for other in vitro systems and in vivo. DD35 CTX0E16 neurons were found to express PSD-
95 puncta along their dendrites at an average density of 3.38 ± 0.32 per 10 µm, while GluN1 was 
expressed at a comparable density of 3.07 ± 0.41 puncta per 10 µm of dendrite (see Figure 4.3.2, A). 
Taken together, these data indicate that not only do DD35 CTX0E16 neurons express a wide 
variety of excitatory and inhibitory, pre- and postsynaptic proteins in a pattern reminiscent of synaptic 
structures seen in previous studies in human and rat neurons  in vitro (Brennand et al., 2011b; Ippolito 
and Eroglu, 2010). Furthermore, analysis of the density of synaptic puncta along MAP2-positive 
dendrites in DD35 CTX0E16 neurons suggested that synapses were expressed in these neurons at a 
comparable level to that seen in immature rat primary cortical neurons and neurons derived from human 
iPSC lines, suggesting that the CTX0E16 cell line may provide a useful platform for studying the early 
development of synapses in human neurons. 
4.3.2 PRE- AND POST-SYNAPTIC PROTEINS COLOCALISE ALONG DENDRITES IN 
CTX0E16 NEURONS 
A key feature of functional, mature synapses is the presence of highly specialised pre- and 
postsynaptic structures at sites directly adjacent to one another (McAllister, 2007). Following the 
previous findings of putative dendritic spines and punctate staining for a wide variety of key presynaptic 
proteins, DD35 CTX0E16 neurons were further assessed to determine whether the postsynaptic density 
marker PSD-95 colocalised with markers of excitatory and inhibitory presynaptic boutons. Although 
PSD-95 is typically used as a marker of excitatory synapses, previous research has found PSD-95 to 
also localise to the postsynaptic densities of a subset of inhibitory synapses (Fattorini et al., 2009). 
DD35 CTX0E16 neurons were double fixed as described previously and immunostained for MAP2, 
PSD-95 and one of three presynaptic markers: the excitatory markers Synapsin and VGlut1 and the 
inhibitory synapse marker VGAT. Immunostained cultures were imaged using confocal microscopy with 
a 63x oil immersion objective, and images were background subtracted and Z-projected as described 
previously. Qualitative assessment of the dendrites of MAP2-positive CTX0E16 neurons revealed that 
postsynaptic PSD-95 puncta could be observed directly juxtaposed with puncta staining positive for 
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both excitatory (Synapsin, VGlut1) and inhibitory (VGAT) presynaptic markers. Taken together with the 
previous findings in Section 3.3.8 of the appearance of dendritic spine-like structures along the 
dendrites of DD35 CTX0E16 neurons, these results indicate that CTX0E16 neurons are capable of 
producing key structural features of mature excitatory and inhibitory synapses after five weeks of 
differentiation. 
 
Figure 4.3.2: Synaptic density and hallmarks of putative synapses in differentiated CTX0E16 neurons. 
A: Quantification of PSD-95 and GluN1 puncta density in DD35 CTX0E16 neurons (puncta per 10 µm: 
PSD-95, 3.4±0.32; GluN1, 3.1±0.4). B-D: Representative confocal images of DD35 CTX0E16 neurons 
immunostained for MAP2, PSD-95 and either bassoon (B), synapsin 1 (C) or VGAT (D). As previously 
seen, all synaptic proteins display punctate distribution along MAP2-positive dendrites. In addition, a 
subset of PSD-95 puncta colocalised with all three pre-synaptic proteins (red arrows), indicating the 
presence of putative synapses; colocalisation is indicated in white. Not all presynaptic puncta 
colocalised with PSD-95 (white open arrowheads), suggesting that synaptogenesis was ongoing. 
Scale bars = 5 µm. 
4.3.3 DIFFERENTIATED CTX0E16 NEURONS EXPRESS PROTEINS IMPLICATED IN 
NEUROPSYCHIATRIC DISEASE MECHANISMS 
Synaptic structures are a common convergence point for pathways involved in the 
pathophysiology of several neuropsychiatric diseases (Penzes et al., 2011). Autism, schizophrenia and 
bipolar disorder all feature distinct pathological changes in synaptic structure and function (Bourgeron, 
2009; Eastwood and Harrison, 2001), and a number of synaptic proteins have been implicated in the 
mechanisms underlying these complex diseases. To determine whether the CTX0E16 cell line would 
be a useful platform from which to conduct experiments investigating these mechanisms, the expression 
of several disease-related synaptic proteins was qualitatively expressed in CTX0E16 neurons. These 
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included Disc1, a postsynaptic density protein implicated in the pathophysiology of schizophrenia, 
bipolar disorder and depression; Shank3, a postsynaptic scaffolding protein thought to be involved in 
mechanisms underlying ASD and schizophrenia; and Neuroligin 3 (NL3), a postsynaptic adhesion 
protein associated with autism (Bourgeron, 2009; Craddock et al., 2005). DD35 or DD30 CTX0E16 
cultures were immunostained for MAP2 in addition to the synaptic proteins Disc1, Shank3 and NL3. 
Images for each disease-associated protein were assessed for the presence of discrete synaptic puncta 
along MAP2-positive dendrites of CTX0E16 neurons (see Figure 4.3.3, A-C). For each protein, 
punctate staining could be observed along the MAP2-positive dendrites of CTX0E16 neurons at DD35, 
in a manner consistent with previous research (Budreck and Scheiffele, 2007; Durand et al., 2012; 
Wang et al., 2011b). These observations suggest that the CTX0E16 cell line may be a useful platform 
from which to launch investigations into the functions of several key neuropsychiatric disease-
associated proteins - and how they relate to synaptic mechanisms – in human neurons. 
 
 Figure 4.3.3: Differentiated CTX0E16 neurons express synaptic proteins associated with 
neurodevelopmental disease. A-C: Representative confocal images of DD30 and DD35 CTX0E16 
neurons immunostained for MAP2 and endogenous Shank3 (A), neuroligin 3 (NL3) (B) or Disc1 (C). 
Puncta were observed along MAP2-positive dendrites of CTX0E16 neurons in a manner consistent with 
previous research (red arrows). Scale bars = 5 µm. 
4.3.4 EXPRESSION OF KEY SYNAPTIC AND SIGNALING PROTEINS IS 
UPREGULATED DURING DIFFERENTIATION OF THE CTX0E16 CELL LINE 
The development of putative synaptic structures and expression of key synaptic proteins 
observed in differentiated CTX0E16 neurons suggested that these cells bear the hallmarks of mature 
neurons. To further investigate whether cells from the CTX0E16 line upregulated a range of key 
neuronal genes during differentiation, q-PCRs were performed on RNA samples from both proliferative 
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and DD28 CTX0E16 cultures. Mean measures of several key genes involved in intracellular signaling 
pathways (PPP1R1B, GSK3B and SLC6A4), neurotransmitter receptors (GRIN1, GRIA2, GRM5, 
GABRA1 and DRD2) and other synaptic proteins (CACNA1C, DLG4 and CAMK2A) were normalised 
against a geometric mean of three housekeeping genes (GAPDH, HPRT1 and RPL13A) and compared 
across the two differentiation time points using an unpaired Student’s t test with a posthoc correction 
for multiple comparisons (see Table 4.3.4 for a summary of the assessed genes). Expression of the 
NMDA receptor subunit gene GRIN1, the AMPA receptor subunit gene GRIA2, the metabotropic 
glutamate receptor subunit gene GRM5, the GABA receptor subunit gene GABRA1 and the dopamine 
receptor gene DRD2 was significantly upregulated in differentiated CTX0E16 cultures relative to 
proliferative cells (see Figure 4.3.4, A). This increase in GABAergic and glutamatergic receptor 
expression is consistent with the neural lineages observed in differentiated cultures in Section 3.2.5. 
Furthermore, expression of the synaptic genes DLG4 and CAMK2A as well as the calcium channel 
subunit gene CACNA1C increased significantly following 4 weeks of differentiation. This is consistent 
with the emergence of synaptic structures and expression of synaptic protein puncta observed in 
Sections 4.3.1 and 4.3.2. Finally, expression of the signaling protein gene PPP1R1B was significantly 
reduced in DD28 CTX0E16 neurons in comparison to proliferative cells, while GSK3B and SLC6A4 
expression was upregulated in the differentiated cultures in comparison to the hNPC cultures. Taken 
together, these data indicate that CTX0E16 hNPCs express a wide range of neurotransmitter receptor 
subunits, intracellular signaling proteins and other synaptic proteins which are upregulated after several 
weeks of differentiation. These findings also mirror the predominately glutamatergic identity of 




Figure 4.3.4: Upregulation of genes involved in neuronal function in CTX0E16 cultures after four weeks 
of differentiation. A: Expression of a subset of neurotransmitter receptors, synaptic and signalling 
proteins is increased in DD28 CTX0E16 neurons in comparison to proliferative (DD0) CTX0E16 hNPCs 
shown by quantitative PCR (q-PCR); n = 4 independent experiments carried out in triplicate; error bars 
represent SD; **p <0.01; ***p <0.001 (Student’s unpaired t test). This work was carried out by Dr. Greg 
Anderson. 
4.3.5 IMMATURE CTX0E16 NEURONS EXHIBIT MORPHOLOGICAL PLASTICITY IN 
RESPONSE TO PROLONGED DEPOLARISATION 
As demonstrated in Section 3.3.8 in the CTX0E16 cell line and in previous studies, the 
morphology of a neuron and functional identity of outgrowing neurites (both axonal and dendritic) is 
progressively established early on in development. The extension and arborisation of dendritic and 
axonal processes is highly regulated and critical to the formation of neural circuits and synaptic 
connections as well as the processing of synaptic inputs. During development neuronal morphology is 
highly plastic and susceptible to manipulation in response to a wide range of physiological and 
pathological mechanisms. Neuronal activity can act as an important regulator of neuronal development 



























































































































Crucially, the impact of neuronal activity on neurite extension and retraction hinges on several factors 
including the maturity of the neurons studied, the species and brain region from which the neurons are 
derived, the intracellular calcium concentration induced by the neuronal activity and the duration of 
depolarisation. Typically, short bursts of neuronal activity appear to arrest or even reverse neurite 
outgrowth in neuronal cultures (Cohan and Kater, 1970; Fields et al., 1990; Schilling et al., 1991). 
However, prolonged depolarisation of neuronal cultures appears to enhance neurite outgrowth via a 
calcium-dependent process. Interestingly, a previous study conducted by Krey et al. (2013) found that 
prolonged depolarisation of hiPSC-derived neurons resulted in a significant increase in neurite length 
via a calcium-dependent mechanism. To determine whether CTX0E16 neurons exhibited comparable 
morphological plasticity at an early stage of differentiation in response to prolonged depolarisation, 
DD13 CTX0E16 cultures were transfected with a CMV-driven pEGFP plasmid as described previously. 
Cultures were treated with one of three conditions for 7 hours: control NDM media, an osmotic control 
consisting of NDM supplemented with 30 mM NaCl and depolarisation media consisting of NDM 
supplemented with 30 mM KCl. A one way ANOVA with Tukey post-hoc analysis for multiple 
comparisons was performed on neurite tracing data for each of the three conditions; this revealed that 
neuronal cells from cultures treated with 30 mM KCl for 7 hours were found to possess significantly 
longer neurites than those of the two control culture conditions (average neurite length (μm): control, 
20.46 ± 1.76 μm; 30 mM NaCl, 21.03 ± 1.20 μm; 30 mM KCl, 31.95 ± 6.02 μm; n = 12−22 cells, ANOVA, 
p <0.05) (see Figure 4.3.5, A & B). This finding indicates that DD15 CTX0E16 neuronal cells are 
capable of exhibiting morphological plasticity in response to prolonged depolarisation in a manner 
consistent with previous studies (Krey et al., 2013), indicating that they display the functional 




Figure 4.3.5: Differentiated CTX0E16 neurons exhibit morphological plasticity in response to activity-
dependent stimulation. A: Representative binary images of GFP-expressing CTX0E16 neurons (DD 
15) following treatment with control conditions (vehicle or osmotic control (30 nM NaCl)) or activity-
dependent stimulation with 30 nM KCl for 7 hours. B: Measurement of average neurite length in 
response to stimulation demonstrates that activity-dependent stimulation results in an increase in 
average neurite length; n = 14–22 neurons from 3–5 independent experiments carried out in triplicate; 
error bars represent SEM; *p <0.05 (one way analysis of variance with Tukey post hoc analysis). Scale 
bar = 50 μm. 
4.3.6 DIFFERENTIATED CTX0E16 CELLS EXHIBIT ELECTROPHYSIOLOGICAL 
CHARACTERISTICS OF FUNCTIONAL NEURONS 
Based on the immunostaining data in Sections 3.3.3, 3.3.6, 4.2.1 and 4.2.2, and the data on 
morphological plasticity in Section 4.3.5, CTX0E16 neurons exhibit the structural characteristics of 
functional synapses and express a wide range of signaling, scaffolding and neurotransmitter receptor 
proteins, and these cells respond to depolarising stimuli by exhibiting morphological plasticity, indicating 
that they also possess key ion channels even at an early stage of differentiation. To determine whether 
these proteins are functionally integrated in CTX0E16 neurons and subsequently, whether these cells 
possess physiological characteristics consistent with mature, functional neurons, the 
electrophysiological properties of CTX0E16 neurons were assessed using current and voltage clamp 
recordings via whole cell patch clamps at several time points during differentiation. CTX0E16 cultures 
were differentiated up to DD61, with voltage clamp recordings being carried out at DD33, DD36 and 
DD50 to record NMDA receptor-mediated spontaneous excitatory postsynaptic currents (EPSCs), 
AMPA receptor-mediated EPSCs and action potentials respectively. Current clamp recordings of cell 
resting membrane potentials took place at DD29, DD33 and DD61. Resting potentials of CTX0E16 
neurons were initially depolarised and steadily became more negative at later stages of differentiation 
(DD29: −31.3 mV, n = 6; DD33: −51.25 mV, n = 4; DD61: −56.4 mV, n = 3) (see Figure 4.3.6, A); this 
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is highly consistent with previous studies indicating that neuronal resting membrane potentials are 
typically less polarised but highly variable in immature neurons and gradually become more polarised 
but less variable over the time course of differentiation (Johnson et al., 2007; Magnuson et al., 1995; 
Vierbuchen et al., 2010). 
One of the key stages in the development of mature, functional neurons both in vivo and in vitro 
is the attainment of action potential generation, a crucial form of cell-cell communication within the brain 
(Khazipov and Luhmann, 2006; Luhmann et al., 2000; Nunes et al., 2003). To determine whether cells 
from differentiated CTX0E16 cultures reproduce this critical event, CTX0E16 neurons were assessed 
at several time points from DD33 to DD61 via cell-attached voltage clamp recordings. Action potentials 
only became apparent in CTX0E16 cultures from DD50 onwards, while burst firing of CTX0E16 neurons 
did not develop over the time course investigated in the current experiment (Figure 4.3.6, B). Another 
hallmark of functional synapses is the generation of spontaneous EPSCs (via excitatory synapses) and 
IPSCs (via inhibitory synapses). To determine whether CTX0E16 neurons possessed the ability to 
produce spontaneous EPSCs and IPSCs, differentiated CTX0E16 cultures (DD33-35) were monitored 
using cell-attached voltage clamp recordings. AMPA receptor-mediated EPSCs were recorded using a 
holding potential of -70mV; a holding potential of +40mV was used to record NMDA receptor mediated 
EPSCs; and GABA-mediated IPSCs were recorded using a holding potential of +0mV. Whole-cell 
voltage clamp recordings revealed that after around five weeks of differentiation a subset of neurons in 
CTX0E16 cultures exhibited spontaneous EPSCs, mediated by both AMPA and NMDA receptors 
(Figure 4.3.6, C & D). These findings are consistent with the results seen in Sections 3.2.5 and 4.3.1, 
where the expression of multiple markers of glutamatergic neurons and excitatory synaptic structures 
were observed in a majority of differentiated CTX0E16 neurons. However, spontaneous IPSCs could 
not be detected in CTX0E16 cultures at this stage of differentiation, indicating that these cells had not 
yet develped functional inhibitory synapses. Taken together, these data indicate that CTX0E16 neurons 
develop key physiological characteristics that progressively grow more consistent with those of mature, 
functional neurons over the course of several weeks of differentiation.  
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Figure 4.3.6: Development of electrophysiological properties in differentiated CTX0E16 neurons. A: 
Resting membrane potential (in mV) recorded using current clamp progressively becomes more 
negative throughout differentiation of CTX0E16 neurons (DD29−DD61); error bars represent SD. B: 
Representative action potential recorded in voltage clamp using the cell attached configuration, 
recorded in DD50 CTX0E16 neurons. C: Representative voltage clamp recording at a holding potential 
of −70 mV in DD36 CTX0E16 neurons. The downward deflections indicate the presence of AMPA 
receptor-mediated spontaneous excitatory postsynaptic currents (EPSCs). D: Example of a 
spontaneous N-methyl-D-aspartate (NMDA) receptor-mediated EPSC recorded in voltage clamp at +40 
mV from DD33 CTX0E16 neurons; n=3–6 cells from at least three independent coverslips. This work 
was conducted by Dr. Ruth Taylor. 
4.3.7 CTX0E16 NEURONS DISPLAY FLUCTUATIONS IN INTRACELLULAR CALCIUM 
CONCENTRATIONS IN RESPONSE TO PHYSIOLOGICAL STIMULI 
Calcium imaging was used to investigate whether differentiated CTX0E16 neurons displayed 
physiological responses to several key neurotransmitters and exhibited oscillations in intracellular [Ca2+] 
due to neuronal activity. DD28 CTX0E16 cultures were loaded with Fura-2 AM ratiometric dye, an 
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intracellular calcium indicator, and then treated with 1 mM glutamate, acetylcholine or dopamine in 
HEPES-buffered physiological saline solution for 1 minute. Successful loading of cultures with this dye 
was demonstrated by fluorescent emissions from CTX0E16 cells at 520 nm following excitation at 380 
nm as described in Section 2.8 of the materials and methods chapter (see Figure 4.3.7, A). DD28 
CTX0E16 cells exposed to the glutamate condition exhibited both rapid, strong responses and slower, 
less pronounced responses after treatment (Figure 4.3.7, B). The former of these responses is likely 
to be brought about via fast-activation of AMPA or NMDA receptors, while the lower magnitude 
responses are likely to be mediated by metabotropic glutamate receptors. Approximately 80% of 
CTX0E16 cells were found to increase intracellular Ca2+ concentrations following treatment with 
glutamate, though these responses were typically modest: just over 30% of cells produced a response 
of 20% above baseline and less than 20% producing a response of 50% above baseline; the average 
increase in intracellular Ca2+ for all cells was approximately 20% above the baseline level (Figure 4.3.7, 
E & F). 
Treatment with acetylcholine produced potent responses in nearly all CTX0E16 cells assessed. 
More than 60% of cells produced responses of 20% above baseline, while 40% of cells produced 
responses of 50% above baseline; the average response for all cells was nearly 50% above baseline, 
a finding that was more than double than that found for glutamate and an order of magnitude greater 
than the average response to treatment with dopamine (Figure 4.3.7, C, E & F). Assessment of 
individual traces indicated that predominately these responses consisted of a rapid yet sustained 
increase in intracellular Ca2+, though a subset of cells showed a slower increase in the magnitude of 
the response.  
In contrast to the responses to glutamate and acetylcholine treatment, dopamine-mediated 
responses were considerably smaller and exhibited a more gradual or delayed increase in intracellular 
Ca2+ (Figure 4.3.7, D). This is consistent with previous research showing that the physiological actions 
of dopamine on neuronal signalling and intracellular calcium are exerted through metabotropic 
receptors (Beaulieu and Gainetdinov, 2011). Less than 40% of total cells exhibited Ca2+ responses that 
were greater than 5% above baseline, and less than 3% of total cells exhibited responses that exceeded 
a level 20% above baseline (Figure 4.3.7, E & F). 
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Figure 4.3.7: CTX0E16 cultures generate neurons that respond to treatment with neurotransmitters. A: 
Representative image of neurons loaded with Fura-2 AM used for single cell Ca2+ imaging. B-F: 
Representative traces of intracellular Ca2+ in response to various neurotransmitter receptor ligands. E: 
Number (%) of total cells generating 5%, 20% or 50% responses following treatment with 
neurotransmitter ligands; n = 3 independent experiments carried out in triplicate (600 cells in total). F: 
Mean maximal response produced by DD28 CTX0E16 neurons following application of 
neurotransmitter ligands; n = 3 independent experiments carried out in triplicate (600 cells in total); error 






4.3.8 CTX0E16 NEURONS DISPLAY SPONTANEOUS CALCIUM OSCILLATIONS 
Another feature of the early maturation of neuronal cells is the development of spontaneous 
rhythmic fluctuations in the intracellular concentration of Ca2+ in response to neuronal activity (Spitzer, 
2002). To determine whether CTX0E16 cells exhibited these Ca2+ oscillations, DD28 and DD42 
CTX0E16 cultures were assessed using single cell Ca2+ imaging with Fluo-4, another fluorescent Ca2+ 
indicator. Fluo-4 fluorescence in individual cells was time lapse recorded using epifluorescent 
microscopy with a temporal resolution of 1 image per second (see Figure 4.3.8, A). Spontaneous 
activity was defined as the presence of a sharp transient increase in fluorescence intensity with a rapid 
rise and slow decay in the soma of CTX0E16 cells with clear dendritic processes (see Section 2.8 for 
the full protocol). No spontaneous oscillations in intracellular Ca2+ concentrations could be detected in 
DD28 CTX0E16 cultures. In DD42 cultures however, Ca2+ oscillations could be detected in 38.0 ± 6.89% 
of CTX0E16 neurons, indicating that by this stage of differentiation CTX0E16 cells exhibit physiological 
events consistent with functionally active neurons in vivo (Figure 4.3.8, B). 
To determine whether intracellular Ca2+ concentrations in CTX0E16 neurons could also be 
manipulated through treatment with depolarising or activity-blocking stimuli, DD42 CTX0E16 cultures 
were loaded with Fluo-4 dye, treated with 50 mM KCl or 1 µM TTX and imaged as described previously. 
Application of KCl resulted in a marked influx of Ca2+ in 79.1 ± 4.2% of DD42 CTX0E16 neurons, 
indicating the presence of voltage-gated Ca2+ channels (Figure 4.3.8, C). Treatment with TTX, a 
voltage-gated sodium channel blocker, halted spontaneous Ca2+ transients in DD42 CTX0E16 cultures, 
indicating that these transients were mediated by neuronal activity via voltage-gated sodium channels 
(Figure 4.3.8, D). Taken together, these data demonstrate that not only do differentiated CTX0E16 
neurons respond to several key neurotransmitters, but they also exhibit spontaneous and evoked 
fluctuations in the intracellular concentration of calcium that were blocked by the addition of TTX, further 




Figure 4.3.8: Development of spontaneous calcium oscillations in CTX0E16 neurons. A: 
Representative image of DD42 CTX0E16 neurons loaded with Fluo-4 AM and used for single cell Ca2+ 
imaging. B: Representative time series of 18 neurons displaying spontaneous Ca2+ transients. 
Spontaneous activity was classified as a somatic calcium event greater than 5% ΔF/F0. 38.0 ± 6.89% 
of DD42 CTX0E16 cells displayed spontaneous activity over an 80-second period of imaging (n = 155 
cells from 14 coverslips). C & D: Representative traces of intracellular Ca2+ in response to 50 mM KCl 













This chapter has provided data on the development of putative excitatory and inhibitory 
synapses in neurons from the CTX0E16 cell line, outlining the broad variety of presynaptic and 
postsynaptic proteins, including several disease-relevant proteins, expressed in these cells. This 
chapter has also shown the relative density of these synaptic puncta along the MAP2-positive dendrites 
of these cells, and the upregulation of genes involved in neurotransmission and intracellular signaling 
after several weeks of differentiation in the CTX0E16 cell line. Morphological plasticity during early 
neurite outgrowth is described Data is also presented on the spontaneous and activity-induced 
fluctuations in intracellular calcium concentrations observed in differentiated CTX0E16 cultures. 
The broad range of excitatory and inhibitory synaptic proteins expressed by differentiated 
CTX0E16 neurons at DD35 indicate that even at this relatively early stage the development of functional 
synapses is well underway. Synaptic proteins were found to be expressed in discrete puncta 
reminiscent of synaptic immunostaining in vivo. Furthermore, both excitatory and inhibitory presynaptic 
proteins were found to colocalise with the postsynaptic density protein PSD-95, suggestive of mature, 
functional synapses with both pre- and postsynaptic structures. Although PSD-95 is predominately 
localised to excitatory synapses, it has also been found to localise to a subset of inhibitory synapses. 
Furthermore, VGAT and VGlut1 have been found to colocalise at a subset of synapses, permitting 
selective release of both glutamate and GABA as a potential preventative measure against systemic 
overexcitability (Fattorini et al., 2009; Zander et al., 2010). Supporting this, spontaneous excitatory 
postsynaptic currents observed at a similar time point (DD33 and DD36 for ionotropic NMDA and AMPA 
receptor-mediated currents respectively), but inhibitory postsynaptic currents could not be observed at 
all during the time course assayed in the present study. This suggests that the immunostaining of 
synaptic puncta in DD35 CTX0E16 neurons is representative of functional excitatory synapses with 
both NMDA- and AMPA-receptor mediated EPSCs. Furthermore, the lack of spontaneous GABA 
receptor-mediated IPSCs in these neurons may be a result of multiple factors, including the relative 
paucity of GABAergic neurons in the differentiated cultures, the early stage of differentiation of these 
cells relative to foetal brain development in vivo and the possibility that at this early stage of 
differentiation GABAergic synapses in these neurons are excitatory (Cherubini et al., 1991). Previous 
research has found that GABA acts as an excitatory neurotransmitter early on in development, and later 
switches to an inhibitory neurotransmitter due to a shift in the cross-membrane chloride ion gradient 
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(Taketo and Yoshioka, 2000). It is therefore possible that there are functional excitatory GABAergic 
synapses in these cultures that will adopt an inhibitory role later in differentiation. 
CTX0E16 neurons also express several synaptic proteins which have been implicated in severe 
neuropsychiatric illness in discrete puncta along MAP2-positive dendrites in a manner consistent with 
previous studies (Budreck and Scheiffele, 2007; Durand et al., 2012; Wang et al., 2011b), including 
Disc1, Shank3 and Neuroligin 3. Prior research has found a balanced chromosomal translocation 
disrupting the gene coding for Disc1 to segregate with severe mental illness in a large Scottish pedigree 
(Millar et al., 2000); subsequent studies have reported that mutations in the DISC1 gene were 
associated with schizophrenia-relevant endophenotypes and there is evidence to suggest rare DISC1 
variants are associated with both schizophrenia and bipolar disorder (Callicott et al., 2005; Kamiya et 
al., 2005; Saetre et al., 2008; Serretti and Mandelli, 2008). Mechanistic studies have found the Disc1 
protein to be involved in a wide range of cellular mechanisms including the regulation of cell adhesion, 
neurite outgrowth, dendritic spine morphology and synaptic activity (Hattori et al., 2007, 2010; Hayashi-
Takagi et al., 2010; Wang et al., 2011b). The SHANK3 gene codes for a scaffolding protein that is 
recruited to the postsynaptic density early on in synaptic maturation and has been found to regulate 
dendritic spine density and morphology and metabotropic glutamate receptor-mediated signaling 
(Durand et al., 2012; Roussignol et al., 2005; Sheng and Kim, 2000; Verpelli et al., 2011). Mutations in 
this gene have been associated with an increased risk of developing autism spectrum disorder (ASD) 
and schizophrenia (Durand et al., 2007; Gauthier et al., 2010). Neuroligin 3, a cell adhesion protein at 
glutamatergic and GABAergic synapses, has been found to play a role in the regulation of inhibitory 
neurotransmission (Budreck and Scheiffele, 2007; Südhof, 2008); mutations in NLGN3, the gene coding 
for the neuroligin 3 protein, have also been found to be associated with an increased risk of ASD 
(Südhof, 2008). The findings of the current investigation indicate that the CTX0E16 cell line may provide 
a useful platform for studying disease-relevant mechanisms involving these proteins in human cortical 
neurons without the considerable delays and expense associated with performing similar experiments 
in hiPSC lines. 
The alterations in expression of several genes observed in the CTX0E16 cell line during 
differentiation offered an interesting insight into the changing profile of these cells over time. Several of 
these genes have been implicated in the pathological mechanisms underlying neuropsychiatric 
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diseases, further lending justification to the future use of the CTX0E16 cell line as a platform from which 
to conduct investigations into the pathways contributing to these disorders. Mutations in the dopamine 
receptor gene DRD2 have been associated with schizophrenia (Kukreti et al., 2006); the D2 receptor 
this gene codes for is a target of several antipsychotic drugs employed in the treatment of this disorder 
(Howes and Kapur, 2009). Surprisingly, PPP1R1B expression was found to be downregulated over the 
same time period. The PPP1R1B gene codes for a dopamine and cAMP-regulated neuronal 
phophoprotein (DARPP-32), regulating the activity of both protein phosphatase 1 and PKA and acting 
as an integrator of information from multiple neurotransmitters and other signaling pathways at 
dopaminoreceptive neurons (Blom et al., 2013; Svenningsson et al., 2004). There is some evidence 
also implicating this protein in mechanisms underlying schizophrenia – expression of this protein has 
previously been found to be reduced in the prefrontal cortex of schizophrenic patients (Albert et al., 
2002). The downregulation observed in the current study may be a result of a relative lack of specific 
subtypes of dopaminergic synapses which typically express this protein. Mutations in CACNA1C have 
been found to be associated with an increased risk of developing bipolar disorder and schizophrenia 
(Green et al., 2010). In addition to this, a specific point mutation in an alternatively spliced exon of 
CACNA1C causes Timothy syndrome, a heritable disorder characterised by cardiac arrhythmia, 
hypoglycemia, global delay in development and, in over 60% of patients, autism (Paşca et al., 2011). 
CACNA1C has also been found to mediate morphological plasticity in response to prolonged 
depolarisation in neurons derived from hiPSCs (Krey et al., 2013). 
CTX0E16 cells also exhibit morphological plasticity during early neurite outgrowth in response 
to prolonged depolarisation. This experiment was adapted from a comparable protocol conducted by 
Krey et al. (2013), which showed a similar increase in neurite outgrowth following depolarisation in 
early-stage hiPSC-neurons. This paper went on to apply the same protocol to neurons differentiated 
from hiPSCs derived from Timothy syndrome patient kerinocytes, finding a reversal of the neurite-
extension phenotype observed in neurons derived from control lines. The findings of the current study 
suggest that this paradigm may be similarly employed to study disease mechanisms affecting 
morphological plasticity in the CTX0E16 cell line in future experiments. 
A large proportion of cells in DD28 CTX0E16 cultures exhibited increases in intracellular 
calcium in response to treatment with glutamate, consistent with the previous findings on the neuronal 
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lineages and synaptic proteins expressed in these cultures seen in Section 3.3.5 & 4.3.1. However, 
responses were typically modest, with less than 20% of cells producing a response more than 50% 
above baseline. This may be due to multiple factors including the presence of non-neuronal cells in the 
cultures, glutamatergic receptor expression not yet being sufficient to result in a pronounced increase 
in calcium and glutamate binding to multiple receptor types with contradictory effects on intracellular 
calcium concentration. The calcium responses observed in these cultures followed patterns consistent 
with both ionotropic (AMPA, NMDA and kainate) and metabotropic glutamate receptors. Group 1 
metabotropic glutamate receptors influence intracellular calcium concentrations via slower, indirect 
pathways: mediating Ca2+ release from internal stores and modulating the activity of voltage-gated 
calcium channels (Pin and Duvoisin, 1995). In contrast to this, ionotropic glutamate receptors typically 
mediate a rapid rise in intracellular calcium as Ca2+ ions flow into the cell through the constitutive cation-
permeable channel following ligand binding. AMPA receptors are typically only permeable to sodium 
and potassium, though AMPA receptors lacking the GluA2 subunit will also permit Ca2+ ions to pass 
through (Black, 2005; Hume et al., 1991). NMDA receptors are highly permeable to calcium while the 
permeability of kainate receptors to calcium depends on the configuration of two transmembrane 
segments within the channel, TM1 and TM2 (Huettner, 2003; Petrie et al., 2000). Thus, the modest 
Ca2+ responses observed following glutamate treatment may also reflect specific ionotropic receptor 
subunit compositions at this stage of differentiation. 
Calcium responses to acetylcholine were virtually ubiquitous and tended to be more profound 
than those observed for glutamate. Although cholinergic receptors have not been extensively 
investigated in the present study, several subtypes of nicotinic receptor are expressed within the 
cerebral cortex; the permeability of these ligand-gated ion channels to calcium is dependent on the 
composition of their subunits (Shen and Yakel, 2009; Wallace and Bertrand, 2013). Metabotropic 
cholinergic receptors in the cortex also mediate increases in intracellular calcium via release from 
internal stores (Porter et al., 2002; Rathouz et al., 1995), though these receptors are unlikely to be 
responsible for the calcium responses to acetylcholine treatment seen in the current study as the 




Dopamine receptors have previously been found to regulate intracellular calcium concentration 
via mediating calcium release from internal stores (Lezcano and Bergson, 2002). Intracellular increases 
in calcium in response to treatment with dopamine were relatively low in comparison to both glutamate 
and acetylcholine, with only a minority of DD28 CTX0E16 cells exhibiting a response and less than 5% 
of cells producing an increase in the calcium signal greater than 50% above baseline. Although the 
present investigation has indicated that CTX0E16 neurons are predominately glutamatergic or 
GABAergic, q-PCR analysis of proliferative and differentiated CTX0E16 cultures has indicated that the 
metabotropic dopamine receptor subunit DRD2 is greatly upregulated following several weeks of 
differentiation, indicating that a minority of MAP2-positive neurons may in fact be dopaminergic. This is 
perhaps unsurprising as typically only a fraction of cortical neurons express the dopaminergic marker 
tyrosine hydroxylase, with the majority of dopaminergic afferents originating from various regions within 
the midbrain (Gaspar et al., 1987). 
Treatment of differentiated CTX0E16 cells with KCl also resulted in marked increases in 
intracellular calcium. A high external concentration of KCl acts as a depolarising stimulus in neuronal 
cultures as the cell membrane is highly permeable to potassium ions at rest and so K+ ions will flow into 
the lower concentration of the intracellular environment. The subsequent increase in calcium is due to 
voltage gated calcium channels opening as a result of the depolarisation of the cell (Simms and 
Zamponi, 2014). This result indicates that CTX0E16 neurons express voltage gated calcium channels 
by DD42 and is consistent with the upregulation of CACNA1C expression observed in differentiated 
cultures relative to proliferative cells seen in Section 4.3.4. Spontaneous calcium oscillations, a marker 
of activity in mature neurons, were also found to occur in DD42 CTX0E16 cultures. These transient 
fluctuations in intracellular calcium were blocked by treatment with TTX, confirming that they were 
mediated by neuronal activity as predicted. 
Spontaneous action potentials could only be observed in CTX0E16 cultures after 50 days of 
differentiation. This provided a more direct confirmation of the previous findings via calcium imaging in 
younger cultures. Several previous studies assessing these electrophysiological characteristics in 
neurons derived from other human cell lines were able to observe this phenomenon at an earlier time 
point of differentiation (De Filippis et al., 2007; Gaspard et al., 2008; Nunes et al., 2003). There are 
several factors which may contribute to a shortening of the duration of differentiation required before 
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CTX0E16 cells produce functional synapses and neuronal activity. Co-cultures of MEFs have previously 
been found to aid the rapid differentiation and viability of human neuronal cultures in vitro (Ghasemi-
Dehkordi et al., 2015). Additionally, although differentiated CTX0E16 cultures were found to contain 
small populations of s100β-positive astrocytes, this proportion may not provide the optimal conditions 
for synapse formation and function. Previous studies have found astrocytes to play a critical role in 
synaptogenesis and in the regular function of synaptic transmission at the tripartite synapse – synaptics 
connections consisting of the three way partnership of the presynaptic bouton, postsynaptic density and 
the surrounding astrocytic elements (Faissner et al., 2010; Swanson et al., 1999). In addition to this, in 
vitro investigations have also determined that co-culturing neurons with astrocytes increases the 
efficiency of synaptic transmission and accelerates the onset of synaptic current development (Johnson 
et al., 2007). Thus, optimising the balance of astrocytes or other glial cells via co-cultures with the 
neuronal component of CTX0E16 cultures may accelerate the onset of synaptogenesis and mature 
functional characteristics. Finally, supplements for the culture media which promote differentiation (or 
the use of alternate differentiation media compositions entirely) may further reduce culture times when 
generating mature neurons. Retinoic acid promotes neuronal differentiation of pluripotent stem cells in 
vitro, while forskolin has also been previously used to potentiate neuronal differentiation from both 
hNSC and hNPC lines (Cacci et al., 2007; Wang et al., 2004). Furthermore, a new neuronal medium, 
BrainPhys, has recently been designed to promote rapid neuronal differentiation of human IPSC lines 
(Bardy et al., 2015). This medium has been found to improve the proportion of synaptically active cells 
in these cultures relative to differentiation media based on DMEM or neurobasal. Thus, the application 
of neuronal differentiation-promoting media or supplements to culturing protocols for CTX0E16 cells 
may provide a useful method for reducing differentiation times. 
Finally, the progressive development of an increasingly polarised resting membrane potential 
in neurons from differentiated CTX0E16 cultures not only reflects the increasing maturity of these cells 
but also closely matches the alterations in membrane potential seen during differentiation in other 
human cell lines and in vivo (Johnson et al., 2007; Magnuson et al., 1995; Vierbuchen et al., 2010). 
In conclusion, this chapter has shown that CTX0E16 cells are capable of developing functional 
excitatory synapses containing a wide host of neurotransmitter receptors, intracellular signaling 
proteins, scaffolding proteins and vesicular proteins as well as several proteins relevant to 
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neuropsychiatric disease. Differentiated CTX0E16 neurons were also shown to develop several key 
electrophysiological characteristics and functional responses in a manner consistent with mature 
glutamatergic neurons. These findings, taken together with the conclusions of the previous chapter, 
indicate that the CTX0E16 cell line offers a useful platform from which to launch investigations into 
developmental and disease-relevant mechanisms and pathways in human glutamatergic neurons. 
Future modifications of the differentiation protocol may yield a more rapid attainment of mature, 
functional properties in these neurons and thus improve their use as an experimental model. 
In light of these findings, Chapter 5 will detail the employment of this cell line in conjunction 
with hiPSC-derived neurons and primary rat cortical neurons in a study of the expression and 
subcellular localisation of a protein implicated in schizophrenia and bipolar disorder, ZNF804A. This 
chapter will also discuss these experiments in the context of previous research into the potential 















GENE PROTEIN FUNCTION 
GRIN1 Glutamate receptor subunit 
zeta-1 
Subunit of glutamatergic NMDA receptor; 
involved in excitatory neurotransmission 
GRIA2 Glutamate receptor 2 Codes for several glutamatergic AMPA and 
kainate receptor subunits; involved in 
excitatory neurotransmission 
GRM5 Metabotropic glutamate 
receptor 5 
G protein coupled glutamate receptor; involved 
in excitatory neurotransmission 
GABRA1 Gamma-aminobutyric acid 
receptor subunit alpha-1 
GABA-A receptor subunit involved in inhibitory 
neurotransmission 
DRD2 Dopamine receptor D2 Key component of dopaminergic 
neurotransmission 
CACNA1C Calcium channel, voltage-
dependent, L type, alpha 1C 
subunit 
Voltage dependent calcium channel; regulates 
intracellular calcium concentration 
DLG4 Post-synaptic density protein 
PSD-95 
Core component acting as a protein scaffold at 
the postsynaptic density 
CAMK2A Calcium/calmodulin-dependent 
protein kinase type II alpha 
chain 
Serine/threonine protein kinase that mediates 
long term potentiation and other aspects of 
neuronal plasticity 
PPP1R1B Protein phosphatase 1 
regulatory subunit 1B 
Involved in secondary signalling pathways in 
dopaminergic neurotransmission 
GSK3B Glycogen synthase kinase 3 Serine/threonine protein kinase involved in the 
regulation of neuronal differentiation 
SLC6A4 Solute carrier family 6, member 
4 
Serotonin transporter; key component of the 
serotonergic neurotransmission system 








This chapter details the characterisation of the expression of a protein implicated as a risk 
candidate for schizophrenia and bipolar disorder. This involved an assessment of ZNF804A expression 
at the mRNA level in multiple human cell lines, the identification and validation of the optimal candidate 
for immunostaining for the ZNF804A protein out of several commercially available anti-ZNF804A 
antibodies and the subsequent optimisation of ICC protocols utilising this antibody. This chapter also 
describes the characterisation of ZNF804A protein expression and subcellular localisation in several in 
vitro paradigms including neurons derived from hNPC and hiPSC lines as well as primary rat cortical 
neurons. Finally, this chapter discusses these findings in the context of the pre-existing literature. 
5.2 INTRODUCTION 
ZNF804A was first identified as a schizophrenia risk candidate gene in a GWAS conducted by 
O’Donovan et al. (2008), which discovered an association with a SNP at rs1344706 within an intronic 
region of the ZNF804A gene. This association grew stronger when bipolar disorder was included in the 
affected phenotype, suggesting a broader link to psychosis in general. An initial study assessing the 
impact of the risk allele of the rs1344706 SNP on ZNF804A expression in the human brain found a 
reduction in the expression of the full length ZNF804A transcript in second trimester fetal tissue (Hill 
and Bray, 2012). However, a subsequent study found evidence to suggest that this reduction was in 
fact limited to a novel variant lacking the first two exons of the full length transcript, termed ZNF804AE3/E4 
(Tao et al., 2014). 
ZNF804A belongs to the ZNF (zinc finger) family, a class of proteins characterised by the 
presence of a domain consisting of a small motif folded around one or more zinc ions (Laity et al., 2001). 
These ZNF proteins are well known for their ability to bind DNA and act as transcription factors, however 
ZNF motifs have also been found to mediate a wide variety of functions including the regulation of 
protein-protein interactions, protein-lipid interactions and acting as RNA-binding molecules (Laity et al., 
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2001). In the brain, ZNF proteins have been previously found to be involved in several processes 
including neurogenesis (Aruga et al., 1994), neurite outgrowth (Hattori et al., 2007) and synaptic 
function (Fenster et al., 2000). 
Several studies have also attempted to identify the role of ZNF804A and its rodent homologue 
Zfp804A at the cellular and molecular level. Knockdown of ZNF804A has been found to affect 
expression of several genes involved in neurite outgrowth, axonal and dendritic arborisation and cell 
adhesion (Hill et al., 2012); schizophrenia-associated genes (Girgenti et al., 2012); genes involved in 
the cytokine signalling pathway (Chen et al., 2015); and genes involved in TGF-β signalling (Umeda-
Yano et al., 2013). However, despite these findings providing a valuable insight into ZNF804A and 
Zfp804A’s potential role as a transcription factor, there is still currently a lack of reliable data on 
fundamental characteristics of this protein including its localisation due to a lack of well-validated 
antibodies. 
Assessments of the regional, cellular and subcellular localisation of a protein can provide a 
valuable insight into that protein’s potential functions. Prior research into the subcellular localisation of 
ZNF804A and the rodent homologue, Zfp804A, has yielded mixed results, a problem potentially 
compounded by the frequent lack of thorough antibody characterisation and differences in the neuronal 
models studied in these papers. ZNF804A and Zfp804A expression has been reported variously as 
nuclear in rat neural progenitor cells (Girgenti et al., 2012), within the cytoplasm and nuclei of human 
cortical pyramidal neurons (Bernstein et al., 2014; Tao et al., 2014) and from perinuclear regions to a 
wide distribution with particularly strong expression in growth cones during differentiation of cultured 
rodent neuronal cells (Chang et al., 2015). Future research will thus greatly benefit from a more 
thorough characterisation of the subcellular localisation of these proteins with a well-validated antibody 
across several cellular models. 
This chapter presents a study of the subcellular and sub-structural localisation of this protein in several 
neuronal cell lines from both human and rodent sources. Following a thorough validation of a candidate 
anti-ZNF804A antibody, the subcellular expression of ZNF804A and Zfp804A is described in NPCs and 
neurons from the CTX0E16 cell line and hiPSC sources, as well as subcellular and sub-synaptic 
localisation in rat primary cortical neurons. The expression of several ZNF804A transcripts and protein 
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isoforms in these cell lines is also demonstrated. Finally, this chapter discusses the ramifications of this 
work in the context of the findings of previous research. 
5.3 RESULTS 
5.3.1 CHARACTERISATION OF ZNF804A TRANSCRIPT EXPRESSION IN THE 
CTX0E16 CELL LINE 
Several splice variants of ZNF804A have been identified in previous studies, including the full 
length transcript; the disease-relevant E3/E4 variant which lacks exon 1 and 2 (which codes for the 
C2H2 zinc finger domain) and contains a 5’ untranslated region; variant b which lacks the first two exons 
and one of the putative nuclear localisation signals; variant c which is composed almost entirely of exon 
2; and variant 2.2, consisting of exon 2 and a novel exon termed exon 2.2 (see Figure 5.3.1, A) (Hess 
and Glatt, 2013; Okada et al., 2012; Tao et al., 2014). To assess whether several key transcripts were 
expressed in CTX0E16 cells throughout early differentiation, CTX0E16 cultures were differentiated up 
to DD10 and lysed, processed and RNA extracted at DD0, DD2, DD4, DD6, DD8 and DD10. RNA 
samples were then assessed for expression of ZNF804A exon 4 (present in ZNF804A variant b and 
E3/E4 as well as full-length ZNF804A transcripts) via RT-PCR with GAPDH as an expression control; 
experiments were carried out in triplicate. Expression of ZNF804AE3/E4 and ZNF804Aexon2.2 was also 
assessed using transcript-specific primers. All three transcripts could be detected in proliferative 
CTX0E16 cells and throughout early differentiation (see Figure 5.3.1, B). 
As individual transcripts of ZNF804A possess differential sequences which may omit key 
domains in the final translated ZNF804A protein, including the zinc finger region and putative nuclear 
localisation signals, these variants may have also differential functions in neurons. In light of the 
preliminary finding of multiple ZNF804A transcripts being expressed throughout early differentiation of 
CTX0E16 cells, proliferative and differentiated (DD28) CTX0E16 cells were quantitatively analysed 
using q-PCR to determine whether the relative expression of each of these transcripts altered as these 
cells adopted a more mature neuronal fate. RNA samples from DD0 and DD28 CTX0E16 cultures were 
analysed using q-PCR to assess expression of  ZNF804Aexon4, ZNF804AE3/E4 and ZNF804Aexon2.2. 
Expression values for each transcript were normalised to a geometric mean of the expression values 
of three housekeeping genes (GAPDH, HPRT1 and RPL13A) using the 2^-dCT method (Livak and 
Schmittgen, 2001) ZNF804Aexon4 was found to be the most abundant transcript in both proliferative and 
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differentiated CTX0E16 cells (see Figure 5.3.1, C). Interestingly, a Kruskall-Wallis test of the expression 
data with a Dunn’s posthoc multiple comparisons test revealed that expression of this transcript was 
significantly reduced in DD28 cells relative to CTX0E16 hNPCs (relative expression to 3 decimal places: 
0.012±0.003 vs 0.021±0.002, p<0.001). No significant differences in expression between DD28 and 
DD0 cells could be detected for ZNF804Aexon2.2 (0.007±0.001 vs 0.009±0.000 for DD28 and DD0 cells 
respectively, p>0.05) or ZNF804AE3/E4, which was barely detectable at both time points (0.001±0.000 
vs 0.001±0.000 for DD28 and DD0 cells respectively, p>0.05). Overall, these findings indicate that the 
expression profile of these variants alters after several weeks of differentiation; this may have 
implications for differential functions of each of these transcripts throughout development. Previous 
studies have found a psychosis-associated SNP to reduce expression of the full length and E3/E4 
transcripts of ZNF804A in a time-restricted manner in the fetal brain (Hill and Bray, 2012; Tao et al., 
2014); identifying the roles these variants play in the developing brain as their expression profile alters 
may help identify the pathways they mediate which potentially underlie neuropsychiatric disease. 
Figure 5.3.1: Expression of ZNF804A mRNA transcripts in the CTX0E16 cell line. A: Schematic of 
domain structure in known and predicted ZNF804A variants. B: RT-PCR of mRNA for ZNF804Aexon4, 
E3/E4 and exon 2.2 transcripts in proliferative and early-stage differentiated cells derived from the CTX0E16 
cells.  C: q-PCR of mRNA samples for ZNF804Aexon4, E3/E4 and exon 2.2 transcripts in proliferative and 
early-stage differentiated cells derived from the CTX0E16 line. Results show relative expression values 
normalised to three housekeeping genes (n = 3 independent experiments; **p<0.01; ***p<0.001). q-
PCR was performed by Rodrigo Rafagnin using primers optimised by P.J. Michael Deans. 
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5.3.2 SELECTION OF A CANDIDATE ANTIBODY FOR THE INVESTIGATION OF 
ZNF804A EXPRESSION 
As described in Section 5.2, previous studies assessing the expression of the ZNF804A and 
Zfp804A proteins in human and rat cells have typically lacked a thorough validation of the antibodies 
used for western blotting, immunocytochemistry and immunohistochemistry. Thus, the selection and 
validation of a suitable antibody targeted to these proteins is crucial prior to any further investigations 
into the pattern of expression. Two independent antibodies were assessed for their ability to 
successfully detect the full length ZNF804A protein via western blotting; these results were 
subsequently validated using siRNA-mediated knockdown of the ZNF804A protein. Additionally, the 
specificity of each of these candidate antibodies to their corresponding antigens was further determined 
in a peptide preabsorption experiment. The candidate antibodies included the previously described goat 
anti-ZNF804A D-14 Santa Cruz antibody, which recognises an epitope within an internal region of the 
ZNF804A protein; and a rabbit anti-ZNF804A  Genetex antibody (C2C3) targeted to an epitope on the 
C-terminal of the protein. Human neuronal cells are predicted to express several variants of ZNF804A 
with differing molecular weights based on amino acid sequences derived from the NCBI record: the full 
length protein (1209 a.a., ~137 kDa), the E3/E4 variant (1074 a.a., ~125 kDa), variant b (602 a.a., ~68 
kDa) and variant 2.2 (88 a.a., ~9 kDa). One method of providing supporting evidence for the validity of 
an antibody targeted to a particular protein is to assess whether it can specifically detect protein bands 
corresponding to the predicted weights of the known isoforms. DD30 CTX0E16 lysates were probed for 
ZNF804A expression using each of the two antibodies. Western blotting revealed that the Genetex 
C2C3 antibody detected a major protein band at ~135 kDa, as well as minor protein bands at >100 kDa, 
~75 kDa, ~60 kDa and ~40 kDa. The ~135 kDa protein band is the mass predicted to be encoded by 
full length ZNF804A, and the >100 and 75 kDa bands are small enough to be encoded by the E3/E4 
and variant b ZNF804A isoforms. It is also worth noting that only low E3/E4 transcript expression seen 
via q-PCR is similarly reflected by the low expression of the protein band matching this isoform’s 
predicted mass. In contrast to this, the Santa Cruz antibody detected a major protein band at ~40 kDa, 
as well as minor protein bands at ~300 kDa, ~250 kDa, ~200 kDa, ~135 kDa, ~85 kDa, ~60 kDa and 
~45 kDa (see Figure 5.3.2, A). This is of particular interest as in previous studies this antibody had only 
been found to detect a single band at around 135 kDa, with no additional bands corresponding to other 
isoforms or putative non-specific staining being seen in rat NPCs or postmortem human tissue. Taken 
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together, these initial findings suggest that the Genetex anti-ZNF804A antibody may represent a more 
specific probe for ZNF804A than the previously used Santa Cruz antibody. 
siRNA-mediated knockdown of protein expression represents a useful method of verifying 
whether specific protein bands detected by a given antibody represent a true protein signal. To 
determine whether the protein bands seen in Figure 3.3.2, A would be reduced by knockdown of 
ZNF804A expression (an indicator of antibody specificity), DD7 CTX0E16 cultures were treated with 
two siRNAs targeting exon 2 and exon 4 of ZNF804A. These siRNAs have previously been validated 
via microarray and Q-PCR in a sister cell line of CTX0E16, CTX0E03 (Hill et al., 2012). siRNA-treated 
cultures were subsequently lysed and processed for either western blotting with both the Genetex and 
Santa Cruz antibodies, or for Q-PCR. An additional fluorescent oligonucleotide control condition was 
included as a measure of transfection efficiency using the N-Ter tranfection reagent; assessment of 
oligonucleotide uptake in CTX0E16 cells via live epifluorescence imaging revealed a transfection rate 
of 86.08±1.43% (see Figure 6.3.5, A). Knockdown of ZNF804Aexon4 at the mRNA level was confirmed 
using q-PCR followed by subsequent analysis using the 2^2dCT method, normalising values for the 
ZNF804A transcript to three previously validated internal control genes (RPL13A, RPL30 and HPRT1), 
then expressing the values for each condition relative to the scramble siRNA control as described in 
Section 2.6.3. Of these experimental replicates, relative expression of ZNF804Aexon4 was (in arbitrary 
units) 1.02±0.09 for the blank control; 1.00±0.00 for the scramble control; 0.56±0.17 for siRNA 1; and 
0.62±0.08 for siRNA 2 (see Figure 6.3.6, A). A Kruskall Wallis test of these data with posthoc Dunn’s 
multiple comparisons testing revealed that there was an overall significant effect of experimental 
condition (p<0.01) with the reductions in expression of ZNF804Aexon4 in the knockdown conditions 
relative to the scramble siRNA control condition being close to significant at the p=0.05 level (p=0.068 
and p=0.051 respectively). Analysis of ZNF804Aexon4 expression by Q-PCR revealed that both siRNA 1 
and 2 reduced ZNF804A mRNA by ~40%.  
To determine whether knockdown of ZNF804A could also be detected using each of the 
ZNF804A antibodies. For analysis of western blots, average intensities of bands mapping to known 
ZNF804A isoforms were normalised to a β-Actin control and expressed relative to the corresponding 
bands in the scramble siRNA condition. Normalised intensity values for bands corresponding to the 
predicted sizes of the full length (~135 kDa), E3/E4 (>100kDa) and variant b (~80kDa) ZNF804A 
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isoforms were all significantly reduced in siRNA-treated samples relative to untreated and scramble 
siRNA treated controls in western blots stained with the Genetex C2C3 antibody 40-50% reduction in 
protein levels for bands corresponding to predicted sizes for full length, E3/E4 and variant b isoforms 
of the ZNF804A protein, while two additional bands not corresponding to any known ZNF804A isoforms 
were not reduced (see Figure 5.3.2 in Chapter 5, G & H). A two way ANOVA with a posthoc Bonferroni 
multiple comparisons test revealed a highly significant effect of experimental condition (p<0.001) and 
the reductions of all three isoforms in the ZNF804A knockdown conditions to be highly significant 
(p<0.01).  (Figure 5.3.2, G & H). However, two additional bands at around 40 and 50 kDa could also 
be seen in these blots which did not diminish in siRNA-tread conditions, suggesting possible non-
specific staining. Additionally, in a western blot of the siRNA-treated cultures probed with the Santa 
Cruz D-14 antibody major bands seen at ~135, 100 and 80 kDa were reduced in the siRNA 1 and 2 
conditions indicating that this antibody is specific for ZNF804A; however, the presence of numerous 
additional protein bands not seen in the C2C3 antibody-stained western blots suggests that the Santa 
Cruz D-14 antibody may not be as specific as C2C3 (Figure 5.3.2, I). Taken together, these findings 
indicate that despite the presence of apparent non-specific bands in western blots of CTX0E16 lysates 
probed with the Genetex C2C3 antibody, this antibody appeared to provide a more accurate 
determinant of ZNF804A expression than the widely used D-14 Santa Cruz antibody. 
Peptide blocking experiments offer a further method for assessing the specificity of a particular 
antibody to its corresponding antigen. Previous research has found preincubation with a peptide for the 
Santa Cruz anti-ZNF804A antibody to abolish detection of the full length ZNF804A isoform protein band 
via western blotting. To assess the specificity of both antibodies for their respective antigens, and to 
determine the efficacy of these antibodies in ICC experiments, DD0 CTX0E16 cultures were 
immunostained for DAPI and either the Santa Cruz D-14 or the Genetex C2C3 ZNF804A antibody. 
Antibodies were either preincubated with their corresponding peptide or a blank control solution. 
Interestingly, peptide preincubation was not found to abolish immunostaining with the Santa Cruz 
antibody in DD0 CTX0E16 hNPCs as had been seen in western blotting experiments in previous 
research (see Figure 5.3.6, A & B). In contrast to this, peptide preabsorption of the Genetex antibody 
almost completely abolished the strong immunostaining in the DD0 CTX0E16 hNPCs. These results 
demonstrate that the Santa Cruz D-14 antibody does not exclusively target its intended epitope, while 
the Genetex C2C3 antibody appears to specifically bind to its corresponding peptide. 
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Overall, the evidence presented here indicates that of the two antibodies assessed in the 
present investigation, the Genetex C2C3 antibody appears to produce the greatest specificity of staining 
in both western blotting and ICC. However, additional validation of this antibody is required prior to 
further use in investigations of ZNF804A’s expression and distribution in neurons. In particular, the 
detection of both endogenous and exogenous ZNF804A protein must be confirmed in folded (ICC) and 
denatured (western blotting) conformations. Finally, it may also be of use to determine whether the 





Figure 5.3.2 (overleaf): Selection of a candidate anti-ZNF804A antibody. A & B: Western blotting of 
DD30 CTX0E16 lysates with C2C3 Genetex (A) and D-14 Santa Cruz (B) antibodies targeted to the 
ZNF804A protein. Red arrows denote bands corresponding to the predicted full length ZNF804A 
isoform; red arrowheads indicate bands corresponding to the predicted weights of other ZNF804A 
isoforms; asterisks indicate bands not corresponding to any known ZNF804A variants. C: siRNA 
treatment experiments: representative image of fluorescent oligonucleotide control condition assessing 
efficiency of N-Ter siRNA transfection. 86.08±1.43% of CTX0E16 cells were transfected with BLOCK-
iT red fluorescent oligo 1 day post transfection. Yellow arrows indicate transfected cells. D: Q-PCR of 
mRNA for ZNF804Aexon4 transcripts following 7 day siRNA treatment in DD7 CTX0E16-neurons.  E & 
F: Western blot of ZNF804A and quantification of knockdown following 7 day siRNA treatment in DD7 
CTX0E16 cells using Genetex C2C3 anti-ZNF804A antibody. Expression of all three protein isoforms 
was significantly reduced; asterisks indicate nonspecific bands (n = 3 independent experiments 
*p<0.05; **p<0.01). G: Western blot of ZNF804A following 7 day siRNA treatment in DD7 CTX0E16 
cells using the Santa Cruz D-14 anti-ZNF804A antibody. H: Representative confocal imaging of DD0 
CTX0E16 cells immunostained with the Genetex C2C3 or the Santa Cruz D-14 ZNF804A antibody with 
or without pre-incubation using the corresponding antigenic peptide. Yellow arrows indicate 
immunoreactive staining within the cytoplasm of CTX0E16 cells, white arrowheads highlights staining 
within cell nuclei and red arrow heads indicate possible non-specific staining. Note the pre-absorption 
with antigen abolished the granular staining produced by the ZNF804A C2C3 antibody alone, while 
staining using the Santa Cruz D-14 antibody was not abolished by antigen pre-absorption. Scale bars 
= 50 µm (C) and 10 µm (H). Western blots for A, B, E & G were conducted by Pooja Raval. 
5.3.3 FURTHER VALIDATION OF A CANDIDATE ZNF804A ANTIBODY – 
WESTERN BLOTTING 
Following the selection of the Genetex C2C3 antibody as a candidate for further validation, the 
protein bands seen in Figure 5.3.2 were further investigated using peptide pre-absorption and 
immunoprecipitation to determine whether they represented true binding of the antibody to the 
corresponding antigen on the unfolded ZNF804A protein. DD30 CTX0E16 lysates were 
immunoprecipitated with the C2C3 antibody, and probed with this antibody with or without peptide 
preabsorption. Preincubation of the C2C3 antibody with antigenic peptide prevented 
immunoprecipitation of the ~135, ~100 and 75 kDa proteins, demonstrating that binding to the protein 
was specific; a possible band at 40 kDa could potentially be seen, but due to signal from the IgG band 
the presence of this protein in the pre-immune condition could not be confirmed. These results were 
further investigated in rat primary cortical neurons to determine whether the C2C3 antibody also 
detected Zfp804A, the rodent homologue of ZNF804A. In whole cell lysate derived from DIV25 primary 
rat cortical neurons, western blotting using the C2C3 antibody revealed a single major protein band at 
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~140 kDa; this mass is higher than the predicted weight of Zfp804A, but could be due to post-
translational modifications. Immunoprecipitation with C2C3 as well as pre-immune and IgG control 
experiments further support that the ~140 kDa protein was specifically being bound to by the C2C3 
antibody. 
The specificity of a given antibody for a target protein can also be determined using the 
overexpression of a tagged protein construct in a cell line which does not express the endogenous 
protein; thus detection of this protein using the antibody can subsequently verified using an additional 
antibody targeted to the exogenous protein’s tag. As hEK293 cells have previously been demonstrated 
not to express the endogenous ZNF804A protein in detectable quantities (Girgenti et al., 2012), hEK293 
cultures were transfected using a myc-tagged ZNF804A construct and lysed two days later for 
subsequent western blotting. Probing of western blots with an anti-myc antibody revealed a major 
protein band at ~135 kDa, consistent with the predicted mass of the tagged ZNF804A protein. 
Interestingly, additional bands could be detected at lower weights, which may be indicative of protein 
degradation. Probing of the same lysates with the Genetex C2C3 ZNF804A antibody also detected 
proteins that corresponded to those detected by the myc antibody, demonstrating that the C2C3 
antibody specifically detects full length ZNF804A. 
In a final set of control experiments, a polyclonal population of SH-SY5Y cells stably expressing 
full length human ZNF804A with an N-terminally fused halo tag (halo-ZNF804A) was assessed for 
expression of the tagged full length ZNF804A protein using both fluorescence imaging of the 
HaloTagRTMRDirectTM ligand and probing using the Genetex C2C3 antibody. Pure wild type and 
polyclonal halo-ZNF804A SH-SY5Y cultures were lysed for subsequent western blotting. Importantly, a 
single band at >150 kDA was detected by the HaloTagRTMRDirectTM ligand in the halo-ZNF804A 
condition, a size consistent with a fusion of the halo tag and full length ZNF804A (halo tag = 33 kDa, 
ZNF804A = 135 kDa, total predicted weight of fusion protein = 168 kDa). A protein band of the 
corresponding weight was also detected by the Genetex C2C3 antibody in the halo-ZNF804A condition, 
but not wildtype conditions. It should be noted that additional bands of ~140 kDa and lower could be 
detected in both wildtype and halo-ZNF804A conditions. It is likely that these bands represent the 
endogenous protein expressed by these cells; however, it is also possible that these may be non-
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specific bands. Collectively, these data indicate that the C2C3 antibody specifically detects full length 
ZNF804A/Zfp804A, but that some minor non-specific band of low mass are also detected. 
 
Figure 5.3.3: Further validation of a candidate ZNF804A antibody using western blotting. A: Western 
blot of DD30 CTX0E16 cell lysates immunoprecipitated with the C2C3 antibody, and probed using this 
antibody with or without pre-incubation with 10 µg of antigenic peptide. Black arrow denotes band 
corresponding to the predicted mass of the full length ZNF804A protein; black arrow heads denote 
minor bands potentially corresponding to other known or predicted ZNF804A protein isoforms. Red 
asterisks denote non- specific bands. B: Western blot of DIV25 rat primary cortical neuron lysates 
immunoprecipitated with the C2C3 antibody and probed using this antibody with or without pre-
incubation with 10 µg of antigenic peptide. Black arrow denotes band corresponding to the predicted 
mass of the full length Zfp804A protein. C: Western blot of hEK293 cell lysates untransfected or 
transfected with a myc-tagged ZNF804A construct and probed with an anti-myc antibody; note the 
presence of additional smaller bands potentially indicating degradation of the overexpressed protein. 
D: Western blot shown in C but probed with the C2C3 anti-ZNF804A antibody; C2C3 specifically detects 
myc-ZNF804A. E & F: Western blot of wild-type and Halo-ZNF804A- expressing SH-SY5Y cell lysates 
probed with HaloTagRTMRDirectTM ligand (E) and C2C3 (F) antibody. A single band >150 kDa was 
highlighted by the HaloTag ligand in Halo- ZNF804A cells, confirming presence of exogenous Halo-
ZNF804A. An identical band could also be observed in Halo-ZNF804A-expressing, but not wildtype, 
SH-SY5Y cultures (black arrow) probed using the C2C3 antibody. In addition, several smaller proteins 
bands could be detected by the C2C3 antibody in both wildtype and Halo-ZNF804A SH-SY5Y cell 
lysates, further indicating expression of endogenous protein (black arrow heads). Western blots were 




5.3.4 FURTHER VALIDATION OF A CANDIDATE ZNF804A ANTIBODY – ICC 
Antibodies which successfully detect a given protein via western blotting techniques may not 
similarly detect the same protein in experiments using immunocytochemistry (ICC), as alterations in the 
folded protein structure relative to the denatured form may potentially impact the binding of antibodies 
to a given epitope. Therefore, any validation of an antibody for future use in ICC requires similar 
evidence that it may also bind specifically to the protein in its folded configuration. In western blotting, 
the Genetex C2C3 antibody was previously shown to detect a protein band corresponding to the 
predicted weight of the full length ZNF804A protein fused with the HaloTagRTMRDirectTM ligand; this 
band was also detected by the fluorescence signal from the ligand itself. To confirm this observation 
via ICC, a mixed population of halo-ZNF804A and wild type SH-SY5Y cells was immunostained using 
the Genetex C2C3 ZNF804A antibody. Here, ZNF804A immunofluorescence as detected by the 
Genetex C2C3 antibody could be seen to overlap with the halo signal, indicating that the ZNF804A 
antibody successfully detects the halo-tagged protein in SH-SY5Y cells. Non-transfected cells were 
also positive for ZNF804A, albeit at a lower level; this may be endogenous expression of the ZNF804A 
protein in wildtype SH-SY5Y cells as indicated by the previous western blotting experiment.  
In light of the finding that the Genetex C2C3 antibody could also detect exogenous ZNF804A 
tagged with a reporter molecule, hEK299 cultures were again utilised to determine whether the 
expression of exogenous ZNF804A tagged with a reporter molecule in a non-expressing cell line could 
be detected using the Genetex C2C3 antibody via ICC. hEK293 cultures were transfected with a GFP-
tagged human ZNF804A construct and double immunostained with GFP and Genetex C2C3 ZNF804A 
antibodies. GFP-ZNF804A could be observed within the cell nucleus as well within the cytoplasm; the 
protein was also found to accumulate at the plasma membrane of the cells. Examination of the C2C3 
ZNF804A channel revealed that it almost entirely overlapped with the GFP fluorescent signal. This can 
be readily seen in the colocalisation image, which highlights where the GFP and C2C3 channels 
overlap. Taken together with the findings of the halo-ZNF804A SH-SY5Y cell line and western blotting 
experiments, these data indicate that the Genetex C2C3 antibody specifically detects exogenous and 
endogenous ZNF804A and so is suitable for a wide variety of experimental paradigms. 
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Finally, the specificity of the Genetex C2C3 ZNF804A signal in CTX0E16 cells was also 
demonstrated in an ICC evaluation of Genetex immunostaining in both DD7 CTX0E16 cells treated with 
the previously described siRNAs. Here, analysis of ZNF804A immunostaining in cell soma revealed 
that ZNF804A staining intensity was reduced by around 30-40% in cultures treated with the two anti-
ZNF804A siRNAs relative to the two control conditions (see Figure 3.3.4, C & D). A one way ANOVA 
of this data with a posthoc Bonferroni multiple comparisons test revealed a main effect of treatment 
condition (p<0.01) and that the reduction in staining intensity seen in siRNA 1 and 2 treated cultures 
relative to the scramble control condition was also significant (p<0.05 for both comparisons), thus 
providing further support to the validity of the C2C3 antibody as a probe for ZNF804A. (see Figure 
5.3.4, C & D). Overall, these results indicate that siRNA-mediated knockdown of ZNF804A can be 
detected using the Genetex C2C3 antibody via ICC, further indicating that the signal detected by this 
antibody represents true staining of the protein. 
Taken together, the evidence presented in Section 5.3.3 and Section 5.3.4 strongly supports 
the validity of the Genetex C2C3 antibody as a specific probe for the full length ZNF804A protein, both 
via western blotting and ICC. This antibody also detects transgenic expression of this protein while 
fused to several reporter molecules, and further specifically detects the rodent homologue of ZNF804A, 
Zfp804A. Subsequent experiments will thus employ this antibody in a further characterisation of the 
pattern of ZNF804A expression in CTX0E16 NPCs and neurons as well as neurons derived from 




Figure 5.3.4: Further validation of a candidate ZNF804A antibody via immunocytochemistry. A: 
Representative confocal image of fixed SH-SY5Y cells overexpressing Halo-ZNF804A. Cells were triple 
labelled with the HaloTagRTMRDirectTM ligand, Genetex C2C3 antibody, and DAPI. Halo-ZNF804A was 
observed within the cell nuclei, cytosol and processes (magnified images). Moreover, C2C3 
immunofluorescence was strongest in Halo positive cells (red arrow); magnified images demonstrates 
overlap of C2C3 staining with HaloTag ligand signal. C2C3 immunofluorescence could also be 
observed in non- transfected cells (asterisks), suggesting that wildtype SH-SY5Y cells express 
ZNF804A at significant levels. B: Confocal image of hEK293 cell transfected with a GFP-tagged 
ZNF804A construct and doubled immunostained with GFP and Genetex C2C3 ZNF804A antibodies. 
140 
 
Figure 5.3.4, continued: White arrowheads highlights ZNF804A expression within cellular processes, 
and indicates overlapping GFP and ZNF804A immunostaining. Note the colocalisation of GFP and 
ZNF804A staining as shown in the final panel. C: Representative confocal images of DD7 CTX0E16 
cultures treated with a blank control condition (no transfection), a scramble siRNA or one of two siRNAs 
targeting the full length ZNF804A transcript for 7 days and immunostained for ZNF804A using the 
Genetex C2C3 antibody in addition to βIII tubulin as a marker of neuronal cells. D: Quantification of 
ZNF804A staining as seen in C. siRNA treatment of CTX0E16 cells significantly reduced C2C3 staining 
intensity in confocal images relative to control or scramble siRNA conditions (n = 3 independent 
experiments *p<0.05). Scale bars = 10 µm (A & B), 50 µm (C1) and 5 µm (C2). 
5.3.5 SUBCELLULAR LOCALISATION OF ZNF804A IN CTX0E16 NPCS AND 
NEURONS 
ZNF804A has been previously suggested to act as a transcription factor and thus would be 
expected to be expressed within the nuclei of neuronal cells (Girgenti et al., 2012). An assessment of 
the subcellular localisation of this protein may therefore provide valuable information on its potential 
roles within neurons, particularly if it is found outwith the cell nucleus. Following the promising early 
findings of ZNF804A transcript expression in proliferative CTX0E16 cells, the Genetex C2C3 ZNF804A 
antibody was employed using ICC to assess the subcellular localisation the endogenous ZNF804A 
protein in human NPCs from the CTX0E16 cell line, while overexpression of a ZNF804A construct 
tagged with GFP was used to independently confirm this pattern of localisation. DD0 hNPCs were either 
left untransfected or were transfected with a GFP-tagged ZNF804A construct then immunostained for 
DAPI, MAP2, GFP and ZNF804A, using the Genetex C2C3 antibody. Interestingly, granular ZNF804A 
immunostaining could be detected not only in the cell nucleus of CTX0E16 hNPCs (as highlighted by 
co-localisation with DAPI staining), but also could be seen within the cytoplasm of these cells (see 
Figure 5.3.5, A). This was further confirmed in CTX0E16 hNPCs overexpressing the GFP-tagged 
ZNF804A construct, with GFP signal being observed in the nuclei, cytoplasm and even within filopodia 
of transfected cells (Figure 5.3.5, B).  
The localisation of ZNF804A was further explored in neurons derived from the CTX0E16 line, 
to determine whether the subcellular pattern of expression of this protein is altered following several 
weeks of differentiation. DD28 CTX0E16 neuronal cultures were stained with DAPI, MAP2 and the 
Genetex C2C3 ZNF804A antibody. Assessment of ZNF804A staining with the C2C3 antibody in DD28 
MAP2-positive CTX0E16 neurons revealed that ZNF804A was distributed throughout nuclear and 
cytoplasmic compartments in a distinct punctate manner (see Figure 5.3.5, C & E). Interestingly, 
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ZNF804A immunostaining appeared to be predominately cytoplasmic, with greater staining intensity 
being found in MAP2-positive but DAPI-negative regions of the neurons relative to nuclear staining (see 
Figure 5.3.5, C & E). Furthermore, the ZNF804A-positive puncta were surprisingly found to be present 
along MAP2-positive dendrites in a manner reminiscent of staining for synaptic proteins in vivo and in 
vitro. Transfection of DD28 CTX0E16 cultures with a reporter-tagged ZNF804A construct was not 
possible due to cell death and a lack of transfection efficiency. However, early stage (DD7) CTX0E16 
cultures were successfully transfected with a c-myc-tagged ZNF804A construct and immunostained for 
the early neuronal marker βIII-tubulin and c-myc. A qualitative assessment of the pattern of myc 
immunostaining in myc-ZNF804A-positive cells indicated that exogenous expression of the tagged 
ZNF804A construct similarly displayed somatic expression, as well as expression of puncta within the 
developing neurites even at this early stage of differentiation (see Figure 5.3.5, D). 
As the endogenous ZNF804A protein appeared to exhibit differential staining in DD0 NPCs and 
DD28 neurons, the average staining intensity of this protein in cytoplasmic and nuclear compartments 
at both time points was measured to determine whether there was a significant alteration in protein 
distribution after several weeks of differentiation. As expected, quantification of relative ZNF804A 
expression in each compartment revealed that in DD0 cultures, ZNF804A was predominately localised 
to the nuclei of CTX0E16 hNPCs, while in DD28 cultures this localisation had become inverted, with 
ZNF804A expression being seen prominently in cytoplasmic regions while nuclear expression was 
more muted in comparison (see Figure 5.3.5, E). Student’s t tests performed on these data revealed 
that inter-compartmental differences in ZNF804A staining at each time point were significant (nuclear 
vs cytoplasmic expression, arbitrary units: 62.8±2.6 vs 37.2±2.6 (DD0) and 38.7±2.6 vs 61.3±2.6 
(DD28); 3 independent experiments for each time point, p<0.05 and p<0.01 for DD0 and DD28 cultures 
respectively). Overall, these findings suggest that in human NPCs ZNF804A is expressed 
predominately within the nucleus and thus may primarily function within this compartment, while in 
differentiated neurons this protein is mostly expressed outside the neuronal nuclei. 
In addition to this, the density of ZNF804A-positive puncta in distal MAP2-positive dendrites 
was quantified in the immunostained DD28 CTX0E16 cultures. Interestingly, DD28 CTX0E16 neurons 
were found to express ZNF804A-positive puncta at a density of 2.6±0.4 puncta per 10 µm (see Figure 
5.3.6, C); this is comparable to the previous findings of synaptic protein puncta density detailed in 
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Section 4.3.1. Given the similar pattern and density of ZNF804A staining to that previously seen for 
synaptic proteins in CTX0E16 neurons, it may be possible that this staining in fact represents a synaptic 
distribution. This possibility is further explored in Section 5.3.6. 
Figure 5.3.5: Expression of ZNF804A in CTX0E16 hNPCs and immature neurons. A: Distribution of 
endogenous ZNF804A in proliferative (DD0) CTX0E16 cells as determined by C2C3 Genetex. 
ZNF804A immunoreactive puncta were observed within the nucleus (white arrow heads), soma and in 
neurite-like protrusions (yellow arrows). B: Localisation of exogenously expressed GFP-ZNF804A in 
DD0 CTX0E16. This protein was found to localise to cell nuclei, cytosol and processes (inset). C: In 
DD28 CTX0E16 neurons ZNF804A was localised to the nucleus (white arrowheads) and along 
microtubule-associated protein 2 (MAP2)-positive dendrites (yellow arrows) using the GeneTex anti-
ZNF804A antibody. Orthogonal projections confirm ZNF804A presence at nuclear and extranuclear 
sites. D: Exogenous expression of myc-ZNF804A in DD7 CTX0E16-neurons, resulted in the protein 
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localising to punctate structures along doublecortin (DCX) positive neurites and at growth cones. Yellow 
dash box highlights magnified images (inset) of neurite processes demonstrating localisation of myc-
ZNF804A at growth cones. E: Distribution of endogenous ZNF804A in proliferative (DD0) and 
differentiated (DD28) CTX0E16 cells as determined by immunocytochemical analysis using C2C3 
antibody. ZNF804A immunoreactive puncta were observed within the nucleus (white arrowheads), 
soma, and in neurite-like protrusions (yellow arrows). F: Quantification of relative staining intensity of 
ZNF804A in nuclei and cytoplasm of DD0 and DD28 CTX0E16 cells (n = 3 independent experiments; 
**p<0.01). Scale bars = 20 µm (A & E), 10 µm (B) and 5 µm (C & D). 
5.3.6 ZNF804A IS PRESENT ALONG DENDRITES AND CO-LOCALISES WITH 
SYNAPTIC PROTEINS IN CTX0E16 NEURONS 
The expression of ZNF804A along the distal portions of MAP2-positive dendrites in a punctate 
manner echoes the immunostaining pattern characteristic of synaptic proteins in mature neurons, 
suggesting that this protein may be present at synapses. Indeed, several other zinc finger proteins have 
previously been found to localise to and regulate mechanisms at synapses. These include piccolo and 
bassoon, involved in the regulation of neurotransmitter release at glutamatergic and GABAergic 
synapses (Fenster et al., 2000; Waites et al., 2013), Makorin ring zinc finger protein 1 (MKRN1), a 
regulator of synaptic local translation (Miroci et al., 2012); and RIM proteins which interact with a number 
of key proteins at the active zone (Mittelstaedt et al., 2010). In light of this fascinating initial finding and 
with the previous findings of synaptic protein expression in CTX0E16 neurons (see Section 4.3.1), 
DD28 CTX0E16 neurons were immunostained for DAPI, MAP2, Genetex-ZNF804A and either PSD-95 
or GluN1 to determine whether these puncta co-localise with markers of putative excitatory synapses, 
suggestive of a post-synaptic localisation. Additionally, a subset of these cultures was transfected with 
a recombinant AAV vector driving eGFP expression under the control of a CamKII promoter as 
described in Section 2.3.2 and immunostained for C2C3 ZNF804A, DAPI and GFP to determine 
whether ZNF804A could also be found at putative dendritic spines in human neurons. Surprisingly, 
ZNF804A puncta were found to co-localise with a subset of both PSD-95 and GluN1 puncta, with ~44% 
of ZNF804A ROI staining positive for PSD-95 while approximately 40% of ZNF804A puncta co-
expressed GluN1 (puncta per 10 µm: ZNF804A, 2.8±0.38; PSD-95, 3.4±0.32; GluN1, 3.1±0.4; 
ZNF804A & PSD-95, 1.5±0.14; ZNF804A & GluN1, 1.2±0.17) (see Figure 5.3.8, A-C). Moreover, only 
a fraction of these synaptic puncta were themselves positive for ZNF804A staining, indicating that this 
protein may only possess a role at a subset of excitatory synapses in glutamatergic neurons. 
Interestingly, ZNF804A puncta could also be seen in the putative dendritic spines of CaMKII-positive 
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CTX0E16 neurons, further indicating a post-synaptic presence of this protein (Figure 5.3.7, D). These 
findings suggest that in addition to being distributed along MAP2-positive dendrites, a subset of 
ZNF804A also localises to the post-synaptic densities of glutamatergic synapses. 
  
 Figure 5.3.8: ZNF804A localises to putative synapses in DD28 CTX0E16 neurons. A & B: ZNF804A 
is present along distal dendrites of DD28 CTX0E16 neurons, where a sub-set of puncta co-localise with 
putative synaptic markers. White arrow heads indicate co-localisation of ZNF804A with PSD-95 (A) or 
the NMDA receptor subunit, GluN1 (B). C: Quantification of ZNF804A, PSD-95, GluN1 and co-localised 
puncta density in DD28 CTX0E16 neurons (puncta per 10 µm: ZNF804A, 2.8±0.38; PSD-95, 3.4±0.32; 
GluN1, 3.1±0.4; ZNF804A + PSD-95, 1.5±0.14; ZNF804A + GluN1, 1.2±0.17; n = 17 neurons from 3 
independent experiments). D: ZNF804A puncta were present within the heads of dendritic spines of 
DD35 CTX0E16 neurons transfected with peGFP. Yellow arrows indicate ZNF804A puncta within the 
heads of dendritic spines, white arrow heads indicate puncta within the dendritic shaft. Scale bars = 5 





5.3.7 SUBCELLULAR DISTRIBUTION OF ZNF804A IN HIPSC-DERIVED 
NEURONS 
The CTX0E16 cell line offered a useful model through which the subcellular localisation of 
ZNF804A could be characterised in both human neural progenitors and differentiated neurons. 
However, as this cell line is derived from the neuroepithelium of a single fetus, it is important to verify 
these novel findings in neurons generated from multiple sources. hiPSCs offer a powerful new system 
to assess the impact of genetic variation on specific cellular phenotypes, particularly within the context 
of diseases with a genetic component contributing to their overall risk. In addition to the benefit of a 
confirmation of the phenotype seen in CTX0E16 cells, experiments studying ZNF804A in hiPSC-
neurons also offer a “proof of concept” for potential future investigations into the impact of patient-
relevant mutations in the ZNF804A gene on expression and subcellular localisation of this protein. 
hiPSCs were derived from keratinocytes of three apparently healthy individuals via lentiviral 
transduction. These lines were differentiated for five weeks using a protocol which favours the robust 
generation of forebrain excitatory neurons (Shum et al., 2015). A prior in-house characterisation of these 
cell lines revealed that early hiPSC differentiation resulted in a homogenous population of neural 
precursor cells that stained positive for the neural stem cell markers nestin and Sox2, followed by the 
formation of nestin and ZO-1-positive neural rosettes (see Figure 5.3.9, A & B). Upon addition of the 
NOTCH inhibitor DAPT these cells underwent terminal differentiation, producing Tbr1-positive neurons, 
indicative of a deep cortical layer identity (Figure 5.3.9, C). These neurons also expressed VGlut1, 




Figure 5.3.9: Derivation of neurons from hiPSCs. A: Following 8 days of neuralisation, a population of 
early neuroepithelial cells was formed as determined by positive staining for nestin and SOX2. B: 
Subsequent generation of neural progenitor cells (NPCs) was determined by formation of neural 
rosettes. Apical lumen of rosettes were positive for ZO-1 with nestin positive cells forming a radial 
structure surrounding the lumen (yellow arrows). C & D: Terminal differentiation of NPCs resulted in the 
generation of projecting glutamatergic neurons which stained positive for TBR1 (C, yellow arrows) and 
VGlut1 (D, yellow arrows). Scale bars = 100 µm (A & B); 50 µm (C) or 20 µm (D). This work was 
conducted by Dr. Carole Shum. 
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ZNF804A transcript expression was again assessed via q-PCR and quantified using the ΔΔCT 
method in hiPSCs and DD30 hiPSC-derived neurons from three independent experiments in each cell 
line (see Figure 5.3.10, A). ZNF804Aexon4 was found to be the most abundant transcript in both hiPSCs 
and hiPSC-neurons, though surprisingly this expression was significantly upregulated in the neuronal 
cells relative to the hiPSCs (relative expression in arbitrary units: 0.270±0.066 vs 0.016±0.007 for 
hiPSC-neurons and hiPSCs respectively; p<0.05). Although at first this may appear to contradict the  
downregulation of the ZNF804Aexon4 following differentiation of CTX0E16 cells, it may be possible that 
the relatively high expression of this variant in hNPCs may represent a transient increase as these cells 
adopt a neural progenitor cell identity, followed by a modest downregulation as these cells terminally 
differentiate. ZNF804AE3/E4 expression was also found to be significantly increased in hiPSC-neurons 
in comparison to hiPSCs (0.061±0.015 vs 0.007±0.003 respectively; p<0.05); while ZNF804A2.2 was 
also significantly upregulated following several weeks of terminal differentiation though this variant was 
only expressed at very low levels at both stages of development (0.002±0.001 vs 0.001±0.001 for 
hiPSC-neurons and hiPSCs respectively; p<0.05). Taken together, these data support the findings of 
the previous q-PCR of CTX0E16 mRNA samples, indicating that expression of ZNF804Aexon4 is 
upregulated as neuronal cells differentiate.  
With this initial finding in mind, hiPSC-derived neurons were assessed via 
immunocytochemistry to determine whether these cells also recapitulate the extranuclear distribution 
and putative synaptic localisation seen in differentiated CTX0E16 neurons. DD35 hiPSC-neurons were 
immunostained for DAPI, MAP2, Genetex-ZNF804A and either PSD-95 or GluN1. As in CTX0E16 
neurons, MAP2-positive hiPSC-derived neurons were found to exhibit both nuclear and extranuclear 
distributions of ZNF804A, including within the cell soma and along MAP2-positive dendrites (see Figure 
5.3.10, B). In addition, discrete ZNF804A-positive puncta could be observed along the distal portions 
of these dendrites, consistent with the previous findings in differentiated CTX0E16 neurons (Figure 
5.3.7, C). Crucially, approximately 39% of these ZNF804A puncta were found to co-localise with PSD-
95, while ~45% of ZNF804A puncta co-localised with GluN1, a degree of co-localisation which was 
comparable to that seen in CTX0E16 neurons (puncta per 10 µm: ZNF804A, 2.46±0.36; PSD-95, 
3.18±0.30; GluN1, 2.61±0.32; PSD-95 & ZNF804A, 1.21±0.12; GluN1 & ZNF804A, 1.01±0.15) (Figure 
5.3.7, D). This further supports the interpretation that a subset of ZNF804A protein expressed along 
dendrites is localised to putative synapses. Additionally, as only a fraction of GluN1 and PSD-95 puncta 
148 
 
co-localised with ZNF804A, this may represent a subpopulation of glutamatergic synapses with a 
distinct functional identity. Collectively, these findings indicate that hiPSC-neurons will provide a useful 
paradigm for studying alterations in ZNF804A expression resulting from disease relevant mutations in 
this gene, in lines derived from patient subgroups and apparently healthy controls.  
 
Figure 5.3.10: ZNF804A localises to the cytosol and putative synapses in hiPSC-neurons. A: q-PCR 
of mRNA for ZNF804A exon 4, E3/E4 and variant c transcripts in hiPSCs and immature neuronal cells 
derived from three separate hiPSC lines (n = 3 independent experiments from 3 individual lines; 
*p<0.05). B: In 35 day old neurons differentiated from hiPSCs, ZNF804A puncta were observed in the 
nucleus (white arrow heads) and along dendrites (yellow arrows) in XY, XZ and YZ planes. C: ZNF804A 
puncta are also found along distal MAP2 positive dendrites. Co-staining with PSD-95 or GluN1 reveals 
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Figure 5.3.10, continued: that a fraction of ZNF804A puncta co-localise with either synaptic protein. 
D: Quantification of ZNF804A, PSD-95, GluN1 and co-localised puncta in hiPSC-neurons (puncta per 
10 µm: ZNF804A, 2.5±0.36; PSD-95, 3.2±0.3; GluN1, 2.6±0.32; ZNF804A + PSD-95, 1.2±0.11; 
ZNF804A + GluN1, 1.0±0.15; n = 16 neurons from 3 independent experiments). Scale bars = 5 µm (B 
& C). 
5.3.8 SUBCELLULAR LOCALISATION OF ZFP804A IN RAT PRIMARY 
CORTICAL NEURONS 
The description of ZNF804A localisation within various subcellular compartments in CTX0E16 
and hiPSC-derived neurons provided a valuable insight into the potential extranuclear functions of this 
protein. As ZNF804A was found to co-localise with key post-synaptic density proteins in both of these 
cellular models, an interesting further avenue of inquiry would be to investigate whether ZNF804A was 
expressed within dendritic spines, where the post-synaptic densities of excitatory synapses typically 
occur in the mammalian forebrain. However, despite CTX0E16 neurons being capable of developing 
putative dendritic spines (see Section 3.3.8) and previous research establishing that under certain 
protocols hiPSC-derived neurons are also capable of attaining spinogenesis (Marchetto et al., 2010a), 
these paradigms were impractical for assessing the distribution of ZNF804A in spines as the majority 
of synapses in these young developing neurons occur on the dendritic shaft rather than on spines. 
Thus, CTX0E16-neuron spines were too sparse to permit a meaningful analysis of protein expression 
and hiPSC-neuron spines typically require multiple months of culturing before they attain spinogenesis 
(Ricciardi et al., 2012; Verpelli et al., 2013). To address this, GFP-transfected rat primary cortical 
neurons were instead employed to determine whether the pattern of ZNF804A expression observed in 
CTX0E16- and hiPSC-neurons was conserved in neurons derived from another mammalian species 
and additionally to find whether the rat homologue Zfp804A was also located within the dendritic spines 
of these neurons. 
Cultures of primary rat cortical neurons were transfected with Synapsin-driven GFP at DIV23 
and immunostained at DIV25 for GFP or MAP2, Genetex-ZNF804A and DAPI. Qualitative assessment 
of the GFP-transfected and MAP2-positive pyramidal neurons revealed that Zfp804A was again 
localised within both the cell nuclei and the cytoplasm of the cell soma in a distinct punctate staining 
pattern (see Figure 5.3.11, A & B). Furthermore, Zfp804A puncta could also be observed within 
proximal and distal dendrites, consistent with the findings seen in neurons derived from human cell lines 
(see Figure 5.3.11, C & D). Critically, Zfp804A staining could also be observed within dendritic spines, 
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with 44.5±5.9% of spines expressing this protein (Figure 5.3.11, D). As spine morphology is thought to 
be closely related to synaptic function, Zfp804A-positive and –negative spines were categorised 
according to size, length and width. An evaluation of the size distributions of both Zfp804A-positive and 
Zfp804A negative spines found that the majority of dendritic spines containing Zfp804A had a total spine 
area of less than 1.0 µm2 (>70%) (Figure 5.3.11, E). Unpaired Student’s t tests were performed on 
spine length, width and area data to determine whether any differences between the two spine 
populations were significant. No significant differences could be found between the average lengths, 
widths or areas of Zfp804A-positive and negative spines (p>0.05; mean ± SEM of Zfp804A-positive vs 
Zfp804A negative spines: 1.30±0.08 µm vs 1.38±0.05 µm; 1.47±0.09 µm vs 1.60±0.06 µm; and 
0.97±0.07 µm2 vs 1.04±0.09 µm2 for spine length, width and area respectively) (Figure 5.3.11, F-H). A 
subset of Zfp804A-positive puncta could also be observed along putative axons of GFP-positive 
pyramidal neurons, suggesting that this protein may also be part of pre-synaptic or axonal structures 




Figure 5.3.11: Zfp804A is present at synapses in mature primary cortical neurons. A: Representative 
confocal image, including orthogonal views in the XZ and YZ planes, of a 25 days in vitro (DIV25) rat 
primary cortical neuron transfected with eGFP and immunostained for endogenous Zfp804A (rodent 
homologue of ZNF804A). Expression of Zfp804A within the cell nucleus is indicated with white arrow 
heads, while expression of Zfp804A within the cell soma and in proximal dendrites is indicated by yellow 
arrows. A: Endogenous Zfp804A is present in the nucleus and somato-dendritic compartments in 
MAP2-positive cortical neurons. Zfp804A was observed within the nucleus (white arrow heads) and as 
punctate structures along dendrites (yellow arrows). B: Representative confocal image, with orthogonal 
views, of MAP2-positive DIV25 rat primary cortical neuron co-stained for Zfp804A. Expression of 
Zfp804A within the cell nucleus is indicated with white arrow heads, while expression of Zfp804A within 
the cell soma and in proximal dendrites is indicated by yellow arrows. C: Zfp804A Figure 5.3.11, 
continued: -puncta are also found along distal MAP2 positive dendrites (open red arrow heads). D: 
Zfp804A localised to the dendritic shaft (open red arrow heads) and dendritic spines (white arrow heads) 
in the dendrites of mature primary cortical neurons. E: Histogram of the areas of spines that contain 
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Figure 5.3.11, continued: Zfp804A. A larger proportion of spines that contained Zfp804A had small-
to-medium area (<1 µm2), while fewer large spines (>1 µm2) contained Zfp804A signal. F-H: 
Quantification of morphological characteristics in Zfp804A-positive and Zfp804A-negative spines. No 
significant differences could be found for these characteristics in either population. I: Examination of 
endogenous ZNF804A distribution in DIV 25 cortical neurons revealed that a small amount of protein 
was present in axon processes (open red arrow heads). Scale bars = 5 µm (A-D, I). 
To further confirm this observed synaptic distribution, synaptosomal preparations were 
generated from DIV25 rat primary cortical neuron cultures and analysed via western blot using the 
Genetex anti-ZNF804A antibody alongside the whole cell lysates. Consistent with the 
immunocytochemistry data, a band at the expected ~137kDa size could be observed in the whole cell 
lysates and in crude synaptic lysates, further supporting a synaptic localisation of Zfp804A (Figure 
5.3.12, A). Additionally, multiple weaker bands not corresponding to any known ZNF804A isoforms 
could also be seen in these samples; these may have arisen from rat-human differences in the 
expressed variants. Overall, these observations indicate that in mature cortical neurons Zfp804A is 
present along the dendritic shaft and in pre- and post-synaptic structures, consistent with the findings 
in human cell lines. 
 
Figure 5.3.12: Western blot of lysates and subcellular fractions of DIV25 rat primary cortical neurons. 
A: Subcellular fractionation of DIV25 rat primary cortical neurons. Note the full length protein band at 
the predicted size of 137 kDa within the crude synaptosomal fraction. 
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Interestingly, a subset of pyramidal neurons exhibited Zfp804A staining with a greatly increased 
intensity in contrast to the majority of the other Zfp804A-positive neurons (hereafter described as 
“classical” or “type I” neurons; Figure 5.3.13, A & B). Brightly stained neurons could be further 
categorised into those expressing Zfp804A in punctate structures (hereafter described as “type II” 
neurons; see Figure 5.3.13, C) and other brightly-stained neurons expressing Zfp804A in distinct 
elongated “log” structures structures (hereafter described as “type III” neurons; see Figure 5.3.13, D), 
located within the cell nuclei and within dendro-somatic compartments. Although this discovery was 
made relatively late in the present investigation and therefore precluding any further investigation into 
this phenomenon, an interesting avenue of inquiry in future research would be to determine whether 
each of these neuronal subtypes is limited to specific classes or regional identities of neuron. 
Furthermore, as in type II and type III neurons the Zfp804A puncta and “logs” could be observed along 
the dendrites of these cells similarly to classical Zfp804A-positive neurons, it may be possible that these 




Figure 5.3.13, overleaf: Subtypes of Zfp804A staining. A: In DIV25 primary rat cortical cultures, 
Zfp804A-positive cells adopt differential patterns of localisation. A minority of Zfp804A-positive cells 
adopt a particularly strong Zfp804A staining pattern (red arrow) in contrast to the subdued staining of 
the “classical” Zfp804A-positive neuron (yellow arrows). Zfp804A-negative cells (white arrowheads) are 
also shown. B-D: Representative confocal images of each of the three Zfp804A expression subtypes. 
B: A “classical” or “type I” Zfp804A-positive neuron. C: A “bright puncta” or “type II” Zfp804A-positive 
neuron. D: A “bright log” or “type III” Zfp804A-positive neuron. White arrowheads highlight nuclear 
staining, yellow arrows indicate staining along putative neurites. Scale bars = 20 µm (A) & 10 µm (B-
D). 
5.3.9 SUBSYNAPTIC LOCALISATION OF ZFP804A 
Recent research into synaptic protein localisation has resulted in a growing recognition that 
these proteins are organised into sub-synaptic domains (Smith et al., 2014; Willig and Barrantes, 2014). 
Although confocal imaging of Zfp804A in GFP-transfected neurons provided some useful information 
about the general expression of this protein in spines, the limit of resolution possible with this imaging 
technique (~200nm) precludes any characterisation of protein localisation at the sub-synaptic level. To 
address this limitation, GFP-transfected rat primary cortical neurons immunostained as described 
previously were instead imaged using structured illumination microscopy (SIM), a superresolution  
imaging technique which utilises an algorithm based on the diffraction of light through a rotating grid to 
enhance the resolution of standard confocal microscopy (Gustafsson, 2000). SIM imaging revealed that 
this protein was present within nanoscopic structures along the dendritic shaft and in spines see (see 
Figure 5.3.14, A). Furthermore, SIM imaging confirmed putative axonal expression of this protein in 
discrete nanoscale structures (Figure 5.3.14, B). In contrast to the results of confocal imaging which 
indicated Zfp804A was distributed throughout the dendritic spine head and neck (Figure 5.3.14, C), 
SIM imaging revealed Zfp804A clustered in domains within spine heads; intensity profiles of Zfp804A 
staining throughout the spine confirmed this enrichment in spine heads ( Figure 5.3.13, D). Zfp804A-
positive nanodomains could also be observed along dendrites and surprisingly, specific localisation of 
the protein could be seen at the base of a subpopulation of dendritic spines. 
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Figure 5.3.13: Sub-structural localisation of Zfp804A in primary rat cortical neurons. A: Superresolution 
SIM images of Zfp804A sub-cellular localisation in GFP expressing primary rat cortical neurons (DIV 
25). Zfp804A is present in spine heads (white arrow heads) and  along the dendrite (yellow arrow 
heads). B: SIM image of axon from GFP-expressing neuron reveals that Zfp804A is present in small 
puncta along axons (red open arrow heads). C: High magnification confocal image of dendritic spine in 
Figure 5.3.11, D. A line scan through the spine and shaft shows greater Zfp804A fluorescence intensity 
in the head compared to the shaft. D: Superresolution SIM images of Zfp804A subsynaptic localisation 
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Figure 5.3.13, continued: in primary cortical neurons. Zfp804A is present in spine heads (white arrow 
heads) and along the dendrite (red open arrow heads). Outline of neuronal Figure 5.3.13, continued: 
-morphology is indicated by yellow dashed lines. Zfp804A signal could also be detected at the base of 
(red open arrow heads). A line scan through the spine and shaft shows that spines is present within the 
heads of spines. Scale bars = 5 µm (A & B), 1 µm (C) and 500 nm (D). 
5.3.10 ORGANISATION OF ZFP804A WITHIN THE GLUTAMATERGIC 
SYNAPSE 
The post-synaptic density of excitatory synapses contains a wide array of proteins arranged in 
highly organised subsynaptic structures. Previous ultrastructural studies have shown that PSD-95 and 
GluN1 are both core components of the post-synaptic density of glutamatergic synapses (Gerrow et al., 
2006; Kim and Sheng, 2004). To determine the co-localisation rate of Zfp804A with these proteins in 
spines, and additionally to determine how Zfp804A integrates into the post-synaptic density relative to 
these proteins, GFP-transfected DIV25 rat primary cortical neurons were immunostained for GFP, 
Genetex-ZNF804A and either PSD-95 or GluN1 and imaged using confocal and SIM microscopy as 
described in Section 5.3.10. Similarly to previous results in CTX0E16 and hiPSC-neurons, Zfp804A 
puncta were found to co-localise with a subset of synaptic puncta in dendritic spines (Figure 5.3.14, A). 
Confocal images of these proteins in dendritic spines revealed that approximately 53.8±6.9% of PSD-
95-positive spines also expressed Zfp804A. In contrast to this, 89.9±2.5% of GluN1-positive spines 
exhibited Zfp804A (Figure 5.3.14, B). This suggests that in the dendritic spines of mature cortical 
neurons, Zfp804A may preferentially segregate to synapses containing ionotropic NMDA receptors at 
this stage of development. An additional attempt at confirmation of this pattern of immunostaining in 
vivo was carried out in adult mouse cortical sections. Sections were immunostained for the nuclear 
marker DAPI, Genetex-ZNF804A/Zfp804A and the excitatory pre-synaptic marker bassoon. 
Interestingly, in these sections Zfp804A retained the punctate staining pattern seen in vitro, with a 
subset of ZNF804A-positive puncta being juxtaposed or co-localising with the pre-synaptic marker 
bassoon, again indicating a synaptic localisation of this protein (Figure 5.3.14, C & D). Taken together, 
these findings indicate that Zfp804A co-localises with several key synaptic proteins in discrete puncta 




Figure 5.3.14: Endogenous Zfp804A localises to putative excitatory synapses in cortical rodent neurons 
in vitro and in vivo. A: Representative confocal image of GFP-expressing cortical neurons co-stained 
for Zfp804A and either PSD-95 or GluN1. This revealed that a fraction of Zfp804A puncta co-localise 
with PSD-95 and GluN1 in spines (white arrows heads). Open red arrow heads label Zfp804A puncta 
not co-localised.  B: Quantification of Zfp804A, PSD-95, GluN1 and co-localised puncta in dendritic 
spines (spines per 10 µm: total, 5.9±0.68; Zfp804A, 2.9±0.17; Zfp804A + PSD-95, 2.34±0.32; Zfp804A 
+ GluN1, 1.8±0.23). C & D: Representative confocal images of mouse cortical sections stained for 
Zfp804A and the pre-synaptic excitatory marker bassoon. White arrowheads indicate areas of co-
localisation highlighted in white. Scale bars = 5 µm (A, C & D). 
Qualitative assessment of the substructural organisation of these proteins via SIM imaging 
revealed that Zfp804A adopted a non-uniform distribution within spine heads; this domain was found to 
partially co-localise with a surrounding PSD-95-positive region (Figure 5.3.15, A). Linescans across 
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Zfp804A and PSD-95-positive regions in spine heads further supported a partial co-localisation of these 
proteins, while a qualitative assessment of expression within the spine head across the Z-plane 
confirmed that this was not an artifact of Z-projecting multiple planes of a three dimensional structure 
into a two dimensional image (Figure 5.3.15, C). SIM imaging of Zfp804A-positive spines co-stained 
for GluN1 revealed that this protein also partially co-localised with Zfp804A; intensity profiles of these 
puncta confirmed this partial overlap, while an evaluation of the Z-plane of these spines again 
determined that this was not an artifact of the Z-projection of the image (Figure 5.3.15, B & D). Taken 
as a whole, these findings indicate that in a majority of spines expressing the core glutamatergic post-
synaptic density components PSD-95 or GluN1, Zfp804A is co-expressed with either protein. In addition 
to this, within dendritic spine heads Zfp804A appears to be predominately localised to the perisynaptic 
region. Moreover, a small proportion of this protein may potentially be present within the post-synaptic 
density, raising the possibility that a subset of Zfp804A forms complexes with synaptic proteins. 
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Figure 5.3.15: Subsynaptic distribution of Zfp804A in mature rat primary cortical neurons. A & B: High 
magnification SIM image of co-localised ZNF804A and PSD-95 (A) or GluN1 (B) puncta (indicated with 
white triangles) within GFP-transfected dendritic spines (outline of spine indicated with yellow dashed 
lines): co-localisation is indicated by white overlap. Intensity profiles of co-localised ZNF804A and either 
PSD-95 or GluN1 within spine heads demonstrates partial co-localisation of the puncta. C & D: High 
magnification SIM image of co-localised Zfp804A and PSD-95 (C) or GluN1 (D) puncta (indicated with 
red triangles) within GFP-transfected dendritic spines (outline of spine indicated with yellow dashed 
lines), including orthogonal views in the XZ and YZ planes. Co-localisation is indicated by white overlap. 








This chapter has presented evidence validating a candidate anti-ZNF804A antibody for use in                                                                                                                                                                                                                                                                                                       
studies of ZNF804A protein expression and localisation. It has also demonstrated the expression of 
several transcript variants of the ZNF804A gene in neurons derived from several human stem cell lines, 
and has described how expression of these variants alters during terminal differentiation. In addition to 
this, it has demonstrated the subcellular distribution of ZNF804A and Zfp804A proteins in several 
neuronal models, surprisingly finding that these proteins are expressed outwith neuronal nuclei, along 
axons and dendrites and even within putative synapses. Finally, this chapter has demonstrated that 
Zfp804A can be found in distinct nanodomains highly integrated within the architecture of the post-
synaptic density using super-resolution imaging. 
Expression of ZNF804A transcripts in hNPC and hiPSC-derived cultures was found to vary as 
these cells were terminally differentiated. Previous research has found expression of ZNF804A to be 
expressed throughout the lifespan, though expression of both ZNF804AE3/E4 and ZNF804AFL is 
particularly high during fetal development (Tao et al., 2014). In addition to this, ZNF804AE3/E4 has been 
found to be expressed at a higher level than ZNF804AFL at this stage. This is in contrast to the findings 
of this thesis, where ZNF804AE3E4 expression was found to be much lower than ZNF804Aexon4 in both 
CTX0E16 neurons and hiPSC-neurons at a comparable stage of development to the second trimester 
fetal brain. However, it should be noted that this may be due to the predicted b variant of ZNF804A also 
being detected by the ZNF804Aexon4 primers used in this experiment. In rats, expression of the rodent 
homologue Zfp804A peaks at around postnatal day 21 in the dentate gyrus and CA1 of the 
hippocampus, and expression within the lower layers of the cortex was found to be highest at postnatal 
day 1, though the possibility remains that expression could be even higher prenatally. Although there 
are limitations in the comparison of developmental stages in rodents to those of the human fetus (Bayer 
et al., 1993; Clancy et al., 2008), it is worth noting that should the pattern of high but Zfp804A transcript 
expression within the lower layers of the postnatal rodent cortex may be comparable to the 
developmental stage assessed in the fetal brain. These investigations were both past the estimated 
stage of neuronal proliferation during neurodevelopment in their respective species (Bayer et al., 1993). 
However, the possibility remains that expression of these transcripts may be even higher in neural 
progenitor cells, as seen in the current investigation. Indeed, if the trend of a progressive postnatal 
decrease in deep layer cortical Zfp804A expression is extrapolated to prenatal NPCs, this would predict 
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an even higher expression in these multipotent cells. When CTX0E16 expression data is taken in 
conjunction with that taken from hiPSC lines it suggests that peak expression of the full length transcript 
occurs once cells have adopted a neural identity, but that expression decreases as these cells terminally 
differentiate. 
Surprisingly, in contrast to the findings of Tao et al. (2014) the current study found ZNF804AE3/E4 
to be expressed at a much lower level than ZNF804Aexon4 variant in all cell types assessed. However, it 
must be stressed that the relative maturity of the neurons assessed in the present investigation may 
not yet match that of the fetal tissue assessed by Tao et al, and it is possible that the E3/E4 variant may 
be upregulated further later on in differentiation. Other explanations for this divergence in results include 
differences between the cohort from which the hiPSC lines are derived and the cohort assessed in the 
Tao paper, artefacts arising from the use of in vitro systems and the predominately glutamatergic 
identity of the CTX0E16 cultures in contrast to the more diverse environment of the whole brain slices 
used by Tao. 
In western blots of DD7 and DD20 CTX0E16 cells, bands corresponding to the full length, 
E3/E4 and variant b isoforms could be seen after probing with the Genetex C2C3 anti-ZNF804A 
antibody, with two additional bands which did not match to any known ZNF804A isoforms. Interestingly, 
the E3/E4 protein isoform has never been detected before via western blotting; this has previously been 
postulated to be a result of post-translational modifications of this variant increasing its molecular weight 
and thus merging its predicted band with that of the full length protein (Tao et al., 2014). The presence 
of additional bands within these western blots may be suggestive of non-specific binding. As these 
bands did not respond to siRNA treatment it is unlikely that they correspond to ZNF804A isoforms 
containing exon 2 or exon 4, though the possibility remains that they may correspond to an as yet 
unknown ZNF804A variant. Although the current investigation presents considerable evidence to justify 
the use of the C2C3 antibody as a probe for the full length ZNF804A protein – through western blotting, 
immunoprecipitation, ICC, peptide blocking and detection of exogenous protein – future research will 
benefit from with use of transcript-specific constructs and ZNF804A knockout lines to verify whether the 
additional bands detected by this antibody represent other ZNF804A isoforms. This would in turn permit 
an evaluation of the specific functions of each individual ZNF804A isoform. 
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The present investigation found ZNF804A and Zfp804A to not only be expressed within both 
nuclear and extranuclear regions in NPCs and neurons derived from multiple sources. The expression 
of ZNF804A/Zfp804A within multiple cellular compartments is likely to be consistent with multiple 
functions within NPCs and mature neurons. In NPCs ZNF804A is seen predominately within the 
nucleus, consistent with previous work by Girgenti et al. (2012), who found expression of Zfp804A to 
be predominately located within the nucleus of rat neural progenitor cells. This nuclear expression is 
comparatively reduced in mature neurons, reflecting the predominately cytoplasmic but partially nuclear 
immunostaining described by Tao et al. (2014) and Bernstein et al. (2014) in layer III pyramidal neurons 
of the adult inferior parietal cortex and temporal cortex. The full length ZNF804A protein contains a 
C2H2 zinc finger domain, a motif known to mediate DNA-binding in several other proteins (Najafabadi 
et al., 2015). Moreover, previous research has found ZNF804A to regulate expression of a wide range 
of genes involved in cell adhesion, neurite outgrowth (Hill et al., 2012), TGF-β signalling (Umeda-Yano 
et al., 2013), synaptic function (Girgenti et al., 2012) and interferon signalling (Chen et al., 2015). The 
nuclear expression demonstrated in the current investigation and previous studies is therefore likely to 
be consistent with a role as a transcription factor. 
In addition to the nuclear expression demonstrated in the present investigation, ZNF804A was 
found to co-localise with synaptic proteins in multiple human cell lines, and Zfp804A was found in 
nanodomains highly integrated within the post-synaptic densities of dendritic spines in rat cortical 
neurons, highlighting the interesting possibility that ZNF804A may possess additional functions at this 
site. Assessment of Zfp804A expression in crude synaptosomal fractions confirmed enrichment of the 
full length protein at synapses, though it should be noted that these fractions also contain membranes 
and thus the possibility remains that this protein may also be tightly integrated within the membrane. A 
subportion of Zfp804A was also found to be expressed at the base of dendritic spines via 
superresolution imaging. Previous research has found this site to be a critical area in which the local 
translation of mRNAs occurs (Martin and Zukin, 2006). C2H2 zinc finger proteins are also known to act 
as RNA binding partners (Brown, 2005), thus this intriguing extranuclear localisation may be indicative 
of an additional role in local RNA processing, both at the base of spines and within the spine head itself. 
ZNF804A/Zfp804A may bind to specific sequences on mRNAs for proteins involved in synaptic 
formation, maintenance or function, thereby influencing these processes by mediating mRNA transport, 
degradation or translation. Indeed, several RNA-binding proteins localised to the synapse have 
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previously been found to contribute to disease-related processes. For example, the RNA-binding 
protein FMRP is known to mediate both mRNA transport in dendrites and local translation at synapses; 
mutations in the gene coding for this protein (FMR1) result in one of the most common heritable forms 
of autism, Fragile X syndrome. FMR1 mutations have also previously been found to result in synaptic 
dysfunction and reductions in neurite outgrowth in human stem cell models, mouse models and post-
mortem tissue (Dictenberg et al., 2008; Irwin et al., 2000; Liu et al., 2012). In light of the novel synaptic 
localisation and potential RNA-binding functions of ZNF804A and Zfp804A seen in this chapter, the 
impact of these proteins on dendritic spine morphology and function will similarly be explored in Chapter 
6.   
Interestingly, expression of the ZNF804A protein appears to be malleable as hNPCs terminally 
differentiate, switching from a predominately nuclear localisation in NPCs to a more cytoplasmic/neuritic 
distribution in mature neurons. In addition to reflecting the pattern of localisation seen rat NPCs and 
human cortical neurons in previous research (Bernstein et al., 2014; Girgenti et al., 2012; Tao et al., 
2014), this phenomenon has also been noted in rat primary cortical neurons as they differentiate (Hinna 
et al., 2015). In these cells a shift in Zfp804A localisation has been observed, from perinuclear regions 
to a more universal (both cytoplasmic and dendritic) distribution with particularly high expression being 
seen in the growth cones of the more mature neurons. However, it should be noted that the Hinna study 
utilised the Santa Cruz D-14 ZNF804A antibody without any control experiments; based on the 
validation experiments performed in this chapter any results obtained using this antibody must be 
interpreted with caution. Despite this, the shift in ZNF804A distribution seen in CTX0E16 NPCs and 
neurons offers an intriguing insight into the different roles this protein may play at different stages of 
development. Based on the putative role of ZNF804A as a transcription factor, and the potential role 
this protein may play in local translation at synapses, this shift may represent an alteration in the primary 
function of the full length protein: early in differentiation ZNF804A localises primarily to the nucleus and 
regulates expression of several genes including those involved in neurite outgrowth, while later on this 
protein is redistributed to local sites to regulate synaptic formation, function or maintenance through the 
regulation of processes relevant to local mRNA translation. This redistribution may arise as a 
consequence of alterations in trafficking or degradation of the full length protein at various time points 




An alternative explanation for the alterations in the pattern of ZNF804A expression seen in 
CTX0E16 cells may that these changes reflect fluctuations in the expression profile of various ZNF804A 
isoforms throughout differentiation. ZNF804Aexon4 was previously shown to be downregulated in 
neurons relative to NPCs, while no significant differences were seen in ZNF804AE3E4 and 
ZNF804Aexon2.2 expression. The full length variant may act primarily within the nucleus as a transcription 
factor, with other variants being preferentially upregulated following differentiation which adopt 
extranuclear distributions and functions. For example, the disease-linked E3/E4 variant lacks the C2H2 
ZNF domain present within the full length protein and thus possesses no obvious ability to bind to DNA 
or act as a transcription factor (Tao et al., 2014).  
The fascinating discovery of two subsets of primary rat cortical neurons expressing Zfp804A in 
a highly distinct manner raises critical questions about the regional and functional identity of these cells. 
The present investigation focused primarily on the subcellular localisation of the ZNF804a/Zfp804A 
protein, and the consequences of manipulation of expression of these proteins. However, a key 
experiment to conduct in future investigations would be to determine whether each of these patterns of 
expression is associated with markers of specific neuronal subtypes or cortical layers, and further 
whether the brightly stained Zfp804A-positive “logs” along the putative dendrites of type III neurons co-
localise with different proteins to those for type II neurons. Given the morphology of these individual 
domains it is of interest to note that immunostaining of excitatory synapses typically adopts a punctate 
pattern, while immunostaining of inhibitory synaptic proteins such as GAD65 and GAD67 typically 
occurs in an elongated fashion (Schwab et al., 2013) very similar to the “logs” seen in some of the 
intensely stained Zfp804A-positve neurons. Additionally, inhibitory synapses are commonly expressed 
on the cell soma of the post-synaptic neuron similarly to the Zfp804A staining seen in type III neurons 
(Fritschy et al., 2006). Thus, these two subgroups of cells may differentially express Zfp804A at 
excitatory or inhibitory synapses respectively. Such a binarised pattern of expression appears highly 
unusual in neurons possessing both excitatory and inhibitory synapses; thus further investigation must 
be conducted to determine whether this pattern of staining is truly reflective of synaptic localisation as 
seen in type I Zfp804A-positive neurons. 
Interestingly, no other variants of the Zfp804A protein could be detected in whole cell lysates 
or in synaptosomal fractions, raising the possibility that a rodent homologue of the disease-associated 
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E3/E4 variant may not exist, though notably another predicted isoform for this gene is listed on 
ACEVIEW, consisting of exon 2, exon 3 and a truncated exon 4 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=mouse&q=Zfp804a). This finding also 
suggests that the protein expressed at post-synaptic sites in human neurons may indeed be the full 
length protein, possessing the ZNF domain. Thus, if ZNF804A does indeed act locally at the synapse 
via RNA-binding mediated by this ZNF domain, it is likely that this function would be conserved in the 
dendritic spines of rodent neurons. 
This chapter has presented considerable data on the mRNA and protein expression of several 
variants of ZNF804A and Zfp804A in a number of in vitro models, providing a valuable insight into 
potential novel functions of this protein. However, further work is required before an extranuclear 
function of this protein can be definitively established, particularly in the context of expression at 
dendritic spines. The manipulation of expression of a given protein can provide key information about 
its prospective functions. Overexpression, knockdown or even knockout of ZNF804A and Zfp804A can 
indicate whether ZNF804A’s putative role as a transcription factor has functional relevance, while 
subsequently indicating alternative functions outside of the nucleus. These techniques can also provide 
valuable tools to aid in the validation of antibodies targeted to a given protein. The next chapter will 
discuss several experiments attempting the manipulation of ZNF804A and Zfp804A expression in 
human and rodent cell lines. It will further discuss how these techniques can aid in the validation of 
antibodies described in the present chapter, and discuss how the findings of these experiments 








CHAPTER 6: THE ROLE OF ZNF804A 
IN NEURITE OUTGROWTH AND 
DENDRITIC SPINE MAINTENANCE 
AND PLASTICITY 
6.1 SUMMARY 
This chapter describes investigations into the cellular functions of ZNF804A via several 
techniques aimed at altering the expression of this gene by knockout, knockdown or overexpression. 
An initial effort to excise exon 3 of the full length ZNF804A gene from the genome of the previously 
described CTX0E16 hNPC line proved unsuccessful, as did attempts to overexpress two tagged 
ZNF804A constructs in several cell lines. This chapter also outlines several experiments attempting to 
knockdown ZNF804A and Zfp804A in human and rodent neuronal cells using two independent siRNAs, 
and describes how treatment with these siRNAs impacted early neurite outgrowth and maintenance of 
dendritic spines in mature neurons. The impact of inducing chemical-LTP on the subcellular localisation 
of Zfp804A in rat primary cortical neurons is also shown. Finally, these findings are discussed in the 
context of previous studies assessing the function of these proteins using knockdown and 
overexpression techniques. 
6.2 INTRODUCTION 
In Chapter 5 the detailed characterisation of the subcellular localisation of ZNF804A and its 
rodent homologue, Zfp804A, provided a valuable insight into their potential extranuclear and non-
transcriptional functions. This highlighted interesting avenues of experimental inquiry into these roles, 
as well as the predicted actions of these proteins as transcription factors. However, further investigation 
is required to determine whether this extranuclear localisation is reflective of additional functions within 
the cell cytoplasm or even at the synapse. Several previous studies have attempted to assess the 
functions of ZNF804A and Zfp804A through techniques altering the expression of these proteins. 
Specifically, a large number of studies have now strongly implicated ZNF804A and Zfp804A as 
regulators of gene transcription (Hill et al., 2012; Girgenti et al., 2012; Chen et al., 2015; Umeda-Yano 
et al., 2013; Colak et al., 2008; Pereira, Delany, & Canalis, 2004; Jia, Wang, Meltzer, & Zhao, 2010; 
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Miller, Buckley, Seabolt, Mellor, & Kirkpatrick, 2011). However, no studies have yet attempted to 
determine whether these alterations in gene expression have downstream effects on neuronal 
characteristics. As the expression of genes involved in neurite outgrowth and cell adhesion has 
previously been found to be altered in hNPCs following ZNF804A knockdown (Hill et al., 2012), a 
subsequent investigation into whether alterations in ZNF804A expression also impact early neurite 
outgrowth may provide a valuable insight into the links between this protein and the disease 
mechanisms underlying psychiatric disorders. In addition to this, as cell adhesion proteins play a key 
role in the formation of synapses (McAllister, 2007), the alterations in expression of several cell 
adhesion genes seen in hNPCs following ZNF804A knockdown in this study may also indicate that this 
protein mediates synapse development via regulation of transcription. Furthermore, as Zfp804A and 
ZNF804A were found to be expressed at putative synapses in the previous chapter, these proteins may 
possess a role in the formation, maturation or maintenance of dendritic spines in a similar manner to 
other synaptic proteins. 
In light of the lack of information of the downstream consequences of the manipulation of 
ZNF804A/Zfp804A expression on functional characteristics of neurons, the current investigation utilised 
siRNA-mediated knockdown of ZNF804A and Zfp804A, commonly used in in vitro studies as a means 
of assessing the potential functions of a given protein (Hannon, 2002; Ma et al., 2007; Prelich, 2012; 
Santiago et al., 2008). Specifically, this study describes the impact of siRNA treatment on early neurite 
outgrowth in multiple human neural stem cell models, as well as the impact of ZNF804A knockdown on 
expression of adhesion proteins. It further outlines the impact of Zfp804A knockdown on dendritic spine 
maintenance and LTP-dependent spine plasticity as well as the effect of LTP induction on the 
subcellular expression of Zfp804A in mature rat primary cortical neurons. Taken together, these data 
provide a further understanding of both the upstream and downstream pathways involved in ZNF804A 
and Zfp804A function, and thus how these proteins may integrate into the pathophysiological 
mechanisms underlying psychiatric disease. 
6.3 RESULTS 
6.3.1 ZNF804A MEDIATES EARLY NEURITE OUTGROWTH IN CTX0E16 CELLS 
siRNA (Small Interfering RNA)-mediated knockdown of ZNF804A expression has been 
previously used in a sister cell line of CTX0E16 hNPCs, CTX0E03, to study its influence on the 
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expression of other genes (Hill et al., 2012). In this study two independent siRNAs targeting exon 4 
(siRNA 1) and exon 2 (siRNA 2) of the full length ZNF804A transcript were validated using a microarray 
and by q-PCR. Given the high degree of similarity between the cell line used in the previous study and 
the CTX0E16 line, as well as the high efficiency of transfection and efficacy in reducing ZNF804A 
transcript expression, this siRNA protocol would be ideal for the current line of inquiry with only minor 
modifications.  
siRNA-mediated knockdown of ZNF804A was previously validated in CTX0E16 cells in Section 
5.3.2, 5.3.3 and 5.3.4 using q-PCR as well as western blotting and ICC with the Genetex C2C3 antibody. 
The immunostained cultures from these experiments were re-examined to determine the morphological 
characteristics of the differentiating cells: number and length of neurites; cell soma size. Interestingly, 
a modest reduction in total neurite length per cell was observed in the two ZNF804A-knockdown 
conditions relative to the blank and scramble siRNA controls. A one way ANOVA with a posthoc 
Bonferroni multiple comparisons test revealed both a main effect of treatment on total neurite length 
(p<0.05) and that the reduction in neurite length seen in siRNA 1 and 2-treated conditions relative to 
the scramble siRNA control was significant at the p=0.05 level (see Figure 6.3.1, A & B). However, no 
significant differences could be observed between conditions for cell soma size or the number of 
neurites per cell, indicating that this relative reduction in neurite length was not related to other 
morphological changes associated with poor cell culture health and apoptosis. Furthermore, the number 
of neurite branch points per cell was not found to be affected by treatment condition in these cultures 
(data not shown). Taken together, these results indicate that ZNF804A plays a role in mediating early 
neurite outgrowth during human neuronal differentiation, although whether this is due to actions on 




Figure 6.3.1: siRNA-mediated knockdown of ZNF804A in CTX0E16 neurons. A: Representative 
images of neurite length in early stage (DD7) CTX0E16 neurons following a 7 day treatment with control 
(scramble) or ZNF804A-targeting siRNAs. B: Total neurite length  was  significantly reduced  in neurons 
treated with both siRNAs relative to the scramble siRNA control (n = 3 independent experiments; 
*p<0.05; **p<0.01). Scale bar = 50 µm (A). 
6.3.2 NEUROLIGIN 4X RESCUES DEFICITS IN NEURITE OUTGROWTH 
FOLLOWING ZNF804A KNOCKDOWN IN CTX0E16 CELLS 
ZNF804A has been suggested to control the expression of neuroligin 4X (Chen et al., 2015), a 
member of the neuroligin-neurexin family of adhesion proteins. This protein is associated with autism 
spectrum disorders, and it localises to synapses and regulates synapse density (Chih et al., 2004; 
Zhang et al., 2009). To confirm this finding in the CTX0E16 cell line, the siRNA-treated CTX0E16 lysates 
probed for ZNF804A protein expression in Section 5.3.2 were reprobed using an antibody for neuroligin 
4x, as well as the adhesion protein N-cadherin and the AMPA receptor subunit GluA2. As with 
ZNF804A, staining intensity values for protein bands were normalised to a β-Actin control, and values 
for all treatment conditions were normalised to the scramble control condition within each replicate. One 
way ANOVA were conducted on the normalised expression data for each protein, with posthoc Tukey 
multiple comparisons tests. Neuroligin 4x was found to be significantly reduced in cell lysates from 
ZNF804A siRNA CTX0E16 neurons (p<0.05 and p<0.01 for siRNA 1 and siRNA 2 vs scramble control 
respectively); the adhesion protein N-cadherin and the GluA2 AMPA receptor subunit were unaffected 
(p>0.05), suggesting that this result was not due to a nonspecific reduction in adhesion protein 
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expression or synapse number (see Figure 6.3.2, A & B). Neuroligin 4x has previously been suggested 
to be involved in neurite outgrowth (Shi et al., 2013); however, this has not yet been validated. If 
neuroligin 4x was indeed important for neurite outgrowth then exogenous expression of this protein may 
rescue deficits in neurite length in siRNA-treated cells. To investigate this, CTX0E16 cultures treated 
with the ZNF804A-targetting siRNAs were additionally transfected with a NLGN4 construct tagged with 
an HA reporter then immunostained as in the other siRNA experiment conditions (Figure 6.3.2, C). 
Average neurite length values for the siRNA 1/HA-NLGN4 and siRNA 2/HA-NLGN4 conditions were 
then compared to their respective siRNA-alone treatment conditions using a 1 way ANOVA with a 
posthoc Bonferonni multiple comparisons test. Total neurite length in siRNA 1- or 2-treated cells, 
overexpressing HA-NLGN4, was significantly increased compared with siRNA-alone conditions 
(p<0.01) but did not differ from control conditions (p>0.05) (Figure 6.3.2, D). Collectively, these data 
demonstrate that ZNF804A plays a role in early neuritogenesis in human neurons, an effect that may 
be mediated via the control of neuroligin 4x expression. 
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Figure 6.3.2: Neuroligin 4x overexpression ameliorates deficits in neurite outgrowth mediated by 
ZNF804A knockdown in CTX0E16 neurons. (A & B): Western blot analysis of synaptic and adhesion 
protein expression in control and siRNA expressing CTX0E16 neurons. In ZNF804A knockdown cells, 
neuroligin 4x (NLGN4) is significantly reduced; N-cadherin and AMPA receptor subunit 2 (GluA2) are 
unaffected (n = 3 independent experiments; *p<0.05; **p<0.01). C: Representative images of early 
stage (DD7) CTX0E16 neurons after a 7-day treatment with no transfection (blank), control (scramble), 
or ZNF804A-targeting siRNAs, with or without exogenous expression of HA-NLGN4 for 2 days. D: 
Quantification of neurite outgrowth of cells in E. siRNA-treated cells had significantly reduced outgrowth 
compared with blank or scramble conditions. Neurons treated with ZNF804A-siRNA and HA-NLGN4 
had significantly longer neurites than siRNA alone conditions, but they did not differ from control 





6.3.3 ZNF804A MEDIATES EARLY NEURITE OUTGROWTH IN HIPSC-DERIVED 
NEURONS 
In light of this fascinating early finding, a follow-up experiment was carried out by applying the 
same experimental protocol to immature neurons generated from the same hiPSC lines utilised in 
Section 5.3.10, in order to confirm the findings observed in the CTX0E16 cell line and further establish 
whether any morphological phenotypes seen hiPSC-neurons can be further studied in patient and risk-
allele-carrier lines. To this end, NPCs derived from the hiPSC lines generated from keratinocytes of 
three apparently healthy individuals were treated with siRNA 1, siRNA 2 or the scramble control siRNA 
for 7 days until DD30, a stage of rapid neurite outgrowth during terminal differentiation of hiPSC-neurons 
that approximates neuronal development in the second trimester fetal cortex (Brennand et al., 2014). 
Furthermore, transfection efficiency in the hiPSC lines was assessed via transfection with the additional 
fluorescent olignucleotide control described in the previous section. Cell counts of epifluorescence 
images taken of these cultures one day post-transfection revealed that uptake of the fluorescent 
oligonucleotide occurred in around 63.79±6.73% of cells (Figure 6.3.3, A). 
Cells transfected with the ZNF804A siRNAs were terminally differentiated for 7 days and 
immunostained for MAP2, DAPI and ZNF804A with the Genetex C2C3 ZNF804A antibody. 
Interestingly, ZNF804A staining intensity using the C2C3 antibody was again found to be modestly 
reduced by 20-30% in neuronal cultures treated with the anti-ZNF804A siRNAs relative to the scramble 
siRNA control condition (see Figure 6.3.3, C). A one way ANOVA of the C2C3 data revealed a 
significant effect of treatment condition, while a posthoc Dunn’s multiple comparisons test found the 
reductions in neuronal staining intensity in the siRNA 1 and 2 conditions relative to the scramble siRNA 
to be significant or approaching significance (p=0.012 and p=0.053 for scramble vs siRNA 2 and 
scramble vs siRNA 1 respectively). This further lends support to the validity of the C2C3 antibody as a 
specific probe for ZNF804A via immunocytochemistry, and additionally indicates that both anti-
ZNF804A siRNAs are also efficacious in reducing expression of the ZNF804A proteins in immature 
hiPSC-derived neurons. 
Following on from this validation of ZNF804A knockdown in these cells, the cultures were 
assessed for morphological characteristics: cell soma size, average number of neurites per cell, number 
of neurite branch points per cell and total neurite length per cell were all recorded as before, and then 
compared across experimental conditions. Although reductions in total neurite length per cell were seen 
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in the two ZNF804A knockdown conditions relative to the scramble siRNA control, the large degree of 
variability in values within each condition appeared to obscure the true magnitude of the effect of 
ZNF804A knockdown on neurite length. To further assess this variation, values for each condition were 
separated for each hiPSC line to determine whether inter-cell line differences accounted for this 
variability (see Figure 6.3.3, E). Interestingly, neurite length values were found to vary across cell lines 
as well as across experimental conditions, though both siRNA 1 and siRNA 2 were found to consistently 
reduce total neurite length per cell in comparison to scramble siRNA treated controls within each 
individual line. When data was normalised to the scramble siRNA control condition within each hiPSC 
cell line and normalised values were averaged across cell lines instead, the reduction in neurite length 
seen in the two ZNF804A knockdown conditions was retained, but with less variation within the 
individual conditions (Figure 6.3.3, D). A Kruskall-Wallis test of this normalised data revealed a 
significant effect of experimental condition on total neurite length, while a posthoc Dunn’s multiple 
comparisons test found that the reductions in neurite length seen in siRNA 1 and siRNA 2 treated 
cultures in comparison to the scramble control condition were both significant. In addition to this, no 
significant differences could be seen for cell soma size or the number of neurites per cell between 
conditions in hiPSC-derived neurons, suggesting that the differences in neurite length did not occur as 
a function of morphological changes associated with apoptosis. Furthermore, the number of neurite 
branch points per cell did not differ significantly between conditions. A Kruskall Wallis test of normalised 
data for these parameters confirmed the absence of any differences between treatment conditions. 
Overall, these data provide further support of a role of ZNF804A in regulating early neurite outgrowth 
during terminal differentiation of human neurons, and additionally highlight a phenotype that may be 
assessed in future investigations of hiPSC lines derived from samples taken from carriers of risk SNPs 
which reduce expression of the ZNF804A gene, in both psychosis patients and healthy controls. 
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Figure 6.3.3: siRNA-mediated knockdown of ZNF804A in young hiPSC-derived neurons. A: 
Representative image of fluorescent oligonucleotide control condition assessing efficiency of N-Ter 
siRNA transfection. 63.79±6.73% of immature hiPSC-derived neurons were transfected with BLOCK-
iT red fluorescent oligo 1 day post transfection. Yellow arrows indicate transfected cells. B: 
Representative images of ZNF804A staining and neurite length in early stage (DD30) hiPSC-derived 
neurons following a 7 day treatment with control (scramble) or ZNF804A-targeting siRNAs. C: 
Quantification of staining intensity seen in B. ZNF804A expression was significantly reduced in both 
siRNA treatment conditions relative to the scramble siRNA control (n = 3 independent cell lines, carried 
out in duplicate for each line; *p<0.05). D: Normalised total neurite length was significantly reduced in 





















































































































































































Figure 6.3.3, continued: carried out in duplicate for each line; *p<0.05). E: Raw total neurite length 
data for siRNA-treated neurons from each hiPSC line. Scale bars = 20 µm (A), 10 µm (B1) and 50 µm 
(B2).  
6.3.4 ZFP804A REGULATES DENDRITIC SPINE MAINTENANCE AND 
PLASTICITY IN MATURE CORTICAL NEURONS 
As previously described in Chapter 5, the ZNF804A protein and its rodent homologue, 
Zfp804A, have been found to be enriched in perisynaptic regions in human and rat neurons respectively, 
with strong evidence indicating that Zfp804A is highly integrated within the dendritic spines of mature 
rat primary cortical neurons. A number of endogenous proteins located at the post-synaptic density in 
a similar manner play crucial roles in the formation, maturation and maintenance of dendritic spines; 
thus, it is possible that ZNF804A and Zfp804A may possess one or more of these functions. Although 
ZNF804A was previously seen to be expressed at the putative dendritic spines of CTX0E16 neurons 
(see Section 5.3.7), an assessment of the impact of ZNF804A knockdown on spine density and 
morphology in this line would be problematic due to the long differentiation required for the appearance 
of spines as well as the relatively low number of spines observed previously in differentiated cultures. 
To bypass this potential difficulty, siRNA-mediated knockdown of Zfp804A was attempted in rat primary 
cortical neuron cultures, which robustly produce dendritic spines in a comparatively shorter timespan in 
vitro. Based on bioinformatical analysis of the two previously used siRNAs using BLAST, only siRNA 2 
is predicted to specifically target the full length Zfp804A mRNA transcript due to dissimilarities between 
the equivalent human and rat sequences. Taking this into account, DIV18 primary rat cortical neuron 
cultures were transfected with a blank control condition, the scramble control siRNA or siRNA 2 as 
described previously. A subset of these cultures was subsequently transfected with GFP under control 
of the Synapsin1 promoter at DIV23 for later assessment of dendritic spine density and morphology. At 
DIV25, cultures were lysed for western blotting or immunostained for GFP and Genetex 
ZNF804A/Zfp804A. Western blotting of the siRNA-treated rat primary cortical lysates using the C2C3 
ZNF804A/Zfp804A antibody revealed that siRNA 2 reduced expression of the Zfp804A protein by 
around 35% relative to the blank or scramble siRNA-treated control conditions, as assessed by 
normalising intensity values of a band corresponding with the predicted size of the full length protein to 
a loading control (see Figure 6.3.4, A & B). A Kruskall-Wallis test of this data revealed a significant 
effect of treatment condition (p<0.05), with a posthoc Dunn’s multiple comparisons test revealing a 
significant reduction in Zfp804A expression in the siRNA 2 treatment condition relative to the two control 
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conditions (p<0.05). Further assessment of Zfp804A expression in immunostained, GFP-transfected 
rat cortical neurons revealed a comparable reduction in Zfp804A staining intensity in the siRNA 2-
treated condition relative to the two control conditions (Figure 6.3.4, C & D); a one way ANOVA of this 
data with a posthoc Bonferroni multiple comparisons test found a significant effect of condition and a 
significant reduction in the siRNA 2 treatment condition relative to the controls (p<0.05). Taken together, 
these findings indicate that siRNA 2 successfully reduced expression of Zfp804A in the rat primary 
cortical neurons. 
Following on from the validation of siRNA 2 in rat primary cortical neurons, these cells were 
further evaluated to determine whether this reduction in Zfp804A expression had impacted dendritic 
spine density or morphology. Interestingly, neurons treated with siRNA 2 were found to exhibit a 
reduced density of dendritic spines relative to neurons treated with either of the two control conditions 
(dendritic spine density per 10 µm of linear dendrite: blank, 4.6±0.37; scramble siRNA, 3.99±0.32; 
siRNA 2, 3.02±0.2; n = 3 independent experiments) (see Figure 6.3.4, C & E). A one way ANOVA of 
this data revealed a significant effect of experimental condition (p<0.05); a posthoc Tukey’s multiple 
comparisons test found significance in the differences between the siRNA 2-treated neurons and those 
of the two control conditions. However, no significant differences could be seen in the morphological 
attributes – length, breadth and area – of the spines between the three conditions, indicating that the 
elimination of spines caused by Zfp804A knockdown was not restricted to a particular morphological 
subtype (Figure 6.3.4, F). As no significant differences were previously observed between the 
morphologies of Zfp804A-positive and Zfp804A-negative spines in Section 5.3.11, this finding may be 
consistent with a specific elimination of the Zfp804A-positive spines seen in untreated cortical neurons. 
Collectively, these data suggest that Zfp804A influences spine maintenance in cortical neurons, but 
also that this mediation of spine density is not limited to spines of a specific morphology. 
Because loss of ZNF804A in young human neurons correlated with a reduced neuroligin 4x 
expression, a protein known to regulate synapse density (Shi et al., 2013; Zhang et al., 2009), this 
protein was further assessed in the siRNA-treated rat cortical neuron cultures. DIV20 rat primary cortical 
neuron cultures were treated with siRNA 2 for five days as before, then lysed for subsequent probing 
for neuroligin 4x, N-cadherin and SNAP-25 as in the previous experiment in the CTX0E16 line. Western 
blotting of siRNA treated rat primary cortical neuron lysates revealed that neuroligin 4x was reduced in 
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Zfp804A knockdown neurons (Figure 6.3.4, G & H); subsequent significance testing using a one way 
ANOVA with a posthoc Tukey multiple comparisons test revealed this reduction to be significant 
(p<0.05). In contrast to this, no significant changes in expression of the adhesion protein N-cadherin or 
the synaptic protein SNAP-25 were observed (Figure 6.3.4, G & H), suggesting that the decrease in 
neuroligin 4x expression was not due to a general reduction in synaptic or adhesion proteins. 
As altering Zfp804A expression influenced spine density, loss of Zfp804A may additionally 
affect activity-dependent spine plasticity. To investigate this possibility, DIV25 rat primary cortical 
neurons were pre-treated with the siRNA conditions for five days as before, then treated with ACSF 
supplemented with APV or ACSF supplemented with 10 µM glycine, 100mM picrotoxin and 1 µM 
strychnine (inducing chemical LTP (cLTP)) (Xie et al., 2007) 30 minutes prior to fixation. Application of 
cLTP on control cells or neurons expressing scramble siRNA resulted in an increase in density (~33%) 
and spine area (~24%) (Figure 6.3.4, I-K). Two way ANOVA testing with posthoc Tukey’s multiple 
comparisons tests revealed that these increases in spine density and area were statistically significant 
(p<0.001). However, in Zfp804A knockdown neurons, no increase in spine area was observed after 
cLTP treatment, although spine density increased (~35%) to a level similar to unstimulated (basal) 
control levels (Two way ANOVA, posthoc Tukey’s multiple comparisons test; p<0.05) (Figure 6.3.4, I-
K). In addition to this, cLTP did not appear to significantly increase spine area in Zfp804A knockdown 
neurons as occurred in the control or scramble siRNA-treated neurons (Two way ANOVA, posthoc 
Tukey’s multiple comparisons test; p>0.05). Taken with the previous data on the impact of Zfp804A 
knockdown on dendritic spine density, these experiments demonstrate that Zfp804a is required for 




Figure 6.3.4. siRNA-mediated knockdown of zinc finger binding protein 804A (Zfp804A) in rat primary 
cortical neurons. A: Representative western blot of Zfp804A in 26-day in vitro (DIV26) primary rat 
cortical neurons after a 5-day treatment with no transfection (blank), control (scramble), or ZNF804A-
targeting siRNA. B: Quantification of the major protein band found at ~135 kDa, roughly equal to the 
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Figure 6.3.4, continued: predicted molecular mass of Zfp804A, revealed a significant reduction in 
staining intensity compared with blank and control conditions (n = 3 independent experiments). C: 
Representative confocal images of dendrites and dendritic spines after siRNA treatment of neurons as 
in A. D: Quantification of Zfp804A staining intensity after 5-day siRNA treatment. Zfp804A was 
significantly reduced in neurons treated with siRNA 2 in comparison with blank and control conditions 
(n = 3 independent experiments). E: Quantification of spine density after siRNA treatment (n = 3 
independent experiments). F: Spine area was not found to be significantly altered in neurons treated 
with siRNA 2 relative to the two control conditions (n = 3 independent experiments). G: Western blot 
analysis of cell lysates of blank, control, and siRNA-treated neurons. H: Quantification of F reveals that 
neuroligin-4 (NLGN4), but not N-cadherin or synaptosomal-associated protein 25 (SNAP25), is 
significantly reduced in Zfp804A knockdown cells (n = 3 independent experiments). I: Representative 
confocal images of dendritic spines from neurons treated as in A and after chemical long-term 
potentiation (cLTP) stimulation (n = 3 independent experiments). J: Quantification of spine density in 
siRNA-treated cells after cLTP revealed that linear density was increased in all conditions; in Zfp804A 
cells, cLTP increased spine density back to basal levels. K: Quantification of spine size (area) after 
cLTP revealed that loss of Zfp804A impaired the ability of cells to undergo structural plasticity (n = 3 
independent experiments). Scale bar for C & I = 5 µm. Scale bar for A = 5 µm. This work was carried 
out by Pooja Raval. 
6.3.5 NEURONAL ACTIVITY-INDUCING STIMULI INDUCE ALTERATIONS IN 
THE SUBCELLULAR PATTERNING OF ZFP804A EXPRESSION 
This chapter has thus far detailed attempts to manipulate ZNF804A and Zfp804A expression 
in several neuronal lines, and the downstream effects these manipulations have had on cellular 
phenotypes in immature and mature neurons. However, little is currently known about the upstream 
regulators of these proteins. Previous research has found expression of the Zfp804A transcript to be 
upregulated in cultured rat primary cortical neurons following 3 hour treatment with glutamate; this 
upregulation was blocked by addition of the NMDA receptor antagonist, MK-801 (Chang et al., 2015). 
It is currently unknown however whether this upregulation is also reflected at the protein level. 
Additionally, in Chapter 5 extranuclear expression of ZNF804A and Zfp804a was found in both human 
and rodent neuronal cells, and differential localisation of ZNF804A was seen in human NPCs and 
neurons. An investigation into whether the relative expression of these proteins in nuclear and 
extranuclear neuronal compartments is altered following exposure to activity-inducing stimuli may 
therefore also indicate whether the upregulation in expression of the Zfp804A transcript seen in the 
research by Chang et al. (2015) corresponds to a specific cellular region. An initial test of the regulation 
of subcellular expression of the ZNF804A protein in immature human neurons in response to activity-
180 
 
inducing stimuli was carried out in the experiment detailed in Section 4.3.5. As described previously, 
DD13 CTX0E16 neurons were transfected with pEGFP under the control of a CMV promoter and 
treated with either control NDM, NDM supplemented with 30 mM NaCl as an osmotic control or NDM 
supplemented with 30 mM KCl as a depolarising stimulus 7 hours prior to fixation on DD15. Cultures 
were immunostained for DAPI and GFP as described in the prior section, but were additionally stained 
with the Genetex anti-ZNF804A antibody to assess subcellular expression of this protein in each 
experimental condition. A one way ANOVA was performed on the data for each subcellular 
compartment and whole-cell expression for each of the three conditions; treatment of the CTX0E16 
cultures with 30 mM KCl was not found to significantly alter expression of ZNF804A in any single 
subcellular compartment nor within the cell as a whole relative to control conditions (p>0.05; 3-5 
independent experiments) (Figure 6.3.5, B-E). However, a closer evaluation of the images taken of the 
cells from these experiments revealed the ZNF804A immunostaining to be poor quality and not 
exhibiting the pattern of localisation seen in previous experiments (Figure 6.3.5, A). This may be an 
artifact of transfection with the GFP construct used in this experiment, a result of Z-projections 
eliminating differences in staining between the nuclei and cytoplasm of each cell, variations in the 
efficacy of the staining protocol used and non-neuronal cells potentially being included in the analysis. 
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Figure 6.3.5: Initial test of impact of chemically-induced neuronal depolarisation on ZNF804A 
localisation in DD15 CTX0E16 neurons. A: Representative images of GFP-expressing CTX0E16 
neuron (DD 15) following 7 hour treatment with vehicle control condition; yellow dotted lines delineate 
areas where ZNF804A staining intensity was measured. B-E: Measurement of average ZNF804A 
staining intensity in whole cell (B), nuclear (C), cytoplasmic (D) and neurite (E) regions did not 
demonstrate any effect of activity-dependent stimulation (30 mM KCl) on ZNF804A expression or 
localisation; n = 14–22 neurons from 3–5 independent experiments. Scale bar for A = 20 μm. 
To address these issues, another investigation was carried out in primary rat cortical neurons 
to more closely match the experimental paradigm used in the Chang et al. (2015) paper. Briefly, 
untransfected rat cortical neurons were cultured in media containing 200 µM APV (an NMDA receptor 
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by which they typically have developed mature dendritic spines and functional synapses.  These 
neurons were then treated with ACSF supplemented with APV or ACSF supplemented with 10 µM 
glycine, 100mM picrotoxin and 1 µM strychnine (inducing chemical LTP (cLTP)) (Xie et al., 2007) 30 
minutes prior to fixation. Cultures were immunostained for DAPI, Genetex ZNF804A/Zfp804A and PSD-
95 as a marker of mature neuronal cells. Interestingly, treatment of rat neurons with the cLTP condition 
was found to modestly reduce Zfp804A expression in nuclei, but not cytoplasmic regions, relative to 
neurons treated with the control condition (see Figure 6.3.6, A-C). A one way ANOVA revealed a 
significant effect of experimental condition and of the assessed region on the data (p<0.05; 3 
independent experiments); a posthoc Tukey’s pairwise comparisons test revealed the reduction in 
nuclear Zfp804A in cLTP-treated neurons relative to control neurons to be significant (p<0.05). Taken 
together, these data suggest that Zfp804A expression is reduced in neuronal nuclei following induction 
of cLTP.  
183 
 
Figure 6.3.6: Chemically-induced LTP reduces nuclear Zfp804A expression in rat primary cortical 
neurons. A & B: Representative confocal images of Zfp804A-stained DIV25 rat primary cortical neurons 
treated with a vehicle control (A) or a cLTP treatment condition (B). Note the reduction in nuclear 
Zfp804A staining in the cLTP condition. B: Measurement of nuclear and cytoplasmic Zfp804A 
expression in response to cLTP stimulation demonstrates that induction of cLTP results in a decrease 
in average nuclear Zfp804A staining intensity; n = 21–28 neurons from 3 independent experiments; 
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Figure 6.3.6, continued: *p <0.05 (two way analysis of variance with Bonferroni post hoc analysis). 
Scale bars for A & B = 10 μm. The experiment for this work was carried out by Pooja Raval, with imaging 
and analysis conducted by P.J. Michael Deans. 
6.4 DISCUSSION 
This chapter has detailed numerous attempts at the manipulation of expression of ZNF804A 
and Zfp804A in human and rodent neuronal cells in vitro, including overexpression of tagged ZNF804A 
constructs and knockdown via RNAi techniques. It has described how knockdown of these proteins via 
siRNA transfection resulted in alterations in neurite outgrowth in immature neurons, while also impacting 
dendritic spine maintenance and plasticity in mature neurons. Finally, it has provided data indicating 
that induction of LTP via chemical stimuli produces subtle alterations in the pattern of Zfp804A 
expression. 
siRNA treatment of developing neurons derived from the CTX0E16 hNPC line was found to 
attenuate early neurite outgrowth; this was later confirmed in neurons generated from three separate 
hiPSC lines. This finding was particularly intriguing when taken into account with the previous findings 
of the study by Hill et al. (2012), who found that a similar knockdown of ZNF804A expression using the 
same siRNAs also altered expression of STMN3, a gene involved in neurite outgrowth, as well as 
several genes involved in cell adhesion. Here, knockdown of ZNF804A and Zfp804A resulted in a 
significant reduction in neuroligin 4x expression in immature human cortical neurons and rat primary 
cortical neurons. A rescue of neuroligin 4x expression using overexpression of a tagged construct in 
the CTX0E16 cell line was found to ameliorate the neurite outgrowth phenotype found in ZNF804A-
knockdown cells. In light of the previous research and the findings of the present investigation it may 
therefore be possible that the reduction in early neurite outgrowth following ZNF804A knockdown 
occurs via mediation of the expression of STMN3 and/or one or more cell adhesion genes, including 
NLGN4. However, the possibility remains that these effects occur outside any putative role as a 
transcription factor - as previously mentioned, the presence of ZNF804A and Zfp804A within the 
cytoplasm, dendrites and axons of human and rat neurons may be consistent with an extranuclear 
function. Moreover, the work presented in this chapter does not rule out the possibility that any effect 




The finding of a significant reduction in dendritic spine density in primary rat cortical neurons 
treated with siRNA 2 is particularly interesting in context of previous work establishing that ZNF804A 
regulates expression of genes involved in cell adhesion (Hill et al., 2012) as well as the discovery in the 
previous chapter of ZNF804A and Zfp804A expression at putative human and rodent synapses 
respectively. As mature dendritic spines are typically well established by DIV20 in rat neuronal cultures 
(the time point at which siRNA treatment is initiated)(Boyer et al., 1998), this elimination of spines is 
likely to occur via effects on dendritic spine maintenance rather than spinogenesis. Two explanations 
may therefore account for this effect on spine maintenance in these cortical neurons: it may indirectly 
influence synapse number through mediating the expression of genes involved in cell adhesion or, as 
discussed in Chapter 5, ZNF804A/Zfp804A may act directly at the synapse to promote spine 
maintenance by binding directly to specific RNA molecules via its zinc finger domain. Distinguishing 
between these two possibilities is therefore a key avenue for further experimentation in future research 
into these proteins. 
In contrast to the expression of neuroligin-4, the presynaptic protein SNAP-25 was not found to 
be significantly altered in ZNF804A/Zfp804A knockdown conditions, both in early CTX0E16 neurons 
and mature primary rat cortical neurons. This is perhaps surprising in light of previous research 
conducted by Anitha et al (2014), who found that knockdown of ZNF804A in SH-SY5Y neuroblastoma 
cells resulted in a significant reduction in SNAP-25 protein expression. This anomalous result may have 
arisen due to differences in neuroblastoma cells relative to the two cellular systems used in the current 
investigation, or may be due to the greater knockdown of ZNF804A achieved via electroporation with 
the SH-SY5Y cells relative to the transfection method of the present chapter. This interesting previous 
finding may therefore still merit investigation if a knockout line is generated from a neuronal cell line in 
future research. 
Interestingly, knockdown of Zfp804A was additionally found to impact LTP-dependent 
alterations in spine density and size: Zfp804A-knockdown neurons exhibited an increase spine density 
following induction of LTP (though not to the extent of control neurons), while an LTP-dependent 
increase in spine size was not seen in knockdown neurons. These data suggest that Zfp804A actions 
at the synapse may be modulated in part by neuronal activity. Synaptic RNA-binding proteins such as 
FMRP (Fragile X syndrome) have previously been demonstrated to exhibit rapid, activity-dependent 
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transport of mRNAs important for synaptogenesis and plasticity (Dictenberg et al., 2008), and FMRP-
containing RNA granules translocate from dendritic spines to the dendritic shaft after depolarisation 
(Antar et al., 2004, 2005). As Zfp804A was found within both dendritic spines and the dendritic shaft of 
rat primary cortical neurons in Chapter 5, this possibility may be worth additionally exploring for 
ZNF804A in future research. The potential parallels between ZNF804A and FMRP function are 
particularly worth noting given that, like ZNF804A, FMRP isoforms have been previously found to be 
expressed within the nuclei of cortical neurons in a distinct punctate pattern; these nuclear isoforms are 
also known to bind a C2H2 zinc finger domain-containing protein, NUFIP (Bardoni et al., 1999). Such 
similarities highlight intriguing avenues for future research into the potential RNA-binding roles of 
ZNF804A. 
Previous research in rat primary cortical neurons has found that treatment with glutamate 
increases Zfp804A mRNA in an NMDA receptor-dependent manner (Chang et al., 2015). As LTP 
requires NMDA receptor activation (Lüscher and Malenka, 2012), it would be reasonable to assume 
that the induction of NMDA receptor-dependent LTP would also increase Zfp804A mRNA in a similar 
manner. This increase in Zfp804A mRNA following glutamate treatment may be consistent with it 
contributing to mechanisms involved in LTP-dependent increases in dendritic spine size and density; 
upregulation of Zfp804A in response to NMDA receptor activation may further be reflective of 
participation in a feedback mechanism linked to LTP-mediated RNA transport, translation or 
metabolism. 
Zfp804A was additionally shown to demonstrate alterations in distribution in rat primary cortical 
neurons following induction of cLTP in this chapter, specifically a reduction in nuclear Zfp804A. It is 
interesting that the shift in subcellular localisation following induction of LTP appears to represent a 
more polarised form of the predominately cytoplasmic expression seen for both ZNF804A and Zfp804A 
in human and rat neurons respectively in the previous chapter. Given that data presented in the previous 
chapter indicated that relative nuclear expression of ZNF804A is reduced during differentiation in a 
similar manner while cytoplasmic ZNF804A increases, early neuronal activity may be a factor in the 
reduction in nuclear expression seen in differentiated neurons. A reduction in nuclear Zfp804A 
expression may be indicative of transport of this protein out of the nucleus. Although the full length 
Zfp804A sequence lacks a nuclear export signal, analysis of this sequence using the online Eukaryotic 
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Linear Motif (ELM) resource, an online database which provides information on predicted modification, 
binding and cleavage sites of a given protein based on its amino acid sequence, revealed the presence 
of a predicted sumotylation site. Sumotylation is a protein modification which has previously been found 
to promote cytonuclear transport of several other proteins (Pichler and Melchior, 2002) and thus may 
provide a mechanism through which nuclear expression is altered during differentiation and following 
LTP. Chaperone proteins are also a common mediator of nuclear import and export and thus may 
represent another method of Zfp804A and ZNF804A transportation (Echeverría et al., 2009; Galigniana 
et al., 2010; Pemberton and Paschal, 2005). ZNF804A has also been predicted to bind NUP35, a core 
component of the nuclear membrane transport complex in a recent study of the schizophrenia 
interactome; this may be one such mechanism through which ZNF804A exits the nucleus during 
development and after LTP  (Ganapathiraju et al., 2016). However, the possibility remains that the 
reduction in nuclear Zfp804A may reflect a degradation of existing protein within this compartment - 
when coupled with increased mRNA expression this may indicate an increased turnover of the protein 
following NMDA receptor activation. 
In addition to the techniques outlined in the results section of this chapter, genome editing of 
the CTX0E16 line was explored as a potential model to study ZNF804A function. However, efforts to 
establish a ZNF804A knockout line from CTX0E16 cultures using a zinc finger nuclease system 
ultimately proved unsuccessful due to problems with culture viability, an inefficient selection method, 
the considerable time required to expand cultures and wild type cells outcompeting knockout cell 
proliferation in mixed cultures. Future investigations attempting to generate a similar knockout from 
human neuronal lines would benefit from a simultaneous insertion of a reporter gene to detect knockout 
cells in mixed cultures, an alternative means of selection of the knockout cell line (for example, insertion 
of an antibiotic resistance gene) or the use of a more efficient protocol for genome editing such as 
CRISPR/Cas9 (Hsu et al., 2014). In addition to this, attempts to overexpress ZNF804A using 
transfection of tagged constructs ultimately proved unsuccessful in the present investigation, partially 
due to the time requirements necessary for the establishment of a working protocol and a thorough 
characterisation of either plasmid. Future investigations may benefit from exploration of alternate 
transfection reagents and the use of subcloning to insert the full length ZNF804A gene into other vectors 
containing alternative promoters or reporters. Subcloning may also be used in future to generate 
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constructs corresponding to multiple isoforms of ZNF804A to determine whether these isoforms exhibit 
differential patterns of expression and functional roles.  
In conclusion, this chapter has shown that ZNF804A and Zfp804A play a role in the regulation 
of early neurite outgrowth as well as maintenance and plasticity of dendritic spines in mature neurons. 
Furthermore, data presented in this chapter demonstrated that expression of Zfp804A is modulated by 
the induction of cLTP in rat primary cortical neurons. These findings, taken together with the work 
presented in the previous chapter on the subcellular localisation of these proteins, have provided a 
more thorough understanding of the location of ZNF804A at the junction of multiple signalling pathways. 
The following discussion chapter will describe these findings in the greater context of the pre-existing 
literature on ZNF804A’s effects on cognitive and structural phenotypes, and will describe how the data 
presented in the current chapter integrates into previously established disease mechanisms underlying 
schizophrenia and bipolar disorder. It will also discuss how the characterisation of the CTX0E16 cell 
line in chapters 3 and 4 has provided a valuable tool to add to the growing number of in vitro stem cell 













CHAPTER 7: DISCUSSION 
7.1 AIMS OF INVESTIGATION AND SUMMARY OF MAIN FINDINGS 
In this thesis a human neural progenitor line was characterised for future use in studies of 
human neural development and disease. This line was employed alongside several other cellular 
models in a study of the biological functions of the psychosis-linked gene ZNF804A. The first aim of this 
thesis was to determine whether the CTX0E16 hNPC line was capable of generating cultures of 
glutamatergic cortical neurons. This was addressed in Chapter 3, where the CTX0E16 line was subject 
to an assessment of markers of cellular identity and an evaluation of the development of neuronal 
morphology. Here, CTX0E16 cultures were shown to downregulate markers of stem cell identity and 
upregulate markers of neuronal identity in the majority of cells after 4 weeks of differentiation. 
Furthermore, these neurons were found to predominately express markers of glutamatergic identity, 
with markers of cortical neurons and synaptic proteins also being present in these cultures. A subset of 
these neurons also expressed markers of GABAergic interneurons, indicating a heterogeneous 
population. Neurons from these cultures were additionally found to progressively develop key 
morphological features of cortical pyramidal neurons, including a triangular cell soma, polarised axonal 
and dendritic processes, neurite arborisation and even putative dendritic spines. Overall these findings 
are consistent with the generation of cultures predominately consisting of excitatory cortical neurons, 
as expected. 
The second aim of the current research was to determine whether these CTX0E16 neuronal 
cultures also were capable of producing functional synapses and responses to a range of 
physiologically-relevant stimuli. This was examined in Chapter 4, where CTX0E16 neurons were shown 
to express a wide variety of key synaptic proteins in a pattern consistent with developing synapses. 
These neurons also demonstrate Ca2+ oscillations and responses to treatment with key 
neurotransmitters as well as displaying morphological plasticity after prolonged depolarisation. 
Furthermore, these cells also demonstrate a number of electrophysiological hallmarks of functional 
neurons, including action potentials. Collectively, these experiments have shown that CTX0E16 
neurons are capable of producing functional synapses and the physiological responses consistent with 
those of mature glutamatergic neurons. Taken together, Chapters 3 and 4 have demonstrated clearly 
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that the CTX0E16 cell line is an ideal platform for studying early neural development and disease in 
human neurons. 
The third major aim of this study was to elucidate the precise pattern of ZNF804A/Zfp804A 
expression and subcellular localisation in NPCs and neurons. In Chapter 5 the expression of ZNF804A 
isoforms was demonstrated at the mRNA level in NPCs and neurons from the CTX0E16 line as well as 
hiPSCs and hiPSC-neurons from several control lines. This expression was further demonstrated at the 
protein level in CTX0E16 cells using a thoroughly validated anti-ZNF804A antibody; the pattern of 
subcellular localisation of ZNF804A was found to alter as cultures of these cells terminally differentiated. 
The pattern of expression of ZNF804A/Zfp804A was found to be conserved across neuronal models, 
with a predominately punctate, cytoplasmic expression being seen in CTX0E16 neurons, hiPSC-
neurons and rat primary cortical neurons. Additionally, in this chapter expression of ZNF804A/Zfp804A 
was seen at putative synapses in both human and rat cortical neurons. In Chapter 6, the pattern of 
expression of Zfp804A in rat cortical neurons was also found to be modulated by treatment with an LTP-
inducing stimulus. These findings offer a more detailed overview of the pattern of expression of 
ZNF804A/Zfp804A and moreover, demonstrate how this pattern alters during differentiation and after 
LTP induction in a manner that amalgamates the findings of previous studies in both NPCs and neurons. 
The final aim of this investigation was to determine whether ZNF804A/Zfp804a plays a role in 
the development and maintenance of neuronal morphology. This was explored in Chapter 6 using 
siRNA-mediated knockdown techniques in each of the three previously described neuronal models. 
Knockdown of ZNF804A was found to reduce expression of the adhesion protein neuroligin 4x and 
early neurite outgrowth in CTX0E16 and hiPSC-derived neurons during differentiation; overexpression 
of neuroligin 4x in ZNF804A-knockdown cells was found to rescue this phenotype. Knockdown of the 
ZNF804A rodent homologue Zfp804A also resulted in reductions in dendritic spine maintenance and 
deficits in the morphological changes of these spines following LTP induction in mature primary rat 
cortical neurons. Overall, these findings demonstrate that ZNF804A influences the development of early 
neuronal morphology by mediating neurite outgrowth, and the rodent homologue of this protein 





7.2 THE CTX0E16 CELL LINE AS A TOOL FOR INVESTIGATING 
MECHANISMS OF CORTICAL DEVELOPMENT, FUNCTION AND DISEASE 
The data presented throughout this investigation has provided strong evidence that cultures of 
neurons differentiated from the CTX0E16 cell line can adopt the hallmarks of functional pyramidal 
neurons derived from the human cortex. Furthermore, the findings presented in Chapters 3 and 4 
highlight a number of baseline characteristics of this cell line which may be further investigated in the 
context of development and disease. CTX0E16 cells offer a number of advantages over other in vitro 
models of cortical neurons. The CTX0E16 cell line offers greater resilience, requires less culture time 
and provides greater experimental flexibility than hiPSC-based experimental platforms and related stem 
cell technologies. The CTX0E16 line also provides a platform with a greater focus on cortical 
glutamatergic neurons than was previously available with comparable human NSC and NPC lines 
(Carpenter et al., 1999b; De Filippis et al., 2007), thus being a more effective model for the study of 
cortical development and disease. Finally, it offers a distinct advantage over non-human cellular models 
such as rat primary neuron cultures due to the inherent differences in neuronal phenotypes across 
species.  
However, there are several caveats regarding the use of the CTX0E16 cell line instead of 
alternative cellular models. The use of a single immortalised hNPC line from a single individual fetus 
may limit application of certain findings to the population as a whole due to the homogeneity of cultures 
derived from only one such line; thus hiPSC cultures and similar models may provide a better 
representation of the diversity of cortical neuron phenotypes. Moreover, human cellular models like the 
CTX0E16 line are at a disadvantage relative to rodent cell cultures in that the culture time required 
before they produce key hallmarks of neuronal maturity such as action potentials and dendritic spines 
is much greater than that for rodent neurons (Papa et al., 1995). Finally, the CTX0E16 cell line is limited 
by two further properties: it does not produce the same neuronal populations as dorsal telencephalon 
progenitors in vivo, and it does not generate any structures analogous to those seen in early cortical 
development (such as neural rosettes in hiPSC cultures during neuralisation). 
A combinatorial approach integrating experiments using neurons derived from multiple sources 
(as shown in Chapters 5 and 6) can provide a great deal of experimental flexibility and may therefore 
prove to be an effective way of addressing these weaknesses. For example, rodent neurons appear 
best suited for experiments requiring rapid assessment of mechanisms occurring in mature neurons 
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(particularly synaptic function), CTX0E16 neurons appear to be particularly useful in assessing 
phenomena specific to human glutamatergic neurons in the cortex and disease-related mechanisms 
within this structure, while hiPSC lines can be of use in assessing the impact of genetic variants known 
to cause psychiatric diseases on neuronal function or cortical structure in vitro. In addition to this, fate 
specification protocols could be employed to increase the proportion of glutamatergic neurons in 
differentiated CTX0E16 cultures; similar fate-specification protocols have been previously developed in 
hiPSC lines. Finally, the lack of structures analogous to the developing cortex in CTX0E16 cultures may 
be ameliorated by instead focusing studies on the expression of specific markers of cortical identity, 
such as layer-specific markers, to investigate developmental processes in the cortex. 
In addition to studies of human cortical development and disease, CTX0E16 cells may also be 
of use in high-throughput screening of novel drug treatments and other therapeutic molecules by 
assessing how disease phenotypes (induced by genetic manipulation) can be rescued through 
pharmacological intervention. Moreover, genome editing could be used to induce specific disease-
associated mutations or knockout disease-linked genes to determine their functional relevance to 
cortical development and physiology. Indeed, the exploration of ZNF804A function using the CTX0E16 
NPCs in Chapters 5 and 6 may double as pilot work to highlight potential experimental techniques and 
designs for larger scale studies of gene function in future with this cell line. 
7.3 THE CTX0E16 CELL LINE AS A TOOL FOR INVESTIGATING ZNF804A 
In addition to the initial exploration of the functional characteristics of CTX0E16 cultures, this 
line has also been employed as a tool to study the expression and localisation of ZNF804A in human 
neurons, further demonstrating the validity of these cells as a model for studying disease mechanisms 
within the cortex. Critically, CTX0E16 neurons demonstrated similar ZNF804A localisation to that seen 
in hiPSC-derived neurons and rat primary cortical neuron cultures in Chapter 5 as well as in post-
mortem human cortex (Tao et al, 2014). Moreover, siRNA-mediated knockdown of ZNF804A was 
shown to result in a comparable reduction in neurite outgrowth in CTX0E16 and hiPSC-derived neurons. 
Moreover, this effect is in line with previous genetic studies which found that siRNA-mediated 
knockdown of ZNF804A in a sister cell line of CTX0E16, CTX0E03, resulted in altered expression of 
genes involved in neurite outgrowth and cell adhesion. This demonstrates that CTX0E16 cellular 
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phenotypes are consistent with several other in vitro and in vivo findings, thus showing that this cell line 
is an effective platform for studying at the cellular level. 
Genome editing has provided a powerful approach to produce models of human genetic lesions 
and mutations, overexpress genes of interest, and knockout genes entirely in a range of human stem 
cell lines. Knockout (KO) cell lines are a commonly used method of determining the potential functions 
of a given gene (Santiago et al., 2008). Recent advances in genome-editing technology have given rise 
to Zinc finger nucleases (ZFNs) which offer a versatile method through which genes can be specifically 
targeted for removal from the genome of a particular cell line (Urnov et al., 2005). As well as providing 
a valuable tool for investigating the functions of a gene, knockout lines also remain the gold standard 
for negative controls in antibody validation experiments. One of the main difficulties encountered during 
the investigation of ZNF804A function in CTX0E16 cells was the lack of success in generating a 
ZNF804A knockout line using zinc finger nuclease-mediated genome editing, due to a combination of 
a low editing efficiency and difficulties in producing clonal populations. However, since this work was 
halted, advances in new genome-editing technologies such as CRISPR have provided a much more 
effective means of inducing gene knockouts in specific cell lines. Future studies into ZNF804A function 
would greatly benefit from the establishment of such a knockout line, particularly in the study of the 
function of individual ZNF804A isoforms and mechanistic pathways downstream of the full length 
protein. 
Throughout the course of the research presented in this thesis, CTX0E16 NPC and neuronal 
cultures have been successfully subject to a wide variety of experimental techniques, demonstrating 
that these cellular systems are an ideal platform for large screening projects. Indeed, the combination 
of these techniques with high throughput, automated methods for cell culture, assessments of 
pharmacological responses and evaluation of cellular morphology will mark this line as a useful tool for 
screening of novel treatments for psychiatric disease relevant mechanisms in future research.  
7.4 EXPRESSION AND SUBCELLULAR LOCALISATION OF ZNF804A 
/ZFP804A 
Previous research into the functions of ZNF804A has predominately adopted neuroimaging, 
neuropsychological, or genetic approaches, with the few studies assessing this protein using cellular 
models primarily focusing on a putative role as a transcription factor and in particular determining the 
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specific genes regulated by ZNF804A’s transcriptional effects. The current investigation describes 
several findings regarding the expression and localisation of ZNF804A and Zfp804A as neurons 
differentiate and are exposed to physiological stimuli. Based on the findings of western blotting and q-
PCR experiments in human cells and what is known about the rodent protein Zfp804A, the pattern of 
protein localisation seen in Chapter 5 is most likely to reflect that of the full length protein. Thus, a key 
area of ambiguity to be explored in future research would be to further determine the pattern of 
localisation for other ZNF804A isoforms, especially the disease-relevant E3E4 and 2.2 variants 
described in the introduction chapter. As mentioned above, the establishment of a ZNF804A knockout 
line would be invaluable in such studies, as a rescue with tagged ZNF804A constructs for each of these 
isoforms would provide an accurate method of determining their subcellular distribution. 
One key aspect of the full length ZNF804A transcript is the presence of two nuclear localisation 
signals, raising the possibility that this protein may be trafficked into the nucleus. ZNF804A also contains 
a predicted binding site for NUP35, a key component of the nuclear membrane transport apparatus 
(Ganapathiraju et al., 2016; Strambio-De-Castillia et al., 2010); this protein may therefore be a mediator 
of the shifts in nuclear expression seen during differentiation and LTP in the current research. 
Fluorescently tagged ZNF804A constructs could in future be a highly useful method to explore the 
potential redistribution of this protein in live cells over time and in response to physiological stimuli. 
Collectively, the data presented on the expression and subcellular localisation of ZNF804A 
isoforms and homologues in this thesis has provided a significant contribution to the overall knowledge 
of this protein and has thus partially addressed the second aim of this study. The following section of 
this discussion will now detail how these findings, and the subsequent finding of a role for 
ZNF804A/Zfp804A in influencing neuronal morphology and plastic responses, integrate into the 
previous body of work on ZNF804A and how this protein relates to the literature at large on 






7.5 ZNF804A AND NEURONAL MORPHOLOGY: IMPLICATIONS FOR GROSS 
NEUROANATOMICAL CHANGES IN NEUROPSYCHIATRIC DISEASE 
7.5.1 APPROACHES OF THE CURRENT STUDY 
In addition to a thorough characterisation of ZNF804A/Zfp804A localisation in cortical neurons, 
the present investigation further determined the impact of ZNF804A knockdown on early and mature 
neuronal morphology, including responses to plasticity-inducing stimuli. In differentiating neurons from 
both CTX0E16 and hiPSC sources, neurite outgrowth was reduced following ZNF804A knockdown 
while in mature primary rat cortical neurons knockdown of the rat ZNF804A homologue, Zfp804A, 
resulted in a decrease in dendritic spine density and impaired plasticity in response to induction of LTP. 
These findings in particular build on previous research by adding a potential link between studies 
assessing the impact of ZNF804A on gene expression and those examining the effects of ZNF804A on 
gross neuroanatomical features, functional connectivity and cognitive and behavioural phenotypes. 
Moreover, these findings further address the second main hypothesis of the investigation by showing 
that ZNF804A and Zfp804A act as a regulator of early neurite outgrowth and maintenance of dendritic 
spines in cortical neurons, demonstrating a previously unknown role for these proteins in determining 
key aspects of neuronal morphology.  
7.5.2 RELEVANCE OF FINDINGS TO PREVIOUS LITERATURE 
The reduction in neurite outgrowth seen in ZNF804A knockdown neurons is consistent with 
previous research indicating that disease linked variant at rs1344706 in the ZNF804A locus exert their 
effect during the second trimester of foetal development (Hill and Bray, 2012). This developmental stage 
is concurrent with a period of cortical neuron maturation including outgrowth of neurites (Huang et al., 
2006); previously early developmental timepoints have been hypothesised as being crucial periods 
during which early genetic and environmental insults can later impact the development of schizophrenia 
during adulthood, a theory known as the ‘neurodevelopmental hypothesis’ of schizophrenia. A potential 
mechanistic link has previously been described via ZNF804A-mediated effects on expression of 
STMN3, a gene previously reported to be involved in neurite outgrowth (Hill et al., 2011). One alternate 
mechanism through which ZNF804A may impact early neurite outgrowth is via regulation of NLGN4 
expression. In Chapter 6, siRNA-mediated knockdown of ZNF804A/Zfp804A expression was found to 
simultaneously reduce neurite outgrowth and expression of neuroligin 4x; subsequent overexpression 
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of exogenous neuroligin 4x attenuated this neurite outgrowth phenotype. Either one or both of these 
genes may be responsible for ZNF804A-mediated neurite outgrowth phenotypes. However, it should 
be noted that neurite outgrowth is impacted by a vast repertoire of genes, therefore any impact of 
ZNF804A knockdown may not be primarily mediated by NLGN4 and/or STMN3. Moreover, this 
mediation of neurite outgrowth may not be the primary function of this protein or indeed the ultimate 
biological mechanism through which SNPs at the ZNF804A locus convey an impact on neuronal 
function and disease risk, given that the reduction in neurite outgrowth seen following ZNF804A 
knockdown in the current investigation is relatively modest. It is also worth noting that in light of the 
extranuclear localisation of ZNF804A found in Chapter 5, this protein may alternatively influence neurite 
outgrowth via mechanisms within the neurites themselves such as binding to mRNA molecules via the 
C2H2 zinc finger domain and mediating local translation of proteins relevant involved in cytoskeletal 
remodelling; indeed, local translation has previously been found to influence neurite outgrowth in 
cultured neurons (van Kesteren et al., 2006). 
Despite these caveats, the neurite outgrowth phenotype observed in the current investigation may be 
an influence on the alterations in structural and functional connectivity seen in carriers of the risk allele 
of the psychosis associated rs1344706 SNP. In addition to being associated with altered expression of 
ZNF804A isoforms, the risk allele has also been found to be linked to white matter abnormalities, 
including divergent alterations in white matter integrity in the left prefrontal lobe of schizophrenics and 
healthy controls as well as reductions in a proxy measure of white matter integrity within the left 
cingulate gyrus and both parietal lobes in schizophrenic and healthy cohorts (Kuswanto et al., 2012; 
Wei et al., 2012; Zhang et al., 2016). Rs1344706 genotype is further associated with alterations in the 
corpus callosum and left forceps major (white matter tracts connecting the two cerebral hemispheres) 
in healthy controls, as well as abnormalities in a wide ranging white matter network in schizophrenics, 
bipolar patients and healthy individuals (Ikuta et al., 2014; Mallas et al., 2016). These broad alterations 
in white matter microstructure are accompanied with changes in the functional connectivity between 
several regions including the dorsolateral prefrontal cortex, the cingulate cortex and the hippocampus, 
within and across hemispheres (Esslinger et al., 2009, 2011; Paulus et al., 2013; Rasetti et al., 2011; 
Thurin et al., 2013; Zhang et al., 2016). However, the impact of alterations in neurite outgrowth brought 
about by may not be limited to white matter tracts. 
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Based on the findings described in Chapter 6, abnormalities in neurite outgrowth arising from 
altered expression of ZNF804A may additionally contribute to the alterations in dendritic arborisation 
seen in several regions of the schizophrenic brain. Previous studies have found a reduction in dendritic 
arbor complexity in layer III and layer V pyramidal neurons of the frontal cortex, as well as alterations 
in dendritic morphology in CA3 of the hippocampus in schizophrenic brains (Broadbelt et al., 2002; 
Kolomeets et al., 2005). Although no studies have yet attempted to characterise the effect of disease-
associated ZNF804A genotypes on the morphological characteristics of cortical neurons in vivo, it is 
possible that ZNF804A-mediated alterations in early neurite outgrowth may be a contributory factor 
underlying the morphological changes seen in cortical neuron dendrites within the regions affected in 
the schizophrenic brain. 
Zfp804A was found to further mediate dendritic spine maintenance in mature cortical neurons, 
a further potential mechanism through which this protein may impact the etiology of schizophrenia and 
other psychiatric disorders. Dendritic spines are the primary site of glutamatergic neurotransmission 
within the mammalian neocortex (Penzes et al., 2011). Glutamate is the most prevalent excitatory 
neurotransmitter within the brain, and dysfunctional glutamatergic signalling and connectivity has long 
been hypothesised to be a significant component of the underlying pathophysiology of schizophrenia, 
bipolar disorder and autism (Choudhury et al., 2012; Eastwood and Harrison, 2010; Howes et al., 2015). 
In particular, NMDA receptor hypofunction has been proposed as a key feature of schizophrenic 
pathology, specifically being thought to underlie the cognitive and negative symptoms of this disease 
(Stone et al., 2007). Alterations in dendritic spine density are also a common feature in these 
neuropsychiatric diseases: reductions in dendritic spine density have previously been demonstrated in 
layer III of the dorsolateral prefrontal cortex (Glantz and Lewis, 2000), the superior temporal gyrus 
(Sweet et al., 2009b) and CA3 of the hippocampus (Kolomeets et al., 2005) in schizophrenic brains as 
well as in layer III of the dorsolateral prefrontal cortex of bipolar brains (Konopaske et al., 2014). Thus, 
alterations in dendritic spine density within specific regions of the neocortex may be a common cellular 
substrate in the pathophysiology of psychotic disorders. 
In schizophrenic brains loss of dendritic spines has previously been found to correlate with 
increases in neuronal density and reductions in grey matter volume in several brain regions, indicating 
that reductions in dendritic spines are the driving force behind the grey matter alterations seen in 
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schizophrenia rather than loss of neurons (otherwise known as ‘the neuropil hypothesis’ of 
schizophrenia (Selemon and Goldman-Rakic, 1999)). Alterations in grey matter volume in several 
regions have also been observed in individuals possessing the risk allele of the rs1344706 SNP: in 
healthy controls several studies have demonstrated reductions of grey matter in a number of regions 
including the prefrontal cortex, temporal cortex and cingulate cortex (Lencz et al., 2010; Nenadic et al., 
2015). Conversely, in schizophrenic patients possession of the risk allele is associated with an 
attenuation of the pathological changes in grey matter commonly seen in schizophrenia, notably in 
prefrontal, temporal and hippocampal regions (Donohoe et al., 2011; Schultz et al., 2013). ZNF804A-
mediated changes in dendritic spine density may therefore account for some of these alterations in 
healthy controls, and moreover may be a contributing factor in the (albeit attenuated) grey matter 
changes seen in the risk allele carrier schizophrenia subgroup. One potential mechanism which may 
mediate the effects of ZNF804A on cortical spine density is via altering expression of genes involved in 
cell adhesion (Hill et al., 2011). Cell adhesion proteins are involved in a wide variety of cellular 
processes but notably are key regulators of the early formation and subsequent maintenance of 
synapses (Gerrow et al., 2006). Thus, dysregulation of these genes may result in the reduction in 
dendritic spines seen in the current investigation. In addition to this, as ZNF804A and Zfp804a were 
both found to localise to putative synapses in human and rat cortical neurons these proteins may also 
possess novel, extra-nuclear functions directly at the synapse and thereby influence dendritic spine 
maintenance through interactions with proteins within the post-synaptic density. 
In addition to being involved in dendritic spine maintenance in mature cortical neurons, Zfp804A was 
also found to influence LTP-mediated plasticity at these spines, specifically impacting spine 
enlargement following LTP induction and indicating that Zfp804A impacts LTP-induced mechanistic 
pathways involved in spine enlargement but not spine formation. Although impaired LTP-mediated 
spine plasticity cannot currently be investigated directly in patients with schizophrenia or bipolar 
disorder, there is some evidence to suggest that schizophrenic patients exhibit altered plasticity 
(Stephan et al., 2006), and altered synaptic plasticity has also been posited as a contributory factor in 
the pathophysiology of bipolar disorder (Duman, 2002).  Proxy measures of cortical plasticity in studies 
of transcranial magnetic stimulation, fMRI imaging and EEG recordings have previously been found to 
be disrupted in schizophrenic cohorts relative to healthy controls (Stephan et al., 2006; Voineskos et 
al., 2013). Moreover, animal models of schizophrenia have also demonstrated abnormal induction of 
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LTP, particularly in rodent brain regions analogous to the prefrontal cortex in humans (Goto and Grace, 
2006; Tseng et al., 2007). Local translation of mRNAs has previously been demonstrated to be a crucial 
step in LTP-dependent spine enlargement (Lai and Ip, 2013). This protein synthesis is thought to be 
driven by pathways mediated by BDNF signalling, metabotropic glutamate receptor activation and 
mTOR phosphorylation (Lai and Ip, 2013); disruption of these signalling pathways has previously been 
demonstrated to prevent spine enlargement following LTP induction. Zfp804A possesses a C2H2 zinc 
finger domain; as mentioned previously some members of the zinc finger protein family demonstrate 
RNA binding activity via this domain, thus Zfp804A may influence LTP-dependent spine enlargement 
by binding to RNAs and regulating their translation within the spine head. If this is indeed found to be 
the case then future research would benefit from identifying whether ZNF804A and Zfp804A specifically 
mediate LTP-dependent spine enlargement through BDNF and mGluR signalling pathways. 
It is also worth noting that LTP at glutamatergic synapses on dendritic spines is dependent on activation 
of NMDA receptors (Lüscher and Malenka, 2012); spine formation and enlargement following LTP 
induction are also NMDA receptor dependent processes. In the current study both ZNF804A and 
Zfp804A were found to co-localise with the NMDA receptor subunit GluN1, and in rat primary cortical 
neurons Zfp804A was revealed to be tightly integrated within the post-synaptic density of dendritic 
spines, directly adjacent to GluN1. One potential alternative to the hypothesised RNA-binding properties 
of Zfp804A and ZNF804A may be that these proteins instead regulate spine maintenance and structural 
plasticity via direct interaction with members of the postsynaptic density, including GluN1. Members of 
the zinc finger family have previously been demonstrated to mediate protein-protein and protein-RNA 
interactions (Brayer and Segal, 2008), so the possibility remains that the zinc finger domain of ZNF804A 
possesses similar attributes within the postsynaptic density. 
 Aberrant synaptic plasticity may potentially be an additional pathway through which ZNF804A 
impacts psychosis-relevant pathology in the brain. Synaptic plasticity ultimately influences connectivity 
of cortical neurons, and may therefore be a contributory factor in the aberrant cortical connectivity seen 
in carriers of ZNF804A risk alleles and in psychosis patients in general. Furthermore, deficits in spine 
plasticity may also directly impact glutamatergic neurotransmission in the cortex: alterations in spine 
morphology have previously been found to be linked to functional deficits in transmission (Penzes et 
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al., 2011). Thus, altered expression of ZNF804A may induce alterations in glutamatergic 
neurotransmission, a feature common to both schizophrenia and bipolar disorder. 
When taken together, the evidence provided by the previous literature and the findings of the 
current body of work indicates that ZNF804A contributes to the risk of developing psychiatric disorders 
via acting on the expression of a wide range of genes involved in neuronal development and immune 
function, as well as mediating the development, maintenance and plasticity of key aspects of neuronal 
morphology and connectivity. The morphological changes resulting from alterations in the expression 
of ZNF804A in turn impact gross neuroanatomy across a wide range of cortical regions, particularly in 
the prefrontal cortex, cingulate cortex and temporal cortex as well as in several white matter tracts 
interconnecting these regions and both hemispheres. Subsequently, these alterations affect functional 
connectivity between these regions and ultimately, this disruption results in the behavioural and 
cognitive deficits seen in schizophrenia and bipolar disorder. It should be noted however, that the 
alterations in ZNF804A expression associated with SNPs and CNVs at this locus may result in 
differential impacts on neuronal morphology, gross neuroanatomy, functional connectivity, behavioural 
phenotypes and ultimately clinical syndromes. Variants at the ZNF804A locus are also associated with 
a category of psychosis patients consisting of both bipolar and schizophrenia diagnoses, yet 
characterised clinically by more severe and treatment-resistant positive symptoms as well as an 
attenuation of the cognitive deficits typically seen in schizophrenia. This is accompanied by a similar 
attenuation of the neuroanatomical abnormalities typically seen in schizophrenia and is associated with 
an increase in ZNF804AFL expression in the adult prefrontal and temporal cortex but a decrease in fetal 
ZNF804AE3E4 expression in the second trimester.  
7.6 LIMITATIONS OF THE CURRENT WORK AND FUTURE RESEARCH 
Based on the findings of the current investigation and previous studies of ZNF804A and 
Zfp804A, a clear area of ambiguity in urgent need of future research is regarding the functions of the 
known ZNF804A isoforms. The current demonstration clearly demonstrated the subcellular pattern of 
ZNF804A expression in NPCs and cortical neurons from multiple sources, and moreover found that 
reducing the expression of the ZNF804A and ZFP804A genes resulted in alterations in early and mature 
neuronal morphology. However, the study focused primarily on the function of the full length ZNF804A 
transcript and its rodent homologue, ZFP804A. Thus, it did not demonstrate whether the distributions 
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of the full length and disease-associated (ZNF804AE3E4 and ZNF804A2.2) isoforms differed in their 
relative expression within each subcellular compartment. As the impact on neuronal morphology seen 
in ZNF804A-knockdown neurons was not specific to either of the siRNAs used (targeting exon 2 and 
exon 4 of ZNF804A respectively), this effect is unlikely to be mediated by ZNF804A isoforms lacking 
either of these exons such as ZNF804AE3E4. In addition to this, the western blotting data presented in 
Chapter 6 indicates that a homologue of ZNF804AE3E4 is not expressed in rat primary cortical neurons 
alongside the rodent homologue of the full length variant, Zfp804A. Thus, the impact of Zfp804A 
knockdown on dendritic spine maintenance and plasticity is likely to be mediated by the full length 
Zfp804A protein, indicating that the full length ZNF804A isoform (possessing the C2H2 zinc finger 
domain) may mediate the same synaptic functions. A subsequent investigation assessing the influence 
of the disease-associated ZNF804A isoforms on neuronal structure and connectivity would provide 
valuable clues as to whether these isoforms possess different functions, particularly given that the 
ZNF804AE3E4 isoform lacks any obvious DNA or RNA binding domain and thus may not act as a 
transcription factor or impact RNA translation, transport or metabolism (as posited in this chapter) (Tao 
et al., 2014). It is therefore possible that this isoform is expressed entirely outwith the nucleus. Although 
a western blot band consistent with the predicted size of the ZNF804AE3E4 variant could be detected in 
CTX0E16 cell lysates probed with the C2C3 anti-ZNF804A antibody, a knockout of the ZNF804A gene 
followed by rescue via exogenous expression of the ZNF804AE3E4 isoform using a tagged construct 
would be ultimately required to fully verify whether this band truly represents the disease associated 
isoform.  
In addition to this, a similar assessment of whether individual ZNF804A isoforms convey 
different effects on similar aspects of neuronal morphology and function would be highly useful given 
the altered expression of ZNF804AE3E4 isoform seen in carriers of the risk allele of the psychosis-
associated rs1344706 SNP. This would help identify more accurately the ZNF804A-mediated functions 
which are most relevant to the pathophysiology underlying psychosis, and eventually may highlight 
potential targets for therapeutic treatments. 
One potential mechanism suggested in this chapter for the local actions of ZNF804A and 
Zfp804A at the synapse and within dendrites is the direct interaction of these proteins with mRNA 
molecules via the C2H2 zinc finger domain, thus regulating translation of key RNAs involved in spine 
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maintenance and plasticity. Although this hypothesised mechanism has not yet been confirmed, future 
investigations may explore this possibility via several key experiments. Primarily, the impact of 
ZNF804A/Zfp804A knockdown on local translation at the synapse could be studied via a combination 
of transcriptional inhibition with assessments of local protein production in knockdown and control 
cortical neurons, either via puromycin-based assays for translation in synaptosomal preparations such 
as SUnSET (Schmidt et al., 2009) or using direct visualisation of photoconvertible fluorescent protein 
translational reporters (Wang et al., 2009). The specific proteins being translationally regulated by 
ZNF804A/Zfp804A could be further determined using FUNCAT, a technique which uses a proximity 
ligation assay-based strategy to directly visualise newly synthesised target proteins (tom Dieck et al., 
2015). The subsynaptic localisation of ZNF804A could further be assessed to determine whether it 
colocalises with key components of local translation machinery such as RNA granules or ribosomes. 
Moreover, the participation of ZNF804A in mechanisms specific to LTP-dependent spine enlargement 
may be further studied in future experiments utilising exogenous expression of tagged 
ZNF804A/Zfp804A constructs. For example, a combination of overexpression of exogenous Zfp804A 
with inhibition of specific components of the translational pathways involved in LTP-dependent spine 
remodelling (rapamycin to blocks mTOR phosphorylation; MCPG to block metabotropic glutamate 
receptors; or K252a to inhibit BDNF-TrkB signalling) can identify the potential position of Zfp804A in 
mechanistic pathways regulating local translation. Given that the most likely mechanism of action of full 
length ZNF804A/Zfp804A would occur via direct binding to RNA sequences via their zinc finger domain 
to regulate local translation of mRNAs, these proteins are likely to be involved in these mechanistic 
pathways downstream of mTOR phosphorylation. To confirm whether Zfp804A/ZNF804A binds directly 
to RNA, a direct assessment of the RNA binding properties of these proteins could additionally be 
conducted via previously described RNA binding assays (Bardoni et al., 1999); specific RNA sequences 
bound by these proteins could be further assessed using the yeast three-hybrid system (Martin, 2012). 
Taken together, these experiments would determine whether the local actions of ZNF804A are indeed 
mediated by direct binding of RNA molecules, and moreover, whether this mechanism occurs as part 
of local translational machinery involved in the regulation of dendritic spine maintenance and plasticity. 
The use of hiPSC-derived neurons in the current study not only provided a valuable 
confirmation of the findings seen in CTX0E16 neurons, it also indicated the utility of these lines in future 
research regarding ZNF804A. hiPSC studies are particularly well suited for assessing the impact of 
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genetic variants of disease-relevant genes on very specific cellular phenotypes (Brennand et al., 2014). 
An intriguing future experiment would be to assess the impact of psychosis-associated SNPs and CNVs 
on multiple parameters including the expression of multiple ZNF804A isoforms during various stages 
of neuronal differentiation, whether these variants impact the morphological attributes measured in the 
current study, and whether there is a “genetic variant x diagnostic condition” interaction impacting any 
effects conveyed by the mutations on these attributes. As discussed in Chapter 1, recent advances in 
genome editing have provided a relatively simple means of inducing these mutations in control lines, 
and inversely, reverting these mutations in lines derived from carriers of risk alleles. Thus, isogenic lines 
offer a useful means of assessing the biological significance of these disease associated genetic 
variants, both in psychosis patients and healthy controls. 
7.7 FINAL CONCLUSIONS 
This thesis has presented a large body of work demonstrating the suitability of the CTX0E16 
cell line for future cellular studies of human cortical development and disease, showing in particular that 
the neurons differentiated from this line adopt a predominately glutamatergic, deep cortical layer identity 
and exhibit the hallmarks of immature, yet functional neurons. These cells progressively adopt the 
morphological features of pyramidal neurons during differentiation, they exhibit a wide range of synaptic 
and disease-associated proteins, they demonstrate morphological plasticity and functional responses 
to physiologically-relevant stimuli and they display the electrophysiological attributes of functional 
neurons including action potentials. Thus, the CTX0E16 line will provide a highly useful tool for 
investigating the mechanisms of cortical glutamatergic neuron function and dysfunction in future 
research. 
This study has also employed the CTX0E16 cell line, in conjunction with hiPSC lines, rat 
primary cortical neuron cultures and several other immortalised cell lines, to investigate the expression, 
subcellular localisation and function of ZNF804A throughout cortical neuron differentiation. It has shown 
how the expression of ZNF804A alters during neuronal development, explored the shifts in the 
subcellular localisation of this protein as neurons are terminally differentiated and exposed to LTP-
inducing stimuli and demonstrated a novel distribution of this protein within the dendritic spines of 
cortical neurons. Furthermore, this investigation has shown that ZNF804A plays a role in the 
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development and maintenance of cortical neuron morphology, mediating early neurite outgrowth as well 
as dendritic spine maintenance and plasticity in mature neurons. 
Finally, this thesis has integrated the findings of the current research with that of the previous literature, 
showing how the data presented here provides a crucial conceptual link between prior studies 
investigating ZNF804A’s influence on gene expression and those studying the link to neuroanatomy, 
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